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1.0 Introduction
1.1 Structure of the Epstein-Barr virus genome
Epstein-Barr virus (EBV), or human herpesvirus 4 (HHV4), belongs to the 
herpesvirus family. The EBV genome is a linear double-stranded DNA molecule of 
172 kb flanked by terminal repeats (TR). Upon infection of the host cell the linear 
genome undergoes circularisation (Fig. 1) and, as a multicopy episome, is replicated 
during each cell division by the host DNA polymerase together with the host 
chromosomes. The EBV genome encodes over 85 open reading frames (ORFs) (Kieff 
and Liebowitz, 2001).
1.2 EBV infection of the B cells in vitro
In vivo, EBV infects naive B cells (Thorley-Lawson and Babcock, 1999), but in vitro
it will infect any B cell, driving it out of the resting state into continual proliferation 
resulting in the outgrowth of immortal lymphoblastoid cells. The mechanism of EBV 
infection is mostly studied in vitro. There are two reasons for that. First, EBV infects 
exclusively humans and non-human primate mammals. This very narrow host range 
represents an obstacle in the study of EBV infection in in vivo animal models. Second, 
the frequency of infected cells in the EBV positive individual is very low (0.5-50 per 
million, depending on the individual) (Khan et al., 1996). The infection of B cells is 
mediated through interaction of viral gp350/220 with the cellular CD21/CR2, the 
physiological receptor for the complement factor C3d (Fingeroth et al., 1984). 
Following CD21 binding, the viral envelope fuses with the host cell membrane and 
triggers host cell activation. A nucleocapsid is then transported to the nuclear 
boundary and subsequently degraded. The linear viral DNA is released into the 
nucleus. This process is followed by the initial transcription of EBNA2 and EBNA-
LP (Kieff and Liebowitz, 2001). These two proteins are essentially required for the 
initial B cell growth transformation, but their activity is modulated by the subsequent 
expression of Epstein-Barr virus nuclear antigens 3A, 3B and 3C (EBNA3A, 3B and 
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3C, respectively) which are also essential for the process of B cell immortalisation. A 
second event is the circularisation of the viral genome, for which the host cell DNA 
repair machinery is used (Sixbey and Pagano, 1985, Hurley and Thorley-Lawson, 
1988). After circularisation of the genome, a full spectrum of latent proteins is 
expressed: nuclear antigens EBNA1, 2, 3A, 3B, 3C and LP, latent membrane proteins 
1 and 2 (LMP1 and 2, respectively) (Fig.1) and small non-polyadenylated RNAs 
EBER1 and 2. Cells proliferate in the so called “growth programme”. Throughout the 
immortalisation process some of the infected cells enter a proliferative crisis and die 
due to the shortening of telomeres. Only those clones which are able to stabilise their 
telomeres by activating telomerase continue to proliferate indefinitely, i.e., become 
immortal (Counter et al., 1994). Although critical, the telomerase activity is not 
sufficient for the immortalisation process. Unknown genetic events are required for 
final immortalisation.
Figure 1.
The episomal EBV genome.
A simplified circular map of the 172 kb EBV episome showing the relative locations of individual 
EBNA2, EBNA-LP, EBNA3A, EBNA3B, EBNA3C, EBNA1, LMP (LMP1) and TP (LMP2A) genes. 
The positions of the origin of replication during latency (oriP) and the origin of replication active in the 
lytic cycle (oriLyt) are also marked. TR shows the fused terminal repeats.  
(taken from Bornkamm and Hammerschmidt, 2001)
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1.3 Biology of EBV infection in vivo
The common features of all gammaherpesviruses are their lymphotropism, their 
ability to establish life-long latent infection of their host cell and induction of 
proliferation of the latently infected cells (reviewed in Roizman, 2001). 
1.3.1 Viral persistence and reactivation
Recently, information about the mechanism of EBV persistence in vivo has begun to 
accumulate by combining the cell separation methods with very sensitive techniques, 
like a single cell PCR.
Initially, it has been believed that the sites of primary EBV infection are 
oropharyngeal epithelial cells. However, there are increasing evidences that the virus 
requires a B cell compartment for persistence in the host. First, individuals with the 
heritable disorder X-linked agammaglobulinemia lack mature B cells and harbour no 
EBV in their blood or throat washings. Also, they do not have an EBV specific 
memory cytotoxic T cell response. Both findings illustrate that B cells are targets of 
primary EBV infection and are required for the establishment of viral persistence 
(Faulkner et al., 1999). 
B-cell activation requires signals from TH cells, antigen presenting cells and 
regulatory cytokines. Activated B cells either differentiate into low-affinity plasma 
cells or enter the adjacent follicle to initiate the germinal centre (GC) reaction 
(reviewed in MacLennan, 1994 and Kelsoe, 1996). There, in a concert with the 
antigen-specific GC T cells and follicular dendritic cells, B cells mutate their 
immunoglobulin genes. This specialised hypermutation machinery is activated within 
centroblasts, the highly proliferating cells. Centroblasts give rise to less proliferative 
centrocytes which are subjected to the negative selection. Following multiple rounds 
of mutation and selection, centrocytes terminally differentiate into memory B cells 
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or high-affinity plasma cells. B cell receptor (BCR) signalling is required for GC B 
cell differentiation. A further signal is delivered by CD40 as a result of interaction 
with CD40 ligand on activated TH cells. 
EBV mimics the process of normal B cell activation and differentiation through the 
coordinated expression of eight latent proteins, which are under the direction of a 
master transcription factor EBNA2 (Ling et al., 1994). This transcription pattern 
allows a rapid polyclonal expansion (therefore called “a growth programme”) of 
infected B cells as lymphoblasts which proliferate and subsequently differentiate 
through a GC-type reaction. Finally, they enter a peripheral B cell pool as resting 
memory cells latently carrying virus for life-long (Fig. 2) (Rickinson and Lane, 2000,
Thorley-Lawson, 2001). During the period from infection up to the establishment of a 
life-long persistence the viral transcription pattern gradually changes depending on 
the location and differentiation stage of the infected B cell. With respect to the latent 
viral gene expression three transcriptional programmes can be differentiated: (i) a 
growth programme in the initial stage where all latent genes and EBER1 and 2 are 
expressed, (ii) a default programme following the shutting off of EBNA2, 3A, 3B, 3C 
and LP and (iii) a latency programme, a programme in which EBV resides in the 
latent state in memory B cells and where no latent gene is expressed except for 
LMP2A in some cases (Fig. 2). So far it is still unknown which mechanism shuts off 
viral latent genes in this process, but it probably involves signals originating in the 
environment of the germinal centre follicles.
Taken together, in contrast to in vitro infection where cells use the “growth 
programme” and proliferate, in vivo EBV exhibits two, diametrically opposite, 
behaviours (reviewed in Thorley-Lawson, 2001). On one hand, EBV infects a naive B 
cell and drives the activation and proliferation of that cell. On the other hand, the 
virus can reside quiescently in resting memory cells and thus establishes persistence. 
1.0 Introduction
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Figure 2.
EBV exploits the normal pathway of B cell differentiation.
The comparison between EBV and antigen driven B cell activation and differentiation into memory 
cells is illustrated. Signals which drive this process are shown in the upper part of the figure for antigen 
activated B cells and in the lower part of the figure for EBV infected B cells. 
(modified from Thorley-Lawson and Babcock, 1999)
1.4 Pathogenicity of EBV
EBV infects more than 95% of the World’s adult population. Following primary 
infection the individual remains a life-long carrier of the virus. The majority of 
primary infections occurs in early childhood and are generally subclinical. However, 
when primary infection is delayed until adolescence or adulthood it may cause 
infectious mononucleosis (IM), a self-limiting lymphoproliferative disorder 
characterised by an increased number of EBV infected B cells in peripheral blood 
with a heterogeneous EBV gene expression pattern at the single cell level. Persistent 
infection is characterised by a stable number of latently infected B cells in the blood 
(0.5-50 per million, depending on the individual) (Khan et al., 1996). In spite of these 
facts the majority of the individuals who are EBV-positive will never develop any 
kind of lymphoproliferative disease caused by or associated with EBV. The viral 
proteins expressed in the growth programme, except of EBNA1, are highly 
immunogenic and the cells expressing those proteins are immediately diminished by 
the immune response. Thus, only cells expressing the latency programme survive 
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immunosurveillance, but they are not able to proliferate. However, in the absence of 
effective immunosurveillance or due to additional genetic changes, the EBV infected 
cells may express growth or default programme leading to various 
lymphoproliferative diseases. 
Burkitt’s lymphomas (BL) and Hodgkin’s disease (HD) arise in immunocompetent 
individuals. The exact role which the virus plays in the etiology and pathogenesis of 
these malignancies is still controversial. About 95% of endemic BL in Central Africa 
and 20-50% of HD are EBV positive. In Europe and USA the association of BL with 
EBV is only 15-20% (Magrath et al., 1992). In most BLs the only latent gene 
expressed is EBNA1 (Rowe et al., 1986), a protein which cannot be presented by the 
MHC class I due to the specific block of proteasomal degradation (Levitskaya et al., 
1997). Recently, a subset of BLs that show atypical patterns of viral gene expression 
characterised by the use of the Wp promoter has been described (Kelly et al., 2002). 
These cells express EBNA1, -3A, -3B, 3C and truncated –LP. However, EBNA2 is 
deleted in the EBV genome residing in these cells. An important feature of all BLs is 
the presence of the t(8;14) chromosomal translocation which juxtaposes the c-myc 
oncogene to the Ig heavy chain locus on chromosome 14, resulting in overexpression 
of c-myc (Zech et al., 1976). The HD cells express EBNA1, LMP1 and LMP2A 
(default programme) which play an active role in development of HD along with the 
oncogenic changes which occur during tumor development (Kuppers and Rajewsky,
1998). 
EBV is also associated with some non-B cell malignancies like extranodal T-cell and 
NK cell lymphomas, nodal T-cell lymphomas, nasopharyngeal carcinoma (NPC), 
gastric carcinoma and some others (reviewed in Middeldorp et al., 2003) indicating 
the capacity of EBV to infect non-B cells as well.
The lymphoproliferative disorders that arise due to immunosuppression following 
transplant surgery are collectively known as a post-transplant lymphoproliferative 
disorder (PTLD). The majority of EBV-positive PTLD cases exhibit an unrestricted 
pattern of the latent viral gene expression (EBNA1, -2, -3A, -3B, -3C, -LP, LMP1 and 
LMP2) governed by EBNA2. The proliferation of these cells represents the early 
stage of the infected B cells (before shutting off the EBNA2 and EBNA3s), and 
resembles a “growth programme” seen in LCLs in vitro. After the restoration of the 
immune system these lymphomas perish spontaneously (Rooney et al., 1995) 
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implicating that they are primarily driven by EBV. Similar disorders occur in some of 
the inherited immunodeficiencies and in patients with AIDS (Miller, 2001).
1.5. Epstein-Barr virus nuclear antigen 2 (EBNA2)
EBNA2 and EBNA-LP are the first viral genes expressed upon infection of B cells by 
EBV. The inability of P3HR1, an EBV strain carrying a deletion of the EBNA2 gene, 
to immortalise B cells indicates a crucial role of this protein in the transformation 
process (Hammerschmidt and Sugden, 1989, Cohen et al, 1989). EBNA2 is a 487 
amino acid protein which acts as a transcriptional activator to regulate the pattern of 
EBV latency gene expression in B cells, contributes to the changes in surface 
expression of B cell activation antigens and modifies cellular gene expression 
resulting in the stimulation of G0 to G1 cell cycle progression (Sinclair et al., 1994, 
Kempkes et al., 1995a). EBNA2 response elements are described for the viral 
promoters of the LMP2A (Zimber-Strobl et al., 1993) and LMP1 genes and the C 
promoter (Ling et al., 1993, Laux et al., 1994a). This element has been identified to 
bind a protein called RBP-Jκ, also known as CBF-1 (Ling et al., 1993, Henkel et al., 
1994, Grossman et al., 1994, Waltzer et al., 1994, Zimber-Strobl et al., 1994). EBNA2 
does not bind to DNA directly but is (probably as an oligomer (Harada et al., 2001)), 
tethered to DNA through the interaction with RBP-Jκ in order to activate 
transcription. RBP-Jκ is a ubiquitous cellular factor that binds a consensus DNA 
sequence GTGGGAA. RBP-Jκ is also targeted by the intracellular domain of the cell-
surface receptor Notch (NotchIC) which is generated upon ligand-induced protease 
cleavage (reviewed in Artavanis-Tsakonas et al., 1999 and Lai, 2000). RBP-Jκ acts as 
a transcriptional repressor by carrying a histone deacetylase-containing complex to 
the promoter (Tun et al., 1994, Hsieh and Hayward, 1995). EBNA2 and Notch 
activate the RBP-Jκ bound promoters by competing with the co-repressor complex, 
masking a repression domain of RBP-Jκ (Hsieh and Hayward, 1995) and assembling 
the positively activating transcription complex (Zhou et al., 2000a, Zhou et al., 200b). 
Thus, EBNA2 mimics an activated Notch pathway (Fig. 3). In spite of similarities 
between EBNA2 and NotchIC, there are some peculiarities in the function of EBNA2 
since activated Notch was unable to completely substitute for EBNA2 either in the 
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induction or maintenance of B cell proliferation (Gordadze et al., 2000, Höfelmayr et 
al., 2001). 
Figure 3.
Similarity of the mechanism of transcriptional activation by the EBV protein EBNA2 and the 
cellular protein Notch.
RBP-Jκ binds to the consensus sequence GTGGGAA and blocks the transcription by recruiting the co-
repressor complex. EBNA2 and NotchIC binding displaces the co-repressor complex, thus masking the 
RBP-Jκ repression domain and recruiting co-activator complex to positively up-regulate transcription.   
The RBP-Jκ-binding domain in EBNA2 spans amino acids 316 and 326 (Ling et al., 
1993, Yalamanchili et al., 1994). This region is absolutely necessary for successful 
immortalisation by EBV (Cohen et al., 1991) although EBNA2 lacking this region is 
still able to activate the viral LMP1 promoter (Sjöblom et al., 1995, Yalamanchili 
1994). Thus, the EBNA2 responsive element of the viral promoters is more complex.  
A PU.1 protein has been identified as an additional factor involved in transactivation 
by EBNA2 in the LMP1 promoter (Laux et al., 1994b, Johanssen et al., 1995). 
EBNA2 assembles with the transcription machinery, i.e. TFIIB, TAF40, TFIIH, p100 
and RPA70 (Tong et al., 1995a, b, c) and the histone acetyltransferases p300, CBP 
and PCAF (Wang et al., 2000). Furthermore, it interacts with hSNF5/Ini1, a member 
of the family of chromatin remodelling proteins (Wu et al., 1996). A SKIP protein has 
been found to be required for the activation of RBP-Jκ-repressed promoters by 
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EBNA2 (Zhou et al., 2000b). Recently, a potential role of EBNA2 in blockage of 
apoptosis mediated through Nur77, a protein that induces cytochrome c release, has 
been suggested (Lee et al., 2002).
1.5.1 Viral target genes of EBNA2
EBNA2 is induced as one of the first viral genes upon EBV infection and it can 
regulate the expression of other latent viral genes. The viral promoters activated by 
EBNA2 have been studied intensively. The latency W promoter (Wp) is used initially 
after infection and the switch to the EBV latency C promoter (Cp) coincides with the 
appearance of transcripts for the other members of the EBNA-family: EBNA1, 
EBNA3A, 3B and 3C. This process is regulated by EBNA2 (Woisetschlager et al,. 
1990, Rooney et al., 1992).
The viral C promoter and the promoters of two latent membrane proteins, LMP1 and 
LMP2, are up-regulated by EBNA2 (Wang et al., 1990a, Abbot et al., 1990, Fahraeus 
et al., 1990, Tsang et al., 1991, Zimber-Strobl et al., 1991, Jin and Speck, 1992, 
Fahraeus et al., 1993, Zimber-Strobl et al., 1993). As described above, EBNA2 binds 
to DNA indirectly through the cellular protein RBP-Jκ. At least one RBP-Jκ site has 
been mapped in each EBNA2 responsive element of these viral genes (Zimber-Strobl 
et al., 1993, Ling et al., 1993, Laux et al., 1994). Taken together, EBNA2 regulates 
the expression of all latent genes. Among them, LMP1 is a constitutively active 
transmembrane receptor which activates simultaneously several cellular pathways: 
NF-κB (Huen et al., 1995, Mitchell et al., 1995), p38MAPK (Eliopolus et al, 1999, 
Vockerodt et al., 2001) and JNK1/AP1 (Kieser et al., 1997, Kieser et al., 1999) and 
STAT (Gires et al., 1990).  
1.5.2 Cellular target genes of EBNA2
So far, several cellular genes have been identified as directly regulated by EBNA2: a 
chemokine receptor CCR7/EBI1/BLR2 (Burgstahler et al., 1995), the cellular proto-
oncogene c-myc (Kaiser et al., 1999) and a member of the AP-1/ATF super-family 
BATF (Johansen et al., 2003). The increase in the expression of the cell surface 
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molecules CD21 and CD23 by EBV is also partially attributable to the action of 
EBNA2 (Cordier et al., 1990). So far no RBP-Jκ binding site could be identified in 
the promoters of CCR7, c-myc, BATF or CD21. In contrast several RBP-Jκ sites have 
been identified in the promoter of CD23 (Hubmann et al., 2002). Therefore, the 
assumption that RBP-Jκ site in the promoter region plays an important role in the 
gene transactivation by EBNA2 does not hold true for all EBNA2 cellular targets. 
Interestingly enough, Makar et al., 1998 found that the binding of RBP-Jκ in the 
intron 1 region of CD21 causes gene silencing. The CD21 promoter has also been 
described as an NF-κB regulated promoter activated by LMP1 (Wang et al., 1990b). 
Thus, EBNA2 and LMP1 might synergistically regulate CD21 expression by 
derepression and activation. A similar mechanism was described for the CD23 gene. 
The induction of CD23 upon EBV infection has been attributed to the action of LMP1 
(Calender et al., 1987), but the full expression in some lymphoblastoid cell lines was 
observed only if both EBNA2 and LMP1 were present (Wang et al., 1990b). Taken 
together, it seems that EBNA2 opens a cascade of transcriptional events by initiating 
the transcription of primary target genes. The cascade gets broader by the action of 
genes like LMP1 or c-myc encoding for transcriptional effectors. These 
transcriptional effectors then, either synergistically with EBNA2 or individually, 
activate numerous cellular genes which are involved in the process of B cells
immortalisation.
1.5.3 Biological systems used for the identification of primary EBNA2 target  
genes
In order to be able to identify early events upon EBNA2 induction, dependent strictly 
on EBNA2, the EREB2-5 cell line has been developed by Kempkes et al., 1995a. 
EREB2-5 cells are a conditional system developed by the co-infection of P3HR1 EBV 
and mini-EBV expressing EBNA2 as a chimeric fusion protein with the hormone 
binding domain of the oestrogen receptor (ER/EBNA2). As EBNA2 is deleted in the 
P3HR1 virus, the proliferation of EREB2-5 lymphoblastoid cells is strictly oestrogen-
dependent. In the absence of oestrogen about half of the cells enter a quiescent non-
proliferative state whereas the others die by apoptosis. Growth arrest is reversible and 
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cells enter the cell cycle post-oestrogen addition due to a sequential accumulation and 
modification of cell cycle regulating proteins (Fig. 4, upper part). 
The EREB2-5 cellular system had served to characterise the c-myc gene as a primary 
target gene of EBNA2 (Kaiser et al., 1999). c-myc and LMP1 are induced in the 
EREB2-5 cells as quickly as twenty minutes post-oestrogen stimulation so that a 
distinction between target genes which are induced directly through the EBNA2 
activation mechanism and those which are induced indirectly through c-Myc or LMP1 
is virtually impossible. 
One important criterion for a primary EBNA2 target gene is its transcriptional 
activation in the presence of the protein synthesis inhibitors. An additional advantage 
of this cellular system is that ER/EBNA2 is not regulated transcriptionally. 
Independently of whether the protein synthesis inhibitor is added to the culture 
medium or not, EBNA2 is present in the cell. That allows the monitoring of only 
those primary events upon EBNA2 activation by oestrogen which do not require de 
novo protein synthesis. However, the protein synthesis inhibitor cycloheximide may 
lead to the induction and /or stabilisation of mRNA. This EBNA2-independent 
activity of cycloheximide very often represents an obstacle in the identification of 
primary target genes by this approach.
The cell lines P493-6 and BL41-K3 can be used to overcome this problem. 
P493-6 cell line was described by Pajic et al., 2001. It was developed starting from the 
EREB2-5 cells by stably transfecting a tetracycline (Tet) regulated c-myc gene which 
can be switched on by the withdrawal of Tet or switched off by addition of Tet. These 
cells therefore can grow in two different modes: as typical LCLs driven by EBNA2 or 
as germinal centre-like cells with the proliferation driven by c-Myc (Fig. 4, lower 
part). This system makes it possible to distinguish genes induced by c-Myc in contrast 
to those which are induced exclusively by EBV. 
BL41-K3 cells are EBV-negative Burkitt’s lymphoma cells stably transfected with an 
ER/EBNA2 expressing vector (Kempkes et al., 1995b). Due to the translocation of c-
myc to the Igµ locus in these cells these cells proliferate largely and independently of 
EBNA2. 
EBNA2 not only induces the transcription of genes, but it also acts as a repressor of 
genes as it in the case of the Igµ gene (Jochner et al., 1996).The immediate repression 
of Igµ by EBNA2 down regulates c-Myc translocated to the Igµ locus. Therefore 
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BL41-K3 cells cease to proliferate and are growth suppressed soon after oestrogen is 
added to the culture medium. 
The BL41-K3 cellular system provides the opportunity of monitoring very early 
events following EBNA2 activation in the absence of other viral proteins and c-myc.
Figure 4.
Scheme of EREB2-5 and P493-6 cells.
EREB2-5 cells were generated from primary B cells co-infected with a mini-EBV carrying the 
oestrogen receptor domain fused to the EBNA2 gene (ER/EBNA2) and the EBNA2-lacking P3HR1 
EBV strain (Kempkes et al., 1995a). ER/EBNA2 is active in the presence of oestrogen. Cells 
proliferate and show the phenotype of a typical lymphoblastoid cell line (LCL). In the absence of 
oestrogen Hsp90 binds to the oestrogen receptor domain (Jensen et al., 1972) preventing 
conformational changes and translocation into the nucleus. Cells do not proliferate, resembling resting 
B cells. Additional stable transfection of EREB2-5 cells with a vector containing tetracycline (Tet) 
regulated c-Myc gene yielded the cell line P493-6. These cells behave as the parental EREB2-5 LCL 
when growing under Tet/oestrogen conditions (Myc off/EBNA2 on). If they grow in the plain complete 
culture medium (Myc on/EBNA2 off) they behave like germinal-centre cells. The state of resting cells 
is achieved by addition of Tet to the cell culture medium (Myc off/EBNA2 off).
mini EBV 
ER/EBNA2 P3HR1
coinfection
Primary B-cells
+oestrogen
transfection of                     
Tet-regulatable c-Myc 
expression vector
-oestrogen
Resting cellsEREB2-5
+Tet/
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(EBNA2 on/    
c-Myc off
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(EBNA2 off/ c-Myc on)
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1.6. The goal of this project
EBNA2 is one of the first viral gene products expressed post-EBV infection. It plays 
an essential role in the immortalisation process by initiating and maintaining the 
phenotype of the immortalised B cells in vitro. In addition, EBNA2 expression is a 
characteristic feature of EBV positive B cell lymphomas, which can arise in 
immunocompromised patients. EBNA2 acts as a transactivator of viral and cellular 
genes. Primary EBNA2 target genes initiate a cascade of secondary events, which 
subsequently promote cell cycle entry and proliferation. The mechanism by which 
EBNA2 activates cellular target genes directly is complex and only partially 
understood.
The primary goal of the study described here was to compare these target genes in 
order to define cis-regulatory elements reflecting common signal transduction 
pathways shared by these genes.
The second goal of the project was identification of the target genes, which are 
induced specifically in those situations in which EBV drives the proliferation of B 
cells and subsequently to develop techniques in order to analyse the function of the 
corresponding gene products in the context of EBV immortalised B cells.
1.0 Introduction
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2.0 Results
2.1 Identification of EBNA2 target genes
2.1.1 Experimental systems for the identification of EBNA2 target genes
Recent technical and analytical advances have greatly facilitated the simultaneous 
analysis of expression of thousands of genes using DNA microarrays. Since it is 
known that the established techniques differ in sensitivity and these variations can 
even be RNA specific due to the different labelling techniques, three different DNA 
microarray techniques have been applied for the analysis of EBNA2 target genes. 
These were: (i) an ExpressCode™ DNA microarray developed by GPC Biotec 
GmbH, Germany; (ii) a DNA microarray called “lymphochip” developed by L. 
Staudt, National Institutes of Health, USA and (iii) a GeneChip® developed by 
Affymetrix Inc, USA. Basic features, similarities and diversities of each of these 
techniques will be presented in Fig. 6 (a more detailed description of each method is 
placed in the chapter Methods). Differences of these three methods strongly influence 
the results as it will be described later in this chapter. 
Proliferation of the lymphoblastoid cell line EREB2-5 (described in detail in the 
Introduction, section 1.5.1) is strictly dependent on the presence of oestrogen in the 
culture medium. Cells deprived of oestrogen become growth arrested, but can re-enter 
the cell cycle after the addition of oestrogen to the medium. These cells are therefore a 
convenient system to study and identify early events after ER/EBNA2 activation. As 
described in the previous section EBNA2 activation initiates the transcription of a 
cascade of primary and secondary target genes. In addition, primary EBNA2 target 
genes might be co-regulated by the LMP1 protein. Already two hours post-oestrogen 
induction, LMP1 and c-myc are expressed. Thus, secondary screens are required in 
order to dissect EBNA2 primary and secondary induced events.  
In this work the level of mRNA isolated from EREB2-5 across the three cell cycle 
stages has been compared: (i) for the growth arrested cells in G0/G1; (ii) for cells that 
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have just entered G1 phase (2 hours post-oestrogen activation of ER/EBNA2) and (iii) 
cycling cells proliferating at least 48 hours post-oestrogen stimulation. 
2.1.2 Screen I: The analysis of results from the ExpressCode™ DNA microarray
Screen I involved the hybridization of the ExpressCode™ DNA microarrays in 
collaboration with GPC Biotech AG, Germany with radioactively labelled cDNA 
probes derived from the RNA populations of EREB2-5 cells harvested at different 
times after oestrogen stimulation. All hybridisations were performed in four replicates 
for each cDNA probe.
The ExpressCode™ filters had been spotted with 9600 PCR products, which 
represented the inserts of a plasmid library. This plasmid library had been generated 
by the accumulation of cDNAs selected from non-redundant inserts by the 
oligonucleotide fingerprinting mehod (Meier-Ewert et al., 1998) by GPC Biotech AG, 
Germany. Since these PCR products had not been mapped to single genes, an 
unknown fraction of the PCR products could correspond to identical uni gene clusters.
ER/EB2-5 cells were activated by the addition of oestrogen to the cell culture and 
samples were taken at various time points before and after S phase was initiated. Thus 
cells were stimulated with oestrogen for 1, 2, 3, 4, 5, 6, 8, 9, 12 and 16 hours or the 
cells were proliferating for at least 48 hours post-oestrogen stimulation. Clones from 
the cDNA library which represented spots which showed induction were sequenced in 
order to identify the genes they represent. Expression of known EBNA2 target genes 
e.g. myc, cdk4, IgM, LMP1, cyclin D2 and CCR7 was monitored and could be 
confirmed. Additionally, 163 genes were identified to be novel genes potentially 
regulated by EBNA2. Induced genes were clustered according to the expression 
profiles as similar to the marker genes c-myc or CCR7, which are typical primary 
target genes of EBNA2. Cdk4, a typical secondary target gene of EBNA2, or tubulin 
alpha, a gene which gradually increases following a long term kinetic, served as 
further model genes (Fig.5). As shown in Fig. 5A and B the two primary target genes 
of EBNA2, c-myc and CCR7, fall into two different groups. They differ mainly in the 
slope of the curve during the first 2 hours post-induction. In contrast to c-myc and 
CCR7, the secondary target gene cdk4 was induced with a significant delay of 3 to 4 
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hours (Fig. 5C). The last group of RNAs accumulated steadily over time and was 
considered as a group of genes, the induction of which might coincide with growth of 
the cell and entry into the cell cycle (Fig. 5D). Thus they are not directly activated by 
EBNA2 either.
A specific feature of the genes belonging to the group exhibiting profiles similar to c-
myc is the very low base line expression level which upon induction, raised up to 
1000 fold. The basal expression of CCR7 was higher and the increase of expression 
post-induction less pronounced. Since c-myc and CCR7 were both found to be 
induced after two hours, this two hours time point was considered to be the earliest 
time at which a majority of early EBNA2 target can be identified. 
Figure 5.
The examples of expression profile clusters for genes induced on the ExpressCode™ microrray.
Genes induced in EREB2-5 cells post-oestrogen stimulation were clustered into four clusters according 
to the similarity of their expression profile with four marker genes: c-myc (A) or CCR7 (B), cdk4 (C) 
and tubulin-alpha (D). Only a few examples from each cluster are shown. The complete data can be 
found on a CD enclosed (“ExpessCode raw data and profiles”).
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52 genes, induced at least twofold within first two hours post EBNA2 activation, were 
considered to be potential primary target genes. The list of genes and the fold 
induction values are presented in the section Supplementary material, Table 1. A 
further group of 128 genes was identified as potentially EBNA2 directly induced 
genes in proliferating EREB2-5 (the list of genes and the fold induction values are 
presented in the section Supplementary material, Table 2). 
2.1.3 Screen II: The analysis of results generated by “lymphochip” technology
Lymphochip has been designed by L. Staudt (NIH, USA). Data analysed herein were 
obtained as a generous gift from M. Schlee (GSF, Munich), who performed the 
screening. Lymphochip was designed by selecting genes that are preferentially 
expressed in lymphoid cells and genes with known or suspected roles in processes 
important in immunology or cancer. The total number of genes analysed was 12,500, 
but most genes were represented more then once on the chip. Fluorescent cDNA 
probes, labelled with the Cy5 dye, were prepared from mRNA of growth arrested 
EREB2-5 cells and EREB2-5 cells stimulated for one, two or three hours with 
oestrogen. A reference cDNA probe prepared from a pool of mRNAs isolated from 
nine different lymphoma cell lines was labelled with Cy3 dye. Each Cy5-labelled 
experimental cDNA probe was combined with the Cy3-labelled reference probe and 
the mixture was hybridized to the microarray consisting of the PCR products 
synthesized on the glass substrate. The fluorescent ratio Cy5/Cy3 was quantified. The 
experiment was done only once and the genes which did not show increased 
abundance at all three time points after induction were disregarded for further 
analysis. There were 94 genes up-regulated twofold after two hours post-oestrogen 
activation. The list of genes and the fold induction values are presented in the section
Supplementary material, Table 3.
2.1.4 Screen III: The analysis of results generated by GeneChip® technology
The GeneChip® screen was performed in collaboration with Jörg Mages (Institute of 
Medical Microbiology, Munich) and Reinhard Hoffmann (Max von Pettenkofer 
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Institute, Munich). The GeneChip® Human Genome U133 Set is comprised of two 
microarrays (HG-U133A and HG-U133B) containing over 1,000,000 unique 
oligonucleotide features covering more than 39,000 transcript variants which in turn 
represent more than 33,000 well-substantiated human genes. The HG-U133A array 
represents the majority of the known genes, while the HG-U133B contains mostly 
ESTs. As the final goal of this work was to study promoters of EBNA2 directly 
regulated genes only the analysis of the HG-U133A array representing 15 000 genes 
was performed. The RNAs which were analysed derived from growth arrested 
EREB2-5 cells (0 hr), EREB2-5 cells stimulated for 2 hours with oestrogen to induce 
EBNA2 activation and proliferating EREB2-5 cells. Every experiment was repeated 
four times and the gene which was induced 1.4-fold or more in at least two 
independent experiments was considered as an EBNA2 induced gene. The 1.4-fold 
induction was set-up as a threshold for induced vs. non-induced genes since this was 
the induction level measured for the c-myc gene. There were 205 genes induced after 
two hours. The list of genes and the fold induction values are listed in the section
Supplementary material, Table 4. 3228 genes were induced at the stage of 
proliferating cells compared to growth arrested cells. 
2.1.5 The overlapping gene pool identified in the ExpressCode™ DNA 
microarray, lymphochip and GeneChip®
The total number of genes identified two hours after activation of EBNA2 in EREB2-
5 was 351 genes (52 ExpressCode™ microarray, 94 lymphochip, 205 GeneChip®). 
This is however a too large number of genes for further evaluation and study. Also, it 
is not very likely that this number of genes is indeed under direct regulation of 
EBNA2. In order to avoid further analysis of false positives, a subset of genes which 
was found by more then one technique was further evaluated.
There were only three genes, c-myc, RDC1 and CCR7, found to be induced by all 
three experimental systems two hours post-stimulation (Table 1). Also, there were 
only 14 induced genes common to the lymphochip and GeneChip® experiments 
(Table 2). 40 genes were found to be induced in proliferating cells in comparison to 
resting cells by the ExpressCode™ and GeneChip® method (Table 3). These 40 
genes also comprised c-myc, RDC1 and CD83.
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This was rather unexpected since most genes found by the ExpressCode™ and 
lymphochip screens were represented on GeneChip® U133A. Only 13 genes found 
on the ExpressCode™ array and 7 genes found on the lymphochip array were 
represented on GeneChip® U133B and thus could not be tested. In Fig. 6 the three 
techniques are outlined and the major results are summarised.
Table 1.
Overlapping pool of EBNA2 induced genes identified by the ExpressCode™ DNA microarray 
and GeneChip® at two hours post-induction.
Table 2.
Overlapping pool of EBNA2 induced genes identified by lymphochip and GeneChip® at two 
hours post-induction.
CD21NM_00187720554428383, 17364, 25237, 35090, 27987
RDC1AI817004121297715889
LymphotactinNM_00317521456727970
PLABBC00052922157627536
IP-10 NM_00156520453327463
SLAMNM_00303720618119277, 28049
MIP-1 betaNM_00298420410326409
bfl-1NM_00404920568116089, 28639
PI3KM6190621224028377, 16671
MIP-1 alphaNM_00298320511426475
CD83NM_00423320444017066, 27545, 16610
DUSP2NM_004418209457, 20479427686, 17185
EGR-1NM_00196420169424762
c-mycNM_00246720243119381, 29723, 28401, 15841,    
Probe set aLymphochip clone number Accession number Gene
a Unique Affymetrix identifier
RDC1AI8170041212977CLONE 11K11
CD83NM_004233204440CLONE 12H13
c-mycNM_002467202431CLONE 21B16
Probe set aGPC clone number Accession number Gene
a Unique Affymetrix identifier
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Table 3.
Overlapping pool of EBNA2 induced genes in the ExpressCode™ DNA microarray and 
GeneChip® at the stage of cells proliferating for at least 48 hours in the presence of oestrogen.
a Unique Affymetrix identifier. 
eukayotic translation initiation factor 4A (EIF4A1)NM_001416201530; 211787CLONE-16F3
NAD+-specific isocitrate dehydrogenase gamma subunitHSU40272202471; 214333CLONE-16E18
prohibitin (PHB)NM_002634    200658;200659CLONE-15N14
prothymosin alpha NM_002823    200772; 200773; 211921CLONE-15L16
clone 738, translational activator GCN1 HSU88836216232; 212139CLONE-15K5
TNF type 1 receptor assoc.pr.(TRAP2)HSU12596200830CLONE-15K19
malate dehydrogenase 2, NAD (mitochondrial) (MDH2)NM_005918    209036; 213333CLONE-14K13
alpha-tubulinAF141347209118; 212639; 213646; 211058;201090; 211750 CLONE-13L11
SUPT6HNM_003170208420; 208830; 208831CLONE-12N2
G protein beta subunit AF195883220587CLONE-12M13
alpha-tubulinAF141347209118; 212639; 213646; 211058;201090; 211750 CLONE-12K22
CD83, mRNAXM_004500204440CLONE-12H13
N-myristoyltransferase 1 (NMT1)NM_021079    201157;201158; 201159CLONE-12E17
cell division protein FtsJ (FJH1)NM_013393218356; 222130CLONE-12B24
translation initiation factor 1(eIF1(A121/SUI1))NM_005801     202021;211956; 212130; 212225CLONE-12A22
orphan G protein-coupled receptor (RDC1) HSU67784212977CLONE-11K11
30S ribosomal protein S7 homolog, clone MGC:711BC000241217932CLONE-11E6
30S ribosomal protein S7 homologBC000241217932CLONE-11A7
CDC37HSU43077209953CLONE-9J10
ATF5NM_012068    204998; 204999; 217389CLONE-8H4
pleckstrin (PLEK)NM_002664203470; 203471CLONE-6B15
transcription factor ATFxAF305687204999CLONE-5A5
NUDT4NM_019094    206303; 206302; 212181; 212182, 212183CLONE-4N23
p38gamma MAP Kinase mRNAHSU66243218130CLONE-4C16
PTB-associated splicing factorX70944201586; 201585CLONE-3L14
serine hydroxymethyltransferase 2 NM_005412    214095; 214096; 214437CLONE-3K5
p18 (stathmin)X53305,200783; 217714CLONE-3F23
putative chromatin structure regulator (SUPT6H) HSU46691208420; 208830; 208831CLONE-3D16
spermidine synthetaseNM_003132201516CLONE-21N4
CD37HSCD37       204192CLONE-21F17
c-mycHSMYCC202431CLONE-21B16
chaperonin containing TCP1, subunit 4XM_002285200877CLONE-20L2
NUDT4 AF191654212181CLONE-20L19
cDNA DKFZp762A227 HSM802470213113; 210692CLONE-20G22
cDNA DKFZp434G012 HSM801060212223; 212221CLONE-18L6
GOS24HUMGOS24B201531CLONE-17J22 
prothymosin alpha NM_002823    200772; 200773; 211921CLONE-17G5
prothymosin alpha NM_002823    200772; 200773; 211921CLONE-17D12
expressed in activated T/LAK lymphocytes (LAK-4P)NM_007267    204328; 214958CLONE-16M14
insulin induced gene 1 (INSIG1)NM_005542    201625; 201626; 201627CLONE-16I9
GPC clone Probe Seta Accession number Gene
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Figure 6.
Scheme of three different DNA microarray methods.
(A) Basic features of the DNA microarray methods presented in order to point out the fundamental 
differences between these methods. (B) Overlapping pool of EBNA2 induced genes in EREB2-5 cells 
identified by the ExpressCode™ DNA microarray, lymphochip and GeneChip® at two hours post-
induction. (C) Overlapping pool of EBNA2 induced genes identified by the ExpressCode™ DNA 
microarray and GeneChip® in the proliferating EREB2-5 cells. (see text for details)
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On a single gene level the results for given gene varied significantly. On the 
ExpressCode™ DNA microarray the abundance of the c-myc mRNA shows a very 
strong increase (109.3 fold). On the lymphochip the increase is already 10-fold lower 
than on the ExpressCode™ microarray and ranges from 7.4 to 10.4 for different 
clones on the array. The GeneChip® exhibits on the other hand a quite low increase 
of mRNA with only 1.4, 2.2, 2.5 or 5.0-fold. It is noteworthy to say that prior each 
experiment the quality of mRNA was controlled and verified by the Northern blot 
analysis for the c-myc gene. The induction observed in Northern blot explicitly 
indicates a fast and strong induction of c-myc in EREB2-5 at the given time points. 
Thus, the differential outcome of the individual experiments cannot be explained by 
varying RNA qualities, but it rather reflects the differential sensitivities of the 
different techniques.
2.1.6 Screen IV: Evaluation of the potential EBNA2 target genes by the nuclear
run-on experiments 
EBNA2 acts as a transcriptional activator. The nuclear run-on experiment permits a 
direct analysis of transcriptional activity for a given gene. The basic mechanism of 
this technique is the labelling and measuring of a nascent RNA associated with the 
transcription complex. Therefore, the increase or decrease in the transcription rate of 
the gene of a particular interest can be measured. 
Here the nuclear run-on experiment was used to discriminate genes induced by the c-
myc growth programme as opposed to the EBV/EBNA2 growth programme. For that 
purpose P493-6 cells were used. The P493-6 cell line is a B cell line expressing a 
conditional c-myc gene (described in more detail in Introduction, chapter 1.5.1). In 
the presence of tetracycline, c-myc is switched off and cells are growth arrested in the 
G0/G1 phase of the cell cycle. c-Myc can be re-induced by removal of tetracycline 
which induces the cell cycle entry. These cells can also behave like the parental 
EREB2-5 cells in the presence of tetracycline and the addition/deprivation of 
oestrogen.
We compared the run-on profile of nuclei from the P493-6 cells induced for 8 hours 
with oestrogen and tetracycline (cell proliferation driven by EBNA2) and of nuclei 
from the P493-6 cells depleted from tetracycline and grown in the plain complete 
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medium for 8 hours (cell proliferation driven by myc). The purpose of this experiment 
was to identify the genes which are preferentially activated in either the c-myc or the 
EBNA2/EBV driven growth programme. Nuclear run-on has the advantage of 
monitoring the transcriptional activity in the contrast to previous experiments where 
the steady state RNA levels were observed. Run-on RNAs were labelled with 32P-
CTP and hybridised to “self-made” DNA arrays. A “self-made” DNA array was 
generated by spotting PCR products. 14 genes induced in both lymphochip and 
GeneChip® at 2 hours post-stimulation with oestrogen plus 40 genes induced in the 
proliferating cells analysed with the ExpressCode™ microarray and GeneChip® were 
represented on the “self-made” DNA array. The genes LMP1, LMP2A, GAPDH and 
IgM were included as positive controls. The positions of the genes are described in 
Table 4. Signals were detected and quantified after 24 hours by phosphoimaging (Fig. 
7).
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Table 4.
The list and positions of probes in “self-made” DNA arrays used for nuclear run-on.
Row Column Gene Accesion number
A 1 30S ribosomal protein S7 homolog BC000241
2 30S ribosomal protein S7 homolog BC000241
3 RDC1 HSU67784
4 eIF1 NM_005801
5 cell division protein FtsJ NM_013393
6 N-myristoyltransferase 1 (NMT1) NM_021079
7 CD83 XM_004500
8 alpha-tubulin AF141347
9 G protein beta subunit AF195883
10 SUPT6H NM_003170
11 alpha-tubulin AF141347
12 MDH2 NM_005918
B 1 TRAP2 HSU12596
2 GCN1 HSU88836
3 prothymosin alpha NM_002823
4 prohibitin (PHB) NM_002634
5 isocitrate dehydrogenase HSU40272
6 EIF4A1 NM_001416
7 INSIG1 NM_005542
8 LAK-4P NM_007267
9 prothymosin alpha NM_002823
10 prothymosin alpha NM_002823
11 GOS24 HUMGOS24B
12 DKFZp434G012 HSM801060
C 1 DKFZp762A227 HSM802470
2 NUDT4 NM_019094
3 TCP1 XM_002285
4 c-myc HSMYCC
5 CD37 HSCD37
6 spermidine synthetase NM_003132
7 SUPT6H NM_003170
8 p18 (stathmin) X53305,
9 serine hydroxymethyltransferase 2 NM_005412
10 PTB-associated splicing factor X70944
11 p38gamma MAPK HSU66243
12 NUDT4 NM_019094
D 1 ATFx AF305687
2 PLEK NM_002664
3 ATF5 NM_012068
4 CDC37 HSU43077
5 MIP-1 alpha NM_002983
6 SLAM NM_003037
7 PI3K M61906
8 DUSP2 NM_004418
9 Bfl-1 NM_004049
10 MIP-1 beta NM_002984
11 EGR-1 NM_001964
12 PLAB BC000529
E 1 IP-10 NM_001565
2 lymphotactin NM_003175
3 CD21 NM_001877
4 LMP1 V001555
5 LMP2A V001555
6 CCR7 NM_001838
7 GAPDH BE561479
8 IgM BC001872
9/10 EBNA2 V001555
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(D)
Experiment 1 Experiment 2
Gene Arrested
cells
EBV 
growth
c-Myc 
growth
EBV /
c-myc
Arrested
cells
EBV 
growth
c-Myc 
growth
EBV /
c-myc
RDC1 1 73,3 16,6 4,4 1 12 8 1,5
CD83 1 2210 944,8 2,3 1 127,4 60,2 2,1
NUDT4 1 163,6 6,4 25,6 1 272 201 1,4
ATFx 1 202,5 18,8 10,8 1 76,8 83 0,9
PLEK 1 575,8 13,3 43,3 1 126,1 85,9 1,5
ATF5 1 826 151 5,5 1 43 43,1 1
CDC37 1 197,8 55,8 3,5 1 152 46,8 3,2
MIP-1 α 1 114 29,1 3,9 1 176,5 77 2,3
SLAM 1 638 82 7,8 1 13,4 2 6,7
DUSP2 1 57,7 26,9 2,1 1 156 31 5
Bfl-1 1 101 6,9 14,6 1 717 107 6,7
MIP-1 β 1 406,3 16,7 24,3 1 823 101 8,1
EGR-1 1 437,4 165,8 2,6 1 248,3 171,7 1,4
PLAB 1 176,4 31,1 5,7 1 397 295 1,3
IP-10 1 262,7 56,3 4,7 1 183 204 0,9
CD21 1 794,7 29,7 26,8 1 461,5 148,5 3,1
LMP1 1 12,5 4,2 3 1 442,5 156,5 2,8
LMP2A 1 208,5 13,5 15,4 1 995 239 4,2
CCR7 1 5,3 2,3 2,3 1 150,5 71,5 2,1
(E)
Experiment 1 Experiment 2
Gene Arrested
cells
EBV 
growth
c-Myc 
growth
c-Myc/
EBV
Arrested
cells
EBV 
growth
c-Myc 
growth
c-Myc/
EBV
Ftsj 1 115,7 203,4 1,8 1 137,3 141,8 1,0
tubulin 1 21,8 87,7 4,0 1 37,4 59 1,6
G protein 1 91,3 641 7,0 1 5,7 137,7 24,2
SUPT6H 1 13,2 489,3 37,1 1 6 156,5 26,1
tubulin 1 27,1 172,6 6,4 1 27,3 64,5 2,4
LAK-4P 1 108 666,8 6,2 1 50,2 59 1,2
prothymosin 1 6,1 77,4 12,7 1 13 117,1 9,0
prothymosin 1 21,3 291,8 13,7 1 12,1 114,3 9,4
CD37 1 59,6 1045,9 17,5 1 90,5 114,5 1,3
SUPT6H 1 35,7 141,8 4,0 1 30,3 55,8 1,8
(Figure 7. continues)
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(F)
Experiment 1 Experiment 2
Gene Arrested
cells
EBV 
growth
c-Myc 
growth
EBV/
c-Myc
Arrested
cells
EBV 
growth
c-Myc 
growth
EBV/
c-Myc
30S ribosomal pr 1 447,5 511 0,9 1 30,8 29,5 1
30S ribosomal pr 1 779,5 822,5 0,9 1 42 47,5 0,9
eIF1 1 1631,6 2168,2 0,8 1 58,3 74,9 0,8
NMT1 1 121,3 131,9 0,9 1 2,3 2 1,2
MDH2 1 595 894,8 0,7 1 3,6 4,2 0,9
TRAP2 1 175,6 147,6 1,2 1 16 14 1,1
GCN1 1 514,5 458,5 1,1 1 15 15,5 1
prothymosin 1 851,3 823 1 1 9 7,3 1,2
prohibitin 1 339,3 476 0,7 1 32,5 19,5 1,7
isocitrate DH 1 36,1 40,8 0,9 1 2,3 2,3 1
eIF4A1 1 1087,8 1974,8 0,6 1 59,4 62,6 0,9
INSIG1 1 278 348 0,8 1 37,5 34,5 1,1
GOS24 1 249 196 1,3 1 4,6 4 1,2
DKFZp434G012 1 15,8 17,1 0,9 1 34,6 29,1 1,2
DKFZp762A227 1 27,3 22,7 1,2 1 30 26 1,2
TCP1 1 207,2 249,3 0,8 1 49 56 0,9
c-myc 1 2226,8 3753,3 0,6 1 167,3 140,3 1,2
spermidine synt. 1 192,2 198,2 1 1 36,3 26,3 1,4
p18 1 35,7 141,8 0,3 1 30,3 30,8 1
Ser HMT2 1 11 10 1,1 1 8,4 7,6 1,1
PTB 1 171 223,3 0,8 1 36 34,5 1
p38 MAPK 1 184,1 232,5 0,8 1 56 64 0,9
NUDT4 1 30 34,5 0,9 1 0,7 0,6 1,2
PI3K 1 2,7 1,9 1,4 1 0,3 0,3 1
lymphotactin 1 41,9 31,4 1,3 1 1 1 1
GAPDH 1 13,7 16,6 0,8 1 13,1 14,7 0,9
Figure 7. 
Nuclear run-on expression of potential EBNA2 target genes in P493-6 cells.
P493-6 cells were growth arrested (A) or grown in either EBV/EBNA2 (B) or myc (C) growth 
programme for 8 hrs. Run-on RNAs of isolated nuclei were labelled with 32P-CTP and subsequently 
hybridised to “self-made” DNA arrays (each spot contained 400 ng of PCR product and was diagonally 
spotted twice, genes and positions are listed in Table 4). Phosphoimages of the membranes after 24 hrs 
of exposure are presented. Genes which were differentially expressed on the blot hybridised with 
nuclear run-on RNA from EBNA2 on/myc off state and EBNA2 off/myc on state are squared on the 
blots (B) and (C), respectively. Signals were quantified and the phosphoimage values of two 
experiments are shown as fold induction of two growth programs compared to an un-induced state and 
as the ratio of induction between two programmes. (D), (E) and (F) summarise respectively genes 
induced predominantly induced in EBV/EBNA2 growth programme, genes predominantly induced in 
the c-Myc growth programme and genes which were induced approximately at the same level in both 
growth programmes. 
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The control genes spotted onto membrane were LMP1 and LMP2A (viral EBNA2 
target genes), c-myc and CCR7 (cellular EBNA2 target genes), IgM (a gene repressed 
by EBNA2) and GAPDH (a house keeping gene). All control genes show at least in 
one experiment to be induced more than twofold (LMP1, LMP2A, c-myc, CCR7), 
repressed (IgM) or without change in expression (GAPDH) by the EBV/EBNA2 
growth programme.
Any gene induced at least twofold in one programme compared to the other 
programme was considered to be predominantly expressed by that programme. Under 
these conditions, the nuclear run-on analysis revealed a list of 19 genes (Figure 7. and 
Table 5) with increased transcriptional rates for an EBV/EBNA2 growth programme. 
Two of those genes are control viral genes LMP1 and LMP2A. Eleven genes (RDC1, 
CD83, MIP-1 alpha, SLAM, DUSP2, Bfl-1, MIP-1 beta, EGR-1, PLAB, IP-10 and 
CD21) originated from the comparison between the lymphochip and the GeneChip® 
at 2 hours post-induction. Further five genes (NUDT4, ATFX/ATF5*, PLEK, CDC37 
*ATFx and ATF5 might represent the same gene since the sequences in the data bank partially overlap.
position gene
A3 RDC1
A7 CD83
C2 NUDT4
D1 ATFx*
D2 PLEK
D3 ATF5*
D4 CDC37
D5 MIP-1 alpha
D6 SLAM
D8 DUSP2
D9 bfl-1
D10 MIP-1 beta
D11 EGR-1
E1 IP-10
E2 PLAB
E3 CD21
E4 LMP1
E5 LMP2A
E6 CCR7
position Gene
A5 Ftsj
A8 Alpha tubulin
A9 G protein beta subunit
A10 SUPTH6
A11 Alpha tubulin
B8 LAK-4P
B9 Prothymosin alpha
B10 Prothymosin alpha
C5 CD37
C7 SUPTH6
E8 IgM
Table 6.
c-Myc induced genes identified by 
nuclear run-on.
Table 5. 
EBV induced genes identified by nuclear 
run-on.
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and CCR7) came from the comparison of gene induction in the proliferating cells on 
the ExpressCode™ DNA microarray and GeneChip®. All genes show no 
inconsistencies in two experiments except NUDT4. NUDT4 was spotted twice on the 
DNA array, each time from the different clones. Nuclear run-on showed that one 
clone was induced in one experiment, but not in another. The second clone does not 
show induction. However, as the criterion for gene to be considered as induced in one 
of the programmes was to be induced more than twofold in at least one experiment, 
NUDT4 was analysed further. In the c-Myc growth programme eight genes have been 
identified as potential c-Myc target genes (Figure 7. and Table 6): cell division protein 
FtsJ, alpha tubulin, G-protein, SUPTH6, LAK-4P, prothymosin alpha, CD37 and 
IgM. Of those genes, prothymosin alpha has been already identified as putative c-Myc 
target gene (Deng, 1999). As expected, the c-myc gene signal was strongly increased
in both growth programmes, since c-myc is a primary EBNA2 target gene and it is
also highly expressed in cells grown in the absence of Tet (c-Myc growth 
programme).
Finally, 42 % of the genes on the membrane (21 genes out of 50) were induced by 
both growth programmes to the same intensity. 10 % of genes on the membrane (5 
genes out of 50) were not detectable.
2.1.7 Evaluation of the potential target genes by the Northern blot analysis
Candidate EBNA2 target genes were further evaluated by the Northern blot analysis 
in order to verify induction as well as to discriminate potential pathways causing 
induction. For these analyses only a subselection of target genes was chosen which 
scored by the following two criteria: (i) induced by EBNA2 within 2 hours in at least 
two independent screens and (ii) induced by the EBV/EBNA2 growth programme in 
the nuclear run-on analysis. The change of mRNA abundance was monitored in three 
different cell lines (described in Introduction, chapter 1.5.1, and earlier in Results): 
EREB2-5, P493-6 and BL41-K3.
The total RNA was isolated from the EREB2-5 cell at time points 0 and 6 hours post-
oestrogen stimulation. Furthermore, the protein synthesis inhibitor cycloheximide was 
added to the cell culture medium of EREB2-5 cells in order to distinguish EBNA2 
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directly regulated target genes from those indirectly regulated by EBNA2. 
Cycloheximide was added to the medium with or without oestrogen and cells were 
harvested 6 hours later. Very often, however, cycloheximide addition leads to 
induction or stabilisation of mRNA for some genes and it is not possible to say 
whether they are induced in the absence of de novo protein synthesis or they require 
additional stimulus. Therefore two additional cell lines were included. The P493-6 
cell line can be grown in two diverse modes: the c-Myc growth programme or the 
EBV/EBNA2 growth programme. Cells were grown in one of the growing conditions 
and 8 hours later cells were harvested and the total RNA was isolated.
BL41-K3 is an EBV-negative Burkitt’s lymphoma cell line ectopically expressing 
ER/EBNA2. Thus, in this cell line the function of EBNA2 can be studied in the 
absence of other viral proteins. However, a special feature of the cell line BL41-K3 is 
the fact that c-myc is down regulated by ER/EBNA2. Thus, c-myc target genes will 
be down regulated by EBNA2 under these specific conditions. 
Northern blot analysis revealed a classification of genes into five distinct groups 
according to the pattern of expression (Table 7): group I - genes with induction 
directly regulated by EBNA2 in the absence of de novo protein synthesis; group II -
genes potentially regulated directly by EBNA2 in cooperation with another cellular or 
viral protein; group III - genes induced by EBNA2, but which are induced by 
cycloheximide as well, group IV - genes induced by EBNA2/EBV, but are not 
induced in the absence of other viral proteins and group V - c-Myc induced genes.  
All results will be described in the following sections.
2.0 Results
31
Table 7. 
EBNA 2 induced genes classified into five distinct groups according to the expression pattern in EREB2-5, P493-6 and BL41-K3 cells.
The intensity of the signals is presented with +++ for very strong signal to + as moderate signal. Very low signal was denoted as +/-, and no signal with -.
Gene
EREB2 -5
oestr/CHXCHXoestr ØØ
BL41 -K3P493 -6
oestrØtetoestr
c-myc
RDC1
bfl -1
CCR7
+++- -
- - - - -
-
-
+++
+++ ++++++
+++
+++ +++
+++
+++
+
+
+
+
+
--
-/+
-
-
-
- --
-
++++
++
++
++
-/+-/+
-/+
-/+
MIP -1 beta
C D83
+++
+++
+++
+++
+
+
+
+ --
-
-
-
-
++
++
++
CD21
PLEK
EGR -1
+++
+++
+++
+++
+++
-
-
--
-
-
++ ++ +
++
++ -/+-/+
DUSP2
IP -10
SLAM
lymphotactin
PI3K
PLAB
MIP -1 alpha
ATF5
NUDT4
CDC37
++ ++++
- -
-
++++ - +++ -
- -
- ++++ - +++ - - -
- -+++- -/+- - - -
- ++++++ -/+++-
-/+- -+ - +++ - ++
- +++ - ++ - ++
- +++/ -+ - + - ++
-- ++++ ++++ - ++
- ++++
- +++++++
- +++ +
- +++ ++ +++
+++
Group I
Group II
Group III
Group V
Group IV
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2.1.7.1 Group I: EBNA2 direct target genes
Northern blot analysis of the genes c-myc, RDC1 and CCR7 (Fig. 8) revealed that 
they are primary target genes of EBNA2. They are induced in EREB2-5 cells upon 
activation of EBNA2 by oestrogen (Fig. 8A). A low level of induction was 
demonstrated for these genes in cells treated with cycloheximide only, but when the 
cells were stimulated with oestrogen in the presence of the protein synthesis inhibitor 
cycloheximide a significant super-induction was observed. That firmly indicates that 
EBNA2 per se is enough to induce the transcription of this gene. Furthermore, RDC1 
and CCR7 are also induced in the BL41-K3 cells in the absence of viral proteins 
(Fig.8 C). The CCR7 gene is clearly induced by EBNA2 in the P493-6 cells as well 
(Fig 8B). In contrast, RDC1, although induced in EREB2-5 by EBNA2, it is not 
induced in P493-6. This result cannot be explained as P493-6 should behave 
essentially like EREB2-5 cells when growing in the EBV/EBNA2 programme.  
Figure 8.
EBNA2 direct target genes.
The EREB2-5 (A), P493-6 (B) and BL41-K3 (C) cells were grown under conditions and harvested at 
time points as indicated. Total RNA was isolated and 10 µg were loaded on an 1%-denaturing agarose 
gel and electrophoresis was performed. RNA was blotted to the nylon membrane overnight and 
subsequently the membrane was hybridised with DIG-labelled PCR probes for c-myc, RDC1 and 
CCR7. Ethidium bromide staining of rRNA is shown as a loading control for each lane.
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2.1.7.2 Group II: EBNA2 directly regulated genes which require an additional    
action of cellular or viral genes for induction
The genes bfl-1 and MIP-1 beta were classified as potential EBNA2 direct target 
genes. As shown in Fig. 9A they are induced in the EREB2-5 cell by EBNA2, are not 
induced with cycloheximide only, but are induced, although weakly, by oestrogen in
the presence of cycloheximide. Also in BL41-K3 (Fig. 9C) EBNA2 per se is enough 
to up-regulate those genes, although never to the same amount as in EREB2-5 cells,
indicating that EBNA2 per se is sufficient for weak induction, but some other cellular 
or viral protein, which is missing in BL41-K3, is required for a strong induction 
observed in EREB2-5. However this protein is not c-Myc since myc induction in 
P493-6 (Fig. 9B) does not correlate with bfl-1 or MIP-1 beta gene induction.
Figure 9. 
Potential EBNA2 direct target genes.
The EREB2-5 (A), P493-6 (B) and BL41-K3 (C) cells were grown under conditions and harvested at 
time points as indicated. Total RNA was isolated and 10 µg were loaded on an 1%-denaturing agarose 
gel and electrophoresis was performed. RNA was transferred to the nylon membrane and subsequently 
the membrane was hybridised with DIG-labelled PCR probes for Bfl-1 and MIP-1 beta. Ethidium 
bromide staining of rRNA is shown as a loading control.
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2.1.7.3 Group III: EBNA2 induced genes which are also induced by the                                
protein synthesis inhibitor cycloheximide
CD21, CD83 and PLEK are strongly induced by EBNA2, but the induction in the 
presence of the protein synthesis inhibitor is approximately at the same level 
regardless whether EBNA2 is activated or not (Fig. 10A). Therefore, the direct effect 
of EBNA2 cannot be studied easily and it is not clear whether EBNA2 induces these 
genes directly or through some indirect mechanism. The induction in the P493-6 cells 
(Fig. 10B) shows that c-Myc can, induce a very low amount of mRNA of these genes. 
However, if c-Myc would be the key factor for induction of any of these genes, their 
mRNA would be down-regulated in BL41-K3 cells due to the down-regulation of c-
myc in these cells, but instead, they are strongly up-regulated by EBNA2, indicating 
that these genes can be expressed in the absence of c-Myc and do not require viral 
proteins for induction (Fig. 10C). This suggests that CD21, CD83 and PLEK might be 
direct target genes and their mRNA is induced or stabilised in the presence of 
cycloheximide.
Figure 10. 
Genes induced by both EBNA2 and cycloheximide.
The EREB2-5 (A), P493-6 (B) and BL41-K3 (C) cells were grown under conditions and harvested at 
time points as indicated. Total RNA was isolated and 10 µg were loaded on an 1%-denaturing agarose 
gel and electrophoresis was performed. RNA was blotted to the nylon membrane overnight and 
subsequently the membrane was hybridised with DIG-labelled PCR probes for CD21, CD83 and 
PLEK. Ethidium bromide staining of rRNA is shown as a loading control.
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2.1.7.4 Group IV: genes which require viral proteins in addition to EBNA2 
for induction
The following nine genes EGR-1, DUSP2, SLAM, lymphotactin, IP-10, MIP-1 alpha, 
PLAB, PI3K and ATF5 were induced by EBNA2 in EREB2-5 cells. In some cases
cycloheximide induced these genes to varying levels (Fig. 11A). None of these genes 
was induced by c-Myc in P493-6 (Fig. 11 B), but all were induced by EBNA2. 
Lymphotactin is not expressed in P493-6 cells grown in the EBV/EBNA2 growth 
programme which should be cellular equivalent of EREB2-5 cells. Expression in 
BL41-K3 (Fig. 11C) was either not detectable at all, like for EGR-1, DUSP2, SLAM 
and lymphotactin, or there was no up-regulation by EBNA2, as in the case of IP-10, 
MIP-1 alpha, PLAB, PI3K and ATF5. This finding indicates that viral proteins play a 
crucial role in the up-regulation of these genes, and EBNA2 is not directly responsible 
for their up-regulation. Therefore, these genes were excluded from the following 
promoter analysis which focussed on potential primary EBNA2 target genes.
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Figure 11.
Genes which require the contribution of viral proteins in addition to EBNA2 for induction.
The EREB2-5 (A), P493-6 (B) and BL41-K3 (C) cells were grown under conditions and harvested at time points as indicated. Total RNA was isolated and 10 µg were loaded 
on an 1%-denaturing agarose gel and electrophoresis was performed. RNA was blotted on the nylon membrane overnight and subsequently the membrane was hybridised 
with DIG-labelled PCR probes for EGR-1, DUSP2, SLAM, lymphotactin, IP-10, MIP-1 alpha, PLAB, PI3K and ATF5. Ethidium bromide staining of rRNA is shown as a 
loading control.
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2.1.7.5 Group V: c-Myc regulated genes
CDC37 and NUDT4 were up-regulated in EREB2-5 (Fig. 12A), but also in both 
EBV/EBNA2 and c-myc growth programmes in P493-6 cells (Fig. 12B). c-myc is 
down-regulated in BL41-K3 cells because it is translocated to the Igµ locus which is 
transcriptionally repressed by EBNA2. In these cells CDC37 and NUDT4 were also 
down-regulated (Fig. 12C). The up-regulation in the c-myc driven P493-6 cells and 
down-regulation in BL41-K3 cells reveal genes which are c-Myc target genes and are 
not interesting for promoter analysis of this project. These genes had not been 
identified as c-Myc target genes before. In spite of very stringent criteria for choosing 
potential EBNA2 target genes, these two genes were proven to be c-Myc regulated. 
Figure 12. 
Genes regulated by c-Myc.
The EREB2-5 (A), P493-6 (B) and BL41-K3 (C) cells were grown in conditions and harvested at time 
points as indicated. Total RNA was isolated and 10 µg were loaded on an 1%-denaturing agarose gel 
and electrophoresis was performed. RNA was blotted to the nylon membrane overnight and 
subsequently membrane was hybridised with DIG-labelled PCR probes for CDC37 and NUDT4. 
Ethidium bromide staining of rRNA is shown as a loading control.
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2.1.8 Comparative analyses of promoter organisation in silico
Transcription factor (TF) binding sites common to all or a subset of target genes
served as a starting point for the systematic experimental analysis of EBNA2 
signalling pathway(s). A comparison of the putative promoters of the potential 
EBNA2 target genes c-myc, CCR7, RDC1, bfl-1, MIP-1 beta, CD21, CD83 and 
PLEK was performed in order to define a potential common denominator of 
promoters of these genes. 
All promoter modelling and subsequent database searches were carried out by using 
the GEMS Launcher 1.0 software, Genomatix Software GmbH, Germany 
(www.genomatix.de).
2.1.8.1 The identification of potential TF binding sites in the promoters of          
potential EBNA2 target genes by the MatInspector programme
As there is no clear-cut defined 5’-boundary for promoters, the region situated -1000 
upstream of the transcription start site (TSS) was analysed for each gene. The 
promoter function is not coupled to fixed stretches of sequence homology, but rather 
to highly variable elements representing individual TF binding sites that act as a 
recognition site for their cognate protein. The majority of the known TFs recognize 
short DNA stretches of about 10-15 nucleotides in length which show different 
degrees of internal variation. The MatInspector programme is a tool that utilizes a 
large library of predefined matrix descriptions for TF binding sites to locate the 
matching sequences in genes (Quandt et al., 1995). There are two criteria by which 
the quality and relevance of the matched TF binding sites are determined: core and 
matrix similarity. Core similarity denotes the degree of divergence of a sequence 
present in an analysed promoter from the defined core sequence. A matrix is 
represented by a two-dimensional table of numbers that reflects the nucleotide 
preferences for the individual positions of the aligned transcription factor binding 
sites and is ideally derived from a set of functionally characterised binding sites of a 
given transcription factor (Quandt et al., 1995). For all analyses described here the
core similarity was set up to 1.00 and the matrix similarity was defined as optimized. 
Numerous potential cis-acting elements within the promoter region of the analysed 
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genes were identified by using the MatInspector programme (Table 8). Three 
elements were found as a common feature in all eight analysed promoters. These were 
TATA-box elements and the binding sites for NFAT1 and Oct-1 transcription factors. 
The random expectation (RE) is the number of matches per 1000 bp of a random 
DNA sequence. For the NFAT1 binding site the RE value is 2.06 and thus is 
relatively high. In contrast, the RE value for the Oct-1 binding sites is 0.09. As shown 
in Fig.13 both, the NFAT1 and Oct-1 binding sites, form clusters in some putative 
promoter regions. While the appearance of the NFAT1 binding sites could be a simply 
by chance, the Oct-1 binding site appears much more often than randomly expected. 
Figure 13.
Schematic diagram of NFAT1 and Oct-1 binding sites in the putative promoter region of the 
genes belonging to Group I, II and III.
The putative promoter region (-1000 bp region upstream from TSS) was screened for potential NFAT1 
and Oct-1 binding sites with the MatInspector programme (Genomatix Software GmbH, Germany).
Positions of each binding site as well as TSS are indicated.
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Nuclear factors of activated T cells (NFAT) are transcription factors that have been 
implicated in the regulation of genes involved in the immune response of the T cells, 
B cells, NK cells, macrophages, mast cells and eosinophils (Tsai et al., 1996, Rao et 
al., 1997). The importance of the octamer binding protein-1 (Oct-1) for the B cell 
specific transcriptional regulation has also been well established (Staudt et al., 1986, 
Wirth et al., 1987). Taken together these two transcriptional factors are highly active 
in B cells and might have a role in the regulation of these genes by EBNA2 as it will 
be discussed. 
Table 8. 
Number of potential TF binding sites in the putative promoters (-1000 bp region upstream of the
TSS) of genes potentially regulated by EBNA2. The TF binding sites were identified by the 
MatInspector programme.
As described before, the EBNA2 induced genes have been assigned to five groups. Of 
these 5 groups, group I, II and III were shown to be regulated by EBNA2, while group 
IV and V genes are activated by viral genes or c-Myc. The differential induction
patterns of group I-III genes indicated that different molecular mechanisms might 
underline the induction processes. In order to search for molecular mechanisms 
common to single groups, the number of the TF binding sites common to each group 
was analysed. The results of this analysis are summarised in Table 9.
Apart from TATA-box element, and binding sites for NFAT1 and Oct-1, which are 
mentioned before as common to all groups, some binding sites were found within 
single groups only, while others were common to more than one group (Table 9). The 
binding sites for ECAT, EVI1, GATA and PBXC appear in all genes of groups I and 
II. The binding sites for FKHD and HNF1 are common to all genes in groups I and 
Gene Number of identified TF binding sites
c-myc 88
CCR7 99
RDC1 90
bfl-1 78
MIP-1 beta 133
CD21 104
CD83 124
PLEK 82
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III, and the TF binding sites for CREB, MYT1 and NF-κB are common to genes in 
groups II and III.
Table 9.
The list of common TF binding sites identified within each group of genes up-regulated by 
EBNA2. Identification was performed by using the MatInspector programme.
Group Common TF binding sites
Group I
c-myc BARB, ECAT, EVI1, FKHD, GATA,HNF1,
CCR7 NFAT1, OCT1, PBXC, PIT1, TBPF
RDC1
Group II AREB, CREB, ECAT, EVI1, GATA, HMTB,
bfl-1 IKRS, MYT1, NFAT1, NFKB, OCT1, OCTB,
MIP-1 beta PAX5, PBXC, PCAT, RCAT, TALE, TBPF
Group III
CD21 CART, CLOX, CREB, FKHD, HNF1, MEF2,
CD83 MYT1, MZF1, NFAT, NFKB, OCT1, PAX2,
PLEK PDX1, SORY, TBPF
2.1.8.2 Characterisation of higher levels of promoter organisation
Co-regulated genes have been frequently shown to exhibit similarities with regard to 
their promoter organisation at higher level. At this level, transcription factor binding 
sites form promoter modules which act in a coordinated way (either synergistically or 
antagonistically). The contributing elements are arranged within a defined distance 
and sequential order (Firulli and Olson., 1997, Klingenhoff et al., 2002). In the 
promoter module, both sequential order and distance can be crucial for function. The 
ModelInspector programme was used to identify potential promoter modules within 
EBNA2 regulated promoters of genes identified in this study. ModelInspector utilizes 
either a library of predefined and experimentally verified modules or modules 
generated by the programme FastM. Our analysis revealed several modules for each 
gene (Table 10) consisting of two elements each. Exception was the c-myc promoter 
since the promoter module could not be identified. The relevance and quality of a 
given module is represented by the model score and quality assessment. The model 
score is a value that describes the similarity of the found module with a defined one. It 
is a sum of the scores of all individual elements of the model and is given in % of the 
maximum possible score of a model match. Quality assessment is a random 
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expectation of module appearance in a human sequence per 1000 bp. For modules 
identified within the analysed promoters the quality assessment values show that these 
modules do not appear by chance. Nevertheless, model scores were relatively low 
indicating that found modules are not highly authentic. Furthermore, no promoter 
module common to all promoters could be identified. A single module consisting of 
an ETS family protein and an AP1 family protein was found in the promoters of the 
RDC1 and the CCR7 genes. However, the ETS matrix family members in these two 
modules differ: CETS1P54 in CCR7 and ELK1 in RDC1. 
In summary, on the level of high order promoter organisation, the EBNA 2 target 
genes do not show a common module pattern. 
Table 10.
Promoter modules identified in the promoters of primary EBNA2 taget genes. Modules have 
been identified by using the ModelInspector programme. The promoter modules common to two 
genes are underlined. 
Gene Module name Quality assessment Position (bp) 
relative to TSS
Model Score
c-myc No module - - -
ETSF-AP1F 0.544 -152 to -182 91.3 %
MEF2-AP1F FM* -620 to -656 97.3 %
MEF2-T3R FM* -620 to -717 93.0 %
CCR7 GATA-AP1F 0.061 -767 to -817 99.2 %
AP1FAP1F 0.185 -817 to -705 97.8 %
IKRS-AP2F 0.295 -844 to -813 90.3 %
HAML-ETSF 0.097 -881 to -901 90.3 %
ETSF-AP1F 0.073 -901 to -793 97.9 %
SP1F-ETSF 0.170 -367 to -561 91.2 %
RDC1 XBBF-AP1F 0.031 -472 to -438 92.2 %
ETSF-AP1F 0.554 -751 to -780 91.5 %
CEBP-GATA 0.132 -33 to -62 96.2 %
bfl-1 SP1-ETSF 0.178 -422 to -441 90.3 %
NFAT-AP1F 0.354 -957 to -933 91.1 %
MYOD-TBPF 0.139 -250 to – 228 90.4 %
MIP-1 BRAC-NKXH 0.085 -727 to -701 97.0 %
NFKB-AP1F 0.323 -467 to -438 91.2 %
CD21 NF1F-EBOX 0.201 -802 to -828 94.0 %
MYOD-MYOD 0.201 -944 to -909 93.7%
STAT-CEBP 0.022 -200 to -119 96.2 %
CD83 HOXF-HOXF 0.205 -324 to -298 91.5 %
MEF2-AP1F 0.208 -648 to -688 97.0 %
PLEK HAML-SMAD 0.130 -437 to -524 90.0 %
* Generated by the FrameWorker programme (Genomatix Softaware GmbH).
2.0 Results
43
2.1.9 Identification of putative bindings sites for RBP-Jκ, PU.1, NF-κ  
and c-Myc in EBNA2 target genes
The promoter analysis of EBNA2 induced genes had not revealed a common pattern, 
apart from the presence of the NFAT1 and Oct-1 site common to all promoters. As 
described in the introduction, RBP-Jκ binding sites have been found in all viral 
promoters activated by EBNA2. In contrast, the cellular promoters of EBNA2 target 
genes are far less well characterised. Recently, an intronic silencer has been defined in 
the EBNA2 and Notch target gene CD21 (Makar et al., 1998). Subsequently, it was 
shown that RBP-Jκ binding to this intronic silencer is crucial for its repressive 
function (Makar et al., 1998, Ulgiati and Holers, 2001). Thus, the search for potential 
cis-regulatory elements was extended towards the intron 1 region of these genes. This 
search thus involved DNA fragments ranging between 1.2 and 15 kb in size. Since 
already by random expectation numerous TF binding sites will be found on gene 
fragments of this site, the analysis was limited to a subset of TF sites including RBP-
Jκ, PU.1, NF-κB and c-Myc.
PU.1 was included as studies of the LMP1 promoter had revealed a second, RBP-Jκ 
distinct sequence-specific, DNA-binding protein and transcriptional activator PU.1
important for this promoter (Laux et al., 1994b, Johannsen et al., 1995). Both, LMP1 
and c-myc, are not only EBNA2 target genes, but are also potential partners of 
EBNA2 which might cooperate with EBNA2 and thus enhance EBNA2 functions. 
In the next step, the putative promoter region covering 1000 bp upstream of the 
transcriptional start (TSS), exon 1 and intron 1 of the genes from group I, II and III 
were inspected for the RBP-Jκ, PU.1, NF-κB and c-Myc binding sites. A random 
expectation (RE) values for these TFs are: 0.84 (RBP-Jκ), 0.22 (PU.1), 0.88 (NF-κB)
and 0.92 (c-Myc). While the RE value for PU.1 is low (once per 4545 bp), others have 
a high random occurrence rate. Thus, the occurrence of a site within a relatively large 
sequence can be expected at random and the interpretation of the results can only be 
preliminary.
The search was done by the MatInspector programme (Genomatix Software GmbH, 
Germany). Results are presented schematically in Fig. 13. Interestingly enough, none 
of the analysed genes, except bfl-1, was found to contain an RBP-Jκ binding site in 
the putative promoter region (-1000 region), but they all had at least one RBP-Jκ 
binding site in intron 1. An exception was CD83, which has a very short intron 1 of 
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only 101 bp. Even a more extensive search over 15 kb sequence did not reveal any 
RBP-Jκ binding site in the CD83 gene. A PU.1 binding site appeared in all inspected 
genes except in CD83 and MIP-1 beta. An E-box was found in either the putative 
promoter region or in the intron 1 region of the genes CCR7, bfl-1, CD21 and PLEK. 
The biological relevance of these sites is questionable since it has been shown earlier 
in this work that c-myc does not induce any of these genes. An NF-κB binding site 
has been identified in all genes except in CCR7. Interestingly, the NF-κB binding site 
in c-myc and RDC1 (group I) was found outside the putative promoter region, while 
in other genes it was found within the promoter.
A potential interaction of these TFs within the promoter and/or intronic region and the 
importance of that interaction still remain to be addressed experimentally. 
Figure 14.
Scheme of RBP-Jκ, PU.1, NF-κB and c-Myc binding sites in the putative promoter and the intron 
region of the genes belonging to Group I, II and III.
The putative promoter (-1000 bp), exon 1 and intron 1 regions were screened for the potential RBP-Jκ, 
PU.1, NF-κB and c-Myc binding sites. They were identified by the MatInspector programme, 
Genomatix Software GmbH, Germany.
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2.2 Functional analysis of the TRRAP gene in the context of EBV   
immortalisation
The second goal of this project was the identification and functional analysis of a gene 
which is specifically induced in the context of EBV driven proliferation.
In the ExpressCode™ DNA microarray system described in chapter 2.1.2 TRRAP 
was found as an up-regulated gene after the stimulation of EREB2-5 cells with 
oestrogen. The mechanism of TRRAP activation as well as its function in the context 
of EBV immortalization was studied in the following part of this work since TRRAP 
is a relevant element in processes such as cellular transformation (McMahon et al., 
1998), cell cycle check points (Vassilev et al., 1998, Herceg et al., 2001) and the 
DNA damage response (Brand et al., 2001, Martinez et al., 2001, Ikura et al., 2000). 
TRRAP was first identified by its direct interaction with the transactivation domain of 
c-Myc and it was clearly shown that it is an essential cofactor for c-Myc and E1A-
mediated oncogenic transformation (McMahon et al., 1998). Later it was 
demonstrated that TRRAP is a component of four multiprotein histone 
acetyltransferase (HAT) complexes: TIP60 (Ikura et al., 2000), PCAF (Vassilev et al., 
1998), STAGA (Martinez et al., 2001) and TFTC (Brand at al., 1999). A role for 
TRRAP-HAT complexes in mediating transcriptional activation by c-Myc is 
suggested by several pieces of evidence: TRRAP is recruited to certain c-Myc target 
genes during Myc-dependent activation in vivo and induces a Myc-dependent increase 
in histone H3 and H4 hyperacetylation at the target promoters/regulatory DNA 
regions. The role of TRRAP itself in this process is however not known. So far it 
seems not to have any active catalytical function, but it is rather a scaffold element of 
the HAT complex (McMahon et al., 1998).   
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2.2.1 Induction of TRRAP by EBNA2 requires de novo protein synthesis
The fact that TRRAP has an essential role in the transformation process by c-Myc and 
E1A led to the presumption that the induction of TRRAP by EBV infection could play 
an important role for the EBV induced immortalisation. In order to confirm the 
induction of TRRAP, demonstrated previously by the ExpressCode™ DNA 
microarray, growth arrested EREB2-5 cells were stimulated by oestrogen during a 
kinetic similar to the one used in the microarray screen. The RNA abundance was 
monitored during a time course of 24 hours. cDNA was quantified by real time PCR 
following reverse transcription (RT) or the Northern blot analysis (Fig. 13A). The 
level of TRRAP mRNA increases relatively slowly with a significant leap 6 hours 
after EBNA2 had been activated. The maximal peak of approximately 25-fold 
induction is reached 12 hours post-oestrogen stimulation. Well known EBNA2 direct 
target genes, c-myc and LMP1, reach the maximal intensity approximately three 
hours earlier. This kind of induction kinetic therefore indicates that TRRAP is one of 
the secondary EBNA2 target genes. 
To address this question, the abundance of TRRAP mRNA was monitored in the 
presence of the protein synthesis inhibitor cycloheximide (Fig. 13B). Growth arrested 
EREB2-5 cells were cultured for six hours in medium containing oestrogen, 
cycloheximide or both cycloheximide and oestrogen. The TRRAP mRNA expression 
was quantified by real time RT-PCR. Cells stimulated with oestrogen for 6 hours 
induced TRRAP approximately 3-fold. Cells treated with cycloheximide only did not 
raise the TRRAP mRNA abundance above the basal level of the growth arrested cells. 
The activation of EBNA2 in the presence of cycloheximide failed to significantly 
induce TRRAP mRNA. This doubtlessly shows the existence of another (or more then 
one) protein downstream of EBNA2 in the cascade governed by EBNA2 which is 
required to activate TRRAP induction. 
These data confirmed TRRAP induction observed in the ExpressCode™ DNA 
microarray. Further, they show that TRRAP is a secondary target gene of EBNA2 not 
induced in the absence of de novo protein synthesis.
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Figure 15.
TRRAP induction in the EREB2-5 cells. 
EREB2-5 cells were transiently deprived from oestrogen and 72 hours later were stimulated by the 
addition of oestrogen (1µM) (A and B) and/or cycloheximide (50 µg/ml) (C). Total RNA was isolated 
at the given time points. 2 µg of RNA were subjected to reverse transcription. cDNA was quantified 
using real time PCR with TRRAP and GAPDH specific primers (A and C). Raw data were normalised 
versus GAPDH mRNA level and fold induction is shown. For the Northern blot analysis (B) 10 µg of 
total RNA were loaded on a 0.6 %-denaturing agarose gel and blotted for 48 hours to the nylon 
membrane. Membrane was subsequently hybridised with a DIG-labelled TRRAP specific probe. 
Ethidium bromide staining of rRNA is shown as a loading control for each lane.
2.2.2 Potential links between EBNA2 and TRRAP: LMP1 and c-myc
Since EBNA2 did not transactivate TRRAP directly the potential link between these 
two genes had been searched. LMP1 and c-myc are the primary EBNA2 target genes 
(Kaiser et al., 1999). Both are able to activate the transcription of other secondary 
genes. Therefore, LMP1, further viral genes and c-Myc were tested as potential 
mediators in TRRAP induction.
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2.2.2.1 The latent membrane protein 1 (LMP1), a viral EBNA2 target gene, does 
not induce TRRAP
LMP1 mimics a constitutively activated receptor of the tumour necrosis factor 
receptor family (Gires et al., 1997, Eliopoulus et al., 1998) and shares functional 
similarities to CD40 signalling (Zimber-Strobl et al., 1996, Kilger et al., 1998, Uchida 
et al., 1999). It activates four signal transduction pathways: NF-κB (Huen et al., 1995, 
Mitchell et al., 1995), p38 MAPK (Eliopolus et al, 1999, Vockerodt et al., 2001), 
STAT (Gires et al., 1990) and JNK1/AP1 (Kieser et al., 1997, Kieser et al., 1999). In 
order to address whether LMP1 was responsible for TRRAP induction, two 
complementary cell lines, conditional for LMP1 expression were used: 1852.4 and 
1194-3.
Mini-EBV contains all EBV elements necessary for B cell immortalisation. In 1852.4 
cells (Kilger et al., 1998) the LMP1 gene is substituted with an LMP1 gene under the 
control of a conditional, artificial promoter which contains 10 copies of the tet 
operator (tetO) permitting a selective repression or activation of LMP1 transcription 
depending on the absence or the presence of tetracycline in the culture medium, 
respectively. However, this modification does not affect the expression of other viral 
genes. Cells which do not express LMP1 or express a very low level of LMP1 upon 
tetracycline deprivation cease to proliferate, but survive in a resting state. Upon re-
induction of LMP1 by addition of tetracycline, B cells return to normal proliferation. 
Published data (Kilger et al., 1998) indicate that it is not possible to obtain a state of 
cells where LMP1 is absolutely shut off, but is expressed at considerably lower level 
than in normal EBV-immortalised cell. In order to prevent expression of LMP1 by 
residual tetracycline in foetal calf serum, which is a common constituent of the 
complete culture medium, a tetracycline-free approved foetal calf serum was used. By 
doing so, LMP1 mRNA could not be detected even after longer exposure (Fig. 14A). 
Thus it can be presumed that LMP1 was not expressed under these specific culture 
conditions. To test whether TRRAP induction in these cells depends on LMP1, cells 
were cultured in the presence of tetracycline or in the tetracycline-free medium for 
three days. TRRAP mRNA abundance was measured by real time RT-PCR. As shown 
in Fig. 14B there is no difference in TRRAP expression regardless whether LMP1 is 
induced or not. These result shows that LMP1 is not sufficient to super-induce 
TRRAP.
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1194-3 cells were established (Zimber-Strobl et al., 1996) by infection of B cells with 
a mini-EBV carrying the ER/EBNA2 chimeric gene and a constitutive SV40-
promoter driven LMP1 gene. Thus, in the 1194-3 cells LMP1 is expressed in the 
absence of functional EBNA2. The TRRAP mRNA level was analysed in the 
presence or absence of oestrogen. These data show that the TRRAP mRNA 
abundance increases over time after ER/EBNA2 activation in a similar manner as 
detected in EREB2-5 cells. This finding indicates that LMP1 expression is not 
sufficient to maintain TRRAP at increased level in the absence of EBNA2.
Taken together, this data show that TRRAP induction is not caused by LMP1.
Figure 16.
TRRAP is not induced by LMP1.
In two complementary cell lines it has been shown that LMP1 has no influence on TRRAP induction. 
(A and B) 1852.4 cells were cultured in the presence (w) or absence (w/o) of tetracycline (Tet) 
regulated LMP1 for three days. (A) 10 µg of total RNA were used for the Northern blot analysis and 
probed with DIG-labelled LMP1 specific probe. The data show that LMP1 expression is tightly 
controlled by Tet. The loading of samples was controlled by ethidium bromide (EtBr) staining. (B) 2 
µg of total RNA used in (A) were subjected to real time RT-PCR for the quantification of TRRAP 
mRNA using TRRAP specific primers. Raw data were normalised versus GAPDH expression and are 
presented. (C) The cell line 1194-3 constitutively expresses LMP1 and ER/EBNA2. Oestrogen 
deprived cells were growth arrested for 3 days and then stimulated with oestrogen for the indicated 
time. Total RNA was isolated and 2 µg of RNA were subjected to real time RT-PCR with TRRAP 
specific primers. Raw data were normalised versus GAPDH expression and fold induction is shown.    
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2.2.2.2 Viral genes are dispensable for TRRAP induction
Apart from transactivating cellular genes, EBNA2 activates the transcription of the 
LMP1 and LMP2 genes and initiates the transcription from the C promoter of the viral 
EBNA3 genes. In the previous section it was shown that LMP1 on its own cannot 
induce TRRAP expression. Next examined was the impact of viral genes on TRRAP 
induction by EBNA2. The B cell lymphomas BL41 and BJAB transfected with a 
mini-EBV plasmid carrying the chimeric ER/EBNA2 gene were used in order to gain 
cell lines expressing EBNA2 only (BL41-K3 and BJAB-K3) (Kempkes et al., 1995b, 
Kempkes et al., 1996). In addition, the P3HR1 convertants of BL41 and BJAB 
transfected with ER/EBNA2 construct (BL41-P3-9A and BJAB-P3-B6) (Kempkes et 
al., 1995b, Kempkes et al., 1996) were used to analyse the induction of TRRAP in the 
genetic background of virus. EBNA2 was fused to the oestrogen receptor domain and 
hence was functionally dependent on the presence of oestrogen in the medium. Cells 
were stimulated with oestrogen and harvested at time points indicated in Fig. 15. It is 
shown that in BL41-K3 and BJAB-K3 cells EBNA2 per se is already sufficient to 
induce TRRAP up to 3-4-fold (Fig. 15A and B). Latent viral proteins amplify TRRAP 
mRNA abundance up to two fold above the level seen in BL41-K3 and BJAB-K3 
(Fig. 15C and D). 
This finding indicates that viral genes are dispensable for TRRAP induction although 
they facilitate, in an unknown manner, TRRAP induction.
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Figure 17.
Viral genes are dispensable for TRRAP induction, but enhance the rate of induction.
BL41-K3 (A), BL41-P3-9A (C), BJAB-K3 (B) and BJAB-P3-B6 (D) cells were stimulated with 
oestrogen (1 µM) and harvested at the indicated time points post-oestrogen stimulation. Total RNA 
was isolated and 2 µg were subjected to real time RT-PCR analysis using TRRAP and GAPDH 
specific primers in order to determine the TRRAP mRNA level. Raw real time PCR data were 
normalised versus GAPDH mRNA level and fold induction is presented. 
2.2.2.3 c-Myc, a cellular EBNA2 target, does not induce TRRAP
c-Myc is a transcription factor which acts as a key inducer of genes involved in 
cellular growth and proliferation, transformation and apoptosis (reviewed in Dang et 
al., 1999). It has been shown that c-myc is a primary target gene of EBNA2 (Kaiser et 
al., 1999). Therefore, next to be tested was whether c-Myc acts as a link between 
EBNA2 and TRRAP induction. In order to address this question, TRRAP induction in 
the P493-6 cell line was monitored. 
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The B-cell line P493-6 (described in Pajic et al., 2000) is an EREB2-5 transfectant 
conditionally expressing c-myc gene which can be switched off and on depending on 
the presence or the absence of tetracycline, respectively. As described earlier, the 
P493-6 cell line can grow in two phenotypically different programmes: (i) c-myc 
driven growth programme in the absence of both oestrogen and tetracycline (EBNA2 
off/c-myc on) and (ii) EBV/EBNA2-driven growth programme in the presence of 
oestrogen and tetracycline (EBNA2 on/c-myc off). In order to achieve a growth 
arrested state of the cells a tetracycline was added to the culture medium for the time 
period of three days. To re-activate the cells the tetracycline was removed from the 
cell culture and they were either stimulated with oestrogen and tetracycline (EBNA2 
on/c-myc off) or cultured in complete medium (EBNA2 off/c-myc on). 
Since P493-6 cell line had been established, the time required for the entrance of the 
cells from the arrested state into the S phase depending on the two different growth 
programmes had never been defined. EBNA2 and c-Myc are activated through 
different mechanisms in this cell line. EBNA2 is fused to the oestrogen receptor (ER) 
domain. In the absence of oestrogen in the medium, the ER/EBNA2 fusion protein is 
bound to Hsp90 which prevents a proper conformation of this fusion protein and 
dwells it in the cytoplasm. Upon addition of oestrogen to the cell culture, the fusion 
protein readily undergoes conformational changes, enters the nucleus and 
subsequently acts as a transactivator. In contrast to EBNA2, which is constantly 
present as a protein either in the cytoplasm or in the nucleus, c-myc is transcribed not 
before the addition of tetracycline. Thus, the EBV/EBNA2 driven growth programme 
is one step ahead of the c-Myc driven growth programme.
To be sure which time points can be compared during TRRAP induction by the 
EBV/EBNA2 and c-Myc growth programmes, a BrdU incorporation assay was 
performed as a measure of cell entry into the S-phase. Fig. 16 shows that the cells 
grown in the c-Myc programme initiate DNA synthesis 18 hours post-Tet stimulation. 
That is approximately 6 hours later than it is the case for cells grown in the EBNA2 
programme. Since the S phase entry occurs with a significant delay in the c-Myc 
driven P493-6 cells, all further experiments were performed in the time course of a 
complete cell cycle.
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Figure 18.
ER/EBNA2 initiates DNA synthesis more rapidly than Tet-regulated c-myc. 
Proliferating P493-6 cells were growth arrested by addition of tetracycline for 72 hours. Cells were 
washed with PBS/10% FCS three times in order to remove traces of tetracycline and seeded in either 
free medium or in medium supplemented with oestrogen and tetracycline. The BrdU incorporation 
assay was used in order to determine the initiation of DNA synthesis for two growth programmes: c-
Myc (♦) or EBV/EBNA2 (■). Cells were seeded in triplicates in 96-well plate at a density of 5x104 
cells per well and incubated with BrdU for four hours. After incubation with peroxidase-labeled anti-
BrdU antibody and the addition of the ABTS-substrate the extinction was measured at 405 nm. Three 
independent experiments were done. Data from one representative experiment are shown.
The TRRAP mRNA abundance at different time points after re-activation of P493-6 
cells was quantified by real-time PCR (Fig. 17). Cells proliferating in the 
EBV/EBNA2 driven growth programme increase the level of TRRAP up to 5 fold 
with the peak at 12 hours, thus TRRAP accumulates before S phase entry. In 
comparison, cells proliferating in the c-Myc driven programme do not change the 
level of TRRAP during the whole time course even though time points later than 24 
hours were tested. Differential expression of TRRAP is maintained in the proliferating 
P493-6 cells driven by both growth programmes as confirmed by the Western blot 
analysis (Fig. 17B). These results clearly show that c-Myc does not induce TRRAP, 
while EBNA2 does.
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Figure 19.
c-Myc does not induce TRRAP.
P493-6 cells were growth arrested by addition of tetracycline for 72 hours and then washed with 
PBS/10% FCS three times to remove traces of tetracycline. Cells were seeded in either free medium or 
in medium supplemented with oestrogen and tetracycline and harvested at indicated time points. (A) 
Total RNA was isolated and 2 µg were subjected to reverse transcription. TRRAP and GAPDH mRNA
abundance was quantified in real time RT-PCR with TRRAP and GAPDH specific primers. Raw data 
for TRRAP were normalised versus GAPDH and fold induction is presented. (B) Western blot analysis 
of TRRAP expression in proliferating P493-6 cells grown in either of the two growth programmes. 
Proteins were extracted with buffer containing 1 % NP-40 detergent and 80 µg of proteins was
separated on 8% SDS/PAGE. The immunostaining of TRRAP was performed using primary rabitt anti-
TRRAP monoclonal antibody (Serotec, UK). As secondary antibody an anti-rabitt IgG HRP-
conjugated antibody was used (Promega, USA). 
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2.2.3 TRRAP is induced in primary B cells upon EBV infection, but not in B cells 
stimulated with CD40L and IL-4
All data so far presented were obtained examining different cell lines in which 
EBNA2 had been activated by oestrogen. Thus, it could not be excluded that TRRAP 
induction was somehow linked to oestrogen in the cell culture medium. To test 
whether TRRAP induction is an event that occurs under the physiological conditions 
of EBV infection, and is neither an artefact of cell lines kept in culture for longer 
period or cell proliferation itself, nor that TRRAP was induced by the oestrogen 
receptor domain stimulated by oestrogen, the following experiments were performed. 
Primary B cells were infected with B95.8 EBV and TRRAP induction was compared 
to B cells activated with CD40 ligand (CD40L) plus interleukin-4 (IL-4). Cross-
linking of CD40 with immobilised CD40 specific antibodies or fibroblast feeder cells 
expressing CD40L (CD40L cells) induces B cells proliferation in vitro. The addition 
of IL-4 or IL-13 allows the generation of factor-dependent long-term normal human B 
cells lines (reviewed in Banchereau et al., 1994).
Human tonsillar B cells were separated from the rest of tonsillar cells by rosseting 
with sheep red blood cells. The final cell suspension consisting of more than 96% 
CD19+ B cells was cultured on irradiated CD40L cells (Garrone et al., 1995) in the 
presence of IL-4 (100 U/ml). In parallel, the same number of cells was infected with 
B95.8 EBV. Cells without any stimuli were cultured as a negative control. 
PCR following the reverse transcription of total RNA isolated from the cultured 
primary B cells shows that the outgrowth of primary B cells was not caused by the 
EBV already residing in the B cells prior cultivation (shown in Fig. 18 by 
amplification of LMP1 genomic DNA and mRNA). Only cells infected with EBV 
show the induction of LMP1 on day 3 post-infection. The LMP1 genomic DNA was 
readily detected already 24 hours post-infection. Cells cultured with either no stimuli 
or stimulated with CD40L/IL-4 clearly show absence of LMP1 expression once more 
confirming the negative EBV status of the cultured cells.  
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Figure 20.
EBV status of the cultured primary B cells.
Total RNA was isolated from human tonsillar B cells stimulated with either B95.8 EBV, CD40L/IL-4 
or cultured with no stimuli for ten days as well as from cells prior stimulation (day 0). 2 µg of total 
RNA were used to make cDNA. PCR with LMP1 specific primers gave two fragments (upper panel): a 
larger one (625 bp) which corresponds to the amplified genomic fragment and a smaller one (246 bp) 
which corresponds to the amplified cDNA fragment of LMP1. GAPDH was amplified as an input 
control (lower panel).
As expected, cells were able to incorporate 3H-thymidine and proliferate (Fig. 19A 
and B, respectively) if stimulated with CD40L/IL-4 or infected with the virus. In 
contrast, cells kept in culture without stimuli were detained from dying until day 5, 
but then they died extensively. CD40L/IL-4 stimulation resulted in fast incorporation 
of 3H-thymidine in the first 48 hours followed by the outgrowth of B cell clones with 
an increased cell size. The level of 3H-thymidine incorporation then declined and 
from day 5 onwards was kept at the same level. Since the cells were constantly kept 
on the CD40L feeder layer and stimulated with IL-4, this decrease of 3H-thymidine 
incorporation is probably due to the discontinuance of the synchronous cell culture. In 
comparison to that cell number and 3H-thymidine uptake in cells infected with B95.8 
EBV was delayed for approximately three days (Fig. 19A and B, respectively), but 
then it attained the level of CD40L/IL-4 stimulated cells. This delay can be explained 
by the different mechanisms of B cell activation. CD40L and IL-4 are readily 
accessible to B cells and cause the immediate activation of the signal transduction 
machinery. In contrast to that, EBV infection is a multi-step process which 
subsequently leads to B cell transformation. 
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Figure 21.
Growth characteristics of primary B cells stimulated with different stimuli.
Purified B cells (>96% CD19+) were cultured at a density of 2,5x106 cells/well in 6-well plates for up 
to 10 days with different stimuli: no stimuli (♦), cells grown on irradiated CD40L cells plus IL-4 (100 
U/ml) (■) or infected with B95.8 EBV (▲). (A) Cells (1.5 x 105/well in 96-well plates) were pulsed
with 3H-thymidine every 24 hours for 4 hours and the incorporation of 3H-thymidine was measured. 
(B) Cells were counted every 24 hours. Dead cells were excluded by tryphan blue exclusion and the 
number of viable cells is shown.
TRRAP induction was monitored in the cultured B cells in the time intervals of 24 
hours during the course of ten days (Fig. 20A). The TRRAP transcripts were detected 
under all conditions, but the abundance was selectively increased in the EBV infected 
cells. In contrast, in cells without any stimuli or in CD40L/IL-4 stimulated cells the 
TRRAP mRNA abundance did not change beyond the initial basal level. To control 
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the efficiency of B cell activation by CD40/IL-4, c-myc induction was monitored by 
real time RT-PCR (Fig. 20B). The c-myc transcript was induced in both cells 
stimulated with CD40L/IL-4 and infected with B95.8, but at different time points. B 
cells stimulated with CD40L/IL-4 strongly induce c-myc after 5 days while EBV 
infected B cells reach the same level of c-myc expression 8 days after infection. A 
delay of three days in c-myc induction in B95.8 infected B cells coincides with the 
delay in the kinetic of 3H-thymidine incorporation. This delay in c-myc induction in 
EBV infected B cells happens perhaps due to the mechanism of activation discussed
above. c-myc induction was absent in the cells cultured without external stimuli. 
Figure 22.
B-cells infected with B95.8 EBV induce both TRRAP and c-myc, but if stimulated with 
CD40L/IL-4 only c-myc is induced.
The purified tonsillar B cells (>96% CD19+) were cultured in 6-well plates (2.5 x 106 cells/well, 1 x 
106 cells/ml). Every 24 hours cells were harvested. The total RNA was isolated and 2 µg were
subjected to reverse transcription. TRRAP (A) and c-myc (B) mRNA level was quantified using real 
time PCR with TRRAP and c-myc specific primers, respectively. Raw data from were normalised with 
28 S rRNA quantified in the Northern blot analysis.
In summary, TRRAP was detected in all cells irrespective of the growth state. 
However, the induction of TRRAP above basal level was observed only in the context 
of EBV/EBNA2 driven proliferation and precedes or coincides with S phase entry. 
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2.2.4 A vector system for expression of TRRAP specific short interfering RNA 
To test whether the TRRAP protein is rate limiting for the viability of EBV 
immortalised B cells, TRRAP gene expression was inhibited in 721 EBV-positive 
LCL by employing a vector-based expression system to produce endogenous, 
functional short interfering RNA (siRNA) molecules. 
The introduction of double-stranded siRNA has proven to be a powerful tool to 
suppress (knock-down) the expression of a given gene through a process known as 
RNA interference (RNAi) (Sharp, 1999, Elbashir et al., 2001). Nowadays, there are 
several ways of introducing an siRNA for a targeted gene into the cell. While some 
adherent cell cultures can be transfected with efficiencies reaching almost 100 % of 
cells, transfection efficiencies in suspension cultures typically do not exceed 50 % of 
the cells. In general, the transfection efficiencies of LCLs are in the range of 5-15 %. 
In order to monitor the biological effect of negative regulation of a factor within a 
heterogeneous population of transfected and untransfected cells an efficient selection 
procedure is required. Therefore, a vector system (a gift from B. Jungnickel) carrying 
siRNA sequence specific for the targeted gene under the transcriptional control of the 
U6 promoter and subsequently the selection of transfected cells according to the nerve 
growth factor receptor (NGFR) expressed at the cell surface was used (Fig. 21A). 
The U6 RNA polymerase III promoter appeared to be a convenient tool for an siRNA 
expression because of the following reasons. It produces a small RNA lacking a 
polyadenosine tail. It has a well-defined start of transcription and a termination signal 
consisting of five thymidines in a row. Most importantly, the cleavage of the 
transcript at the termination site is after the second uridine yielding a transcript 
resembling the ends of synthetic siRNAs, which also contain two 3’ overhanging U 
nucleotides (Fig. 21B). These 3’ overhangs seems to be essential for functionality of 
siRNA (Elbashir et al., 2001).
Immediately downstream from the U6 promoter a 53-nt oligo was inserted (Fig 21C). 
Within this 53-nt oligo, the 19-nt target sequence derived from the TRRAP transcript 
(position 282-300) was included in both sense and antisense orientation, separated by 
an 8-nt spacer sequence. A 19-nt target sequence design is critical and was done by 
the software tool provided on the web page www.oligoengine.com. The design 
strategy of this programme includes some basic rules for siRNA design such as: at lest 
30 % of sequence should be G or C, the sequence must not contain a stretch of four or 
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more A or T (this would lead to premature termination of the transcript) and the 
sequence should be positioned not closer then 100 bases downstream from the start 
codon. A selected siRNA sequence was also submitted to a BLAST search against the 
human genome sequence to ensure that only one gene of the human genome was 
targeted. An alternative sequence was designed by introducing a single nucleotide 
mismatch in the middle of the targeting sequence (Fig. 21C). It was shown that a 
single nucleotide mismatch abrogates the ability to suppress gene expression 
(Brummelkamp et al., 2002). This construct along with the vector containing only 
NGFR was used as negative control in the following experiments. The resulting 
transcript from the U6 promoter followed by the insert sequence is predicted to fold 
back on itself to form the 19-base pair stem-loop structure (Fig. 21B). This stem-loop 
precursor is a substrate for the enzyme Dicer, which cleaves the hairpin to generate 
the short dsRNA which function as siRNA. 
NGFR cloned in this vector expresses a truncated NGFR protein containing only a 
transmembrane part while the cytoplasmic part is missing. Thus, this form of NGFR 
is not able to activate signalling and does not have any biological effect on the cell 
expressing it. NGFR was used solely to permit the selection of transfected cells from 
those which were not transfeced. The NFGR specific monoclonal antibody recognizes 
the transmembrane part of NGFR and was used for positive selection on magnetic 
beads.
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Figure 23.
Schematic structure of the components of the siRNA expression vector system.
(A) Schematic presentation of the anti-TRRAP siRNA expression vector. (PuroR=puromycin 
resistance gene, EBNA1=Epstein-Barr nuclear antigen 1, oriP=EBNA1-dependent origin of replication, 
ampR=ampicilin resistance gene). (B) The stem-loop precursor transcript is quickly cleaved in the cell 
by the cellular protein Dicer to produce functional siRNA. The Dicer cleavage sites are marked by
arrows. (C) Sequence of the 53-nt oligo insert containing the sense and antisense target sequence for 
TRRAP mRNA separated by the 8-nt spacer sequence. MS537 represents the functional oligo while 
MS537/mm represents a sequence which is a non-functional siRNA due a single mismatch mutation
(mm) in the central part of the 19-nt sequence (squared nucleotides).
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2.2.5 Transfection and selection of 721 cells expressing siRNA specific for 
TRRAP
Cells were transfected with pMS537 (TRRAP specific siRNA expression vector, 
shown in Fig. 21A), pMS537/mm (TRRAP specific siRNA expression vector with the 
mismatch mutation (mm) in the central part of siRNA sequence as indicated in Fig. 
21C) or pBJ3 (empty vector containing NGFR cassette only). Twelve hours post-
transfection cells were further analysed. A scheme of the procedure is presented in 
Fig. 22. 
Figure 24.
Scheme of analyses done with the purpose to analyse a significance of TRRAP in EBV-positive 
721 cells (see text below for details). 
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Cells were analysed by flow cytometry in order to determine the proportion of NGFR 
positive cells. Subsequently, the cells were subjected to MicroBeads assisted cell 
sorting (MACS). Cells were labelled with monoclonal mouse anti-NGFR antibody 
and positively selected by magnetic beads coated with goat anti-mouse IgG 
antibodies. The purity of selected cells was analysed by flow cytometry with the 
NGFR antibodies. The rest of the cells were used for the isolation of total RNA, the 
analysis of cell cycle by propidium iodide staining or for the analysis of the cell 
competence to synthesize DNA. 
A striking finding of the flow cytometry analysis performed 12 hours post-
transfection was that transfection with the construct carrying a TRRAP specific 
siRNA sequence (pMS537) resulted in only 0.33 % of cells positive for NGFR. In 
contrast, cells transfected with either a mutated anti-TRRAP construct (pMS537/mm) 
or an empty vector (pBJ3) showed a significantly higher proportion of NGFR-positive 
cells, 5.4 and 4.8 %, respectively. Another striking result was obtained by the analysis 
of sorted NGFR-positive cells. Approximately 45 % of selected NGFR positive cells 
transfected with pMS537 were shown to be dead by tryphan blue exclusion. For cells 
transfected with pMS537/mm or pBJ3 by the same method only 1-2 % of the NGFR 
positive cells scored as being dead in the tryphan blue assay. This indicates that the 
low number of cells in the NGFR positive fraction of MS537 transfected cells was not 
due to the irregularities during transfection process or the unspecific toxicity of the 
vector, but rather due to a cell death which was an ongoing process in these cells. 
The total RNA was isolated from both NGFR-positive and NGFR-negative fractions 
of the cells after cell sorting. The level of TRRAP mRNA was monitored by semi-
quantitative RT-PCR (Fig. 23). It is clearly shown that TRRAP mRNA is expressed in 
all NGFR-negative cells and also in NGFR-positive cells carrying pMS537/mm or an 
empty vector pBJ3. In contrast, only very low amounts of TRRAP cDNA were 
amplified in the NGFR-positive cells carrying pMS537 construct. This clearly 
demonstrates that a period as short as 12 hours is sufficient for the activation of 
transcription of TRRAP specific siRNA and subsequent down-regulation of TRRAP 
mRNA.
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Figure 25.
TRRAP mRNA is knocked down in cells transfected with the specific siRNA.
The 721 cells transfected with pMS537 (anti-TRRAP siRNA construct), pMS537/mm (anti-TRRAP 
siRNA construct with missense mutation) or pBJ3 (empty vector with NGFR cassette) were labelled 
with the monoclonal mouse anti-NGFR antibody and sorted by anti-mouse IgG magnetic beads. RNA 
isolated from the NGFR-negative (-) and NGFR-positive (+) fractions after sorting and non-transfected 
721 cells was subjected to reverse transcription and subsequently to PCR with TRRAP specific primers
(upper panel). PCR products were loaded on the 1.5 %-agarose gel. Water was used instead of cDNA 
as negative control and previously PCR amplified TRRAP cDNA as positive control. The equal 
amount of RNA used for reverse transcription is controlled by PCR with GAPDH specific primers 
(lower panel). 
In summary, the TRRAP mRNA abundance was significantly knocked-down. This 
process is immediately accompanied by cell death of a major proportion of the 
cultured cells. 
2.2.6 DNA replication and cell cycle stage distribution of TRRAP siRNA 
expressing 721 cells
NGFR-positive cells transfected with pMS537, pMS537/mm and pBJ3 were tested for 
DNA replication by the 3H-thymidine incorporation assay. Fig. 24 demonstrates that 
pMS537 transfected cells do not incorporate 3H-thymidine significantly. In contrast, 
pMS537/mm and pBJ3 transfected cells behave very similar to untransfected 
proliferating 721 cells. In fact, MS537/mm and pBJ3 transfected cells incorporate 
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about 5-10% less 3H-thymidine than control cells. The minor decrease of 3H-
thymidine incorporation could be the consequence of either transfection or sorting 
process.
Figure 26.
TRRAP is rate limiting for DNA replication in 721 cells.
721 cells were transfected with pMS537 (anti-TRRAP siRNA construct), pMS537/mm (anti-TRRAP 
siRNA construct with missense mutation) or pBJ3 (empty vector with NGFR cassette). Twelve hours 
post-transfection cells were labelled with a mouse anti-NGFR antibody and sorted on anti-mouse IgG 
magnetic beads. Twelve and 36 hours after sorting 3 x 104 viable cells were pulsed for 4 hours with 
3H-thymidine and the incorporation was measured. Untransfected, proliferating 721 cells were used as 
a measure of normal DNA synthesis. 
For cell cycle analysis NGFR positive cells were ethanol fixed and the DNA cell 
content was determined by flow cytometry after propidium iodide staining (Fig 25). 
Apoptotic cells were quantified as the percentage of cells with hypodiploid DNA 
content. Fig 25 shows that apoptosis was more pronounced in pMS537 transfected 
cells (39.17 %) compared with cells which were transfected with pMS537/mm, pBJ3 
or untransfected cells which thus have normal levels of TRRAP (18.91, 14.91 or 
17.22%, respectively). There was also a clear decline in the number of G1 phase cells 
in TRRAP knocked-down cells. However, the proportions of S phase and G2/M phase 
cells were essentially the same for all tested cell samples. Since it was shown before 
that pMS537 transfected cells incorporate 3H-thymidine only at a very low level, it is 
unlikely that the cells identified by this assay indeed are in the replicative phase of 
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cell cycle DNA. In contrast, they might reflect a population of cells which either 
ceased to replicate DNA or apoptosed in G2/M phase. 
Figure 27.
TRRAP knocked-down cells show pronounced apoptosis and decrease in the G1 phase cell 
number.
The 721 cells transfected with pMS537 (TRRAP specific siRNA construct), pMS537/mm (TRRAP
specific siRNA construct with missense mutation) or pBJ3 (empty vector with NGFR cassette) were 
labelled with mouse anti-NGFR antibodies and sorted on anti-mouse IgG magnetic beads. Sorted cells 
and untransfected 721 cells were immediately ethanol fixed and subsequently stained with propidium 
iodide and analysed by flow cytometry. The cell cycle profiles were generated by plotting cell number 
(Y-axis) against DNA content (X-axis). The regions mark the populations with sub G1 DNA content, 
cells with G1 DNA content, cells in the apparent S or G2/M phases of cell cycle.
These data strongly suggest that TRRAP expression is intimately involved in the cell 
cycle regulation and EBV immortalised B cells require TRRAP function for viability 
and cell cycle progression. 
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3.0. Discussion
Molecular and genetic analyses indicate that EBNA2 is essential for EBV-mediated B 
cell immortalisation (Hammerschmidt and Sugden, 1989, Cohen et al., 1989). The 
present study was undertaken to elucidate the mechanism of transactivation of cellular 
genes by EBNA2, a process which cannot be separated from the transformation 
function of this gene (Cohen et al., 1991). During the first part of this work, a 
comprehensive screen was performed aiming at the identification of EBNA2/EBV 
target genes activated in EBV immortalized B-cells. Three different techniques, 
differing in various technical aspects, were used to monitor changes in steady state 
RNA levels upon EBNA2 activation. In addition, a subset of genes was screened for 
the activation of run-on transcription in order to monitor transcriptional activation 
more directly. During the second part of this study, a single gene TRRAP, shown to 
be induced by the EBV/EBNA2 growth programme, was chosen for further functional 
analysis.
3.1 A comprehensive screen for EBNA2 target genes
Three different cellular systems were used in order to identify the target genes, and 
thus to define viral and cellular pathways which contribute to target gene activation.
EREB2-5, a lymphoblastoid cell line, is strictly dependent on the presence of 
oestrogen in the cell culture medium. Upon activation by oestrogen, EBNA2 induces 
a cascade of primary and secondary viral and cellular target genes, which initiate a 
physiological growth programme similar to B-cell activation. The advantage of the 
EREB2-5 system is that very early events can be monitored. In addition, the 
activation of EBNA2 can be performed in the absence of de novo protein synthesis, 
thus primary and secondary target genes can be distinguished by adding the protein 
synthesis inhibitor cycloheximide to the culture medium. It was important to identify 
a set of primary EBNA2 target genes, since only this set can be expected to be 
induced by similar mechanisms and thus, would reveal common cis-acting regulatory 
elements. However, since it is known that cycloheximide per se can also influence the 
steady state levels of RNA, the cycloheximide approach could not be used during the 
initial screening process, but rather later in the individual Northern blot experiments.
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The P493-6 cell line is an EREB2-5 derivative, expressing a tetracycline regulated c-
myc gene. P493-6 can switch between two growth programmes in which proliferation 
is either driven by either the c-Myc protein or the EBV/EBNA2 pathway. Thus, this 
cell line can be used to identify target genes specifically activated by the 
EBV/EBNA2 pathway. Target genes belonging to this pathway, irrespective of the 
activating mechanisms involved, might support the proliferation of EBV immortalized 
B-cells and therefore are interesting candidates for therapeutic intervention in the 
EBV associated malignancies.
BL41-K3 cells are stable transfectants of the EBV negative Burkitt’s lymphoma cell 
line BL41 and express a conditional ER/EBNA2 protein. This cell line served as a 
tool in order to identify the subset of the EBNA2/EBV target genes which can be 
activated by EBNA2 in the absence of other viral proteins. In contrast to the 
experiments done with EREB2-5 in the presence of cycloheximide, in the BL41-K3 
experiments de novo protein synthesis is permitted. Thus target genes identified in 
this system can either be secondary target genes induced by primary cellular target 
genes or primary target genes induced by EBNA2 in cooperation with cellular 
proteins. 
As described in the Results section, three independent screens, performed in order to 
identify EBNA2 activated genes, differed in several technical features: (i) the nature 
of the arrayed material, (ii) the handling and labelling of one or more probes which 
are hybridised to the microarray and (iii) the detection system as well as algorithms 
used for data analysis. As summarised in Fig. 5 (Results, chapter 2.1.5) these three 
methods show a lot of diversities in every aspect mentioned above. 
A comparison of all data revealed a surprisingly divergent set of EBNA2 induced 
genes in EREB2-5 cells two hours post-oestrogen stimulation. By criteria that any 
gene that is induce at least twofold (ExpressCode™ and lymphochip) or 1.4-fold 
(GeneChip®) is considered as an up-regulated gene, a relatively high number of 
genes were identified: on ExpressCode™ a total number of 52 genes, on lymphochip 
94 genes and in GeneChip® 205 genes were found to be up-regulated. Surprisingly, 
only three genes were found to be up-regulated in all three screens: c-myc, RDC1 and 
CD83. The subsequent re-evaluation of target genes by the Northern blot analysis or 
nuclear run-on revealed that the rate of false positives within selected target gene is 
low. These results indicate that the limited set of genes found induced in all three 
settings was not due to the fact that false positive results had been generated. The 
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differences were rather due to variations in template dependent sensitivity towards 
different labelling techniques as well as variations and, the dynamic range and the 
detection limits of the different techniques. To demonstrate this, the relative induction 
levels of c-myc, RDC1 and CCR7 in the different screens are summarised in Table 
11. At lest for these three genes the ExpressCode™ system appeared to be the most 
sensitive, followed by lymphochip and GeneChip®.
Table 11.
Sensitivity of different DNA microarray techniques.
The relative induction rates of the c-myc, RDC1 and CD83 RNA are shown for ExpressCode™, 
lymphochip and GeneChip at 2 hours post-oestrogen stimulation in EREB2-5. If the gene was present 
more then once on the microarray all values are shown. The GeneChip® experiments were done four 
times and all four values are shown
Gene ExpressCode™ lymphochip GeneChip®
c-myc 109.3 10.4/7.4 1.4/2.2/2.1/5.0
RDC1 722.3 2.2 2.7/8.7/2.4/2.8
CD83 238.0 2.1 3.3/2.2/1.3/1.3
3.2 Evaluation of the DNA microarray data by the nuclear run-on and
Northern blot analyses
Since the molecular probes for the genes identified by the ExpressCode™ were 
available, a “self-made” array was generated. This “self-made” arrays contained PCR 
products representing 40 up-regulated genes in the proliferating cells tested on both 
ExpressCode™ and GeneChip®. In addition, PCR products for 14 genes up-regulated 
in lymphochip and Gene Chip® were generated by the amplification of gene 
fragments cloned into the plasmid vectors, and were spotted on the membrane. A 
secondary screen using a nuclear run-on technique was performed for the P493-6 cells 
growing in two different growth programmes. By this experiment, the target genes 
were sorted into EBV dependent and independent pathways. 
Since all genes which were spotted onto these arrays were candidate or well known 
EBNA2 target genes derived from the previous screens, it would be expected that all 
of them generate a signal. This was not the case. Even signals of the well 
characterized target gene LMP1, known to be transcriptionally activated by EBNA2 
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were weak, indicating that the efficiency of the nuclear run-on technique can vary 
significantly depending on the individual gene analyzed. 
Genes which seemed to belong to the EBNA2 pathway were further evaluated by the 
Northern blot analysis. In order to sort these genes into primary and secondary 
EBNA2 target genes, three cell lines were used: EREB2-5 in the presence and 
absence of de novo protein synthesis, P493-6 and BL41-K3. The results of the 
Northern blot analyses suggested that some of the genes are not primary EBNA2 
target genes. One group, which encompasses the genes EGR-1, DUSP2, SLAM, 
lymphotactin, IP-10, MIP-1 alpha, PLAB, PI3K and ATF5, showed no change in gene 
expression in BL41-K3 thus, indicating the requirement of another cellular or viral 
protein for the induction of these genes. These genes were considered as secondary 
EBNA2 target genes and were not subjected to promoter analysis. Furthermore, two 
novel c-Myc target genes have been identified. CDC37 and NUDT4 were identified 
as genes induced downstream of c-Myc and thus were also excluded from any further 
promoter analysis. The rest of the genes formed three groups according to the results 
of the Northern blot analyses. 
Group I contained the genes c-myc, CCR7 and RDC1 since these genes are induced in 
the absence of de novo protein synthesis. This indicates that these genes are primary 
EBNA2 target genes. The transcription factor and proto-oncogene c-myc and the 
chemokine receptor, a member of the G-protein-coupled receptor family, CCR7 had 
been shown to be primary target genes of EBNA2 (Kaiser et al., 1999, Burgstahler et 
al., 1995, respectively).  
RDC1 is a novel primary EBNA2 target gene. It is an orphan G-protein coupled 
receptor. The data presented herein convincingly show a strong induction of RDC1 in 
EREB2-5 and BL41-K3. P493-6 cells failed to induce RDC1 according to the 
Northern blot analysis. Since the P493-6 cells are an EREB2-5 transfectants, there is 
no obvious explanation for this finding. The product of this gene is expressed in 
various cell types. RDC1 can act as a co-receptor for HIV (Shimizu et al., 2000), but 
its cellular function is not known. 
Group II included two genes: bfl-1 and MIP-1 alpha. The bfl-1 protein is a member of 
the Bcl-2 gene family which comprises anti- and pro-apoptotic regulators. The protein 
encoded by this gene is able to reduce the release of pro-apoptotic cytochrome c from 
mitochondria and it blocks caspase activation. This gene is a direct transcription target 
of NF-κB (Grumont et al., 1999, Edelstein et al., 2003) in response to inflammatory 
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extracellular signals, such as GM-CSF, CD40, PMA, TNF and IL-1, which suggests a 
cytoprotective function essential for lymphocyte activation as well as cell survival. It 
was also shown by D’Souza et al., 2000 that the EBV protein LMP1 can 
transcriptionally up-regulate bfl-1. A second member of group II, the macrophage 
inflammatory protein 1 beta (MIP-1 beta) directly participates in the activation and 
directional migration of lymphocytes and monocytes to sites of inflammation. It is up-
regulated in human T cells by the induction of the NF-κB pathway (Guo et al., 2002, 
Guo et al., 2003). Given that the induction of these genes is regulated by the NF-κB 
elements, which are among other factors activated by the EBV protein LMP1, it 
becomes clear why the induction of these genes is decreased in the absence of viral 
proteins in comparison to an EBV/EBNA2 situation. 
Group III is formed by the genes CD21, CD83 and PLEK. CD21 is a human 
complement receptor type 2 (CR2). Additionally, it is the receptor for EBV and 
mediates EBV infection. The regulation of expression of this gene has been 
extensively studied (Makar et al., 1998, Ulgiati and Holers, 2001) and it will be 
discussed later in the context of promoter analysis. CD83 is a cell surface
glycoprotein, expressed mainly on dendritic cells. It had been shown that the 
induction of this gene is strictly dependent on the NF-κB element (Berchtold et al., 
2002). PLEK encodes a protein called pleckstrin, a major substrate of protein kinase 
C in blood platelets (Abrams et al., 1995) which is involved in the reorganisation of 
the actin skeleton (Ma and Abrams, 1999). It contains a pleckstrin homology domain 
(PH) which is commonly found in eukaryotic signalling molecules. The 
transcriptional regulation of this gene has not been described to date. All three genes 
are strongly induced by EBNA2. They require neither viral genes nor c-Myc to be 
induced. However, it is not possible to claim that they are directly regulated by 
EBNA2 as their mRNA is induced and/or stabilised by cycloheximide. Thus a 
comparison of the induction level between the activated and non-activated EBNA2 
state in the presence of the protein synthesis inhibitor could not be indicative. 
Although the results described above provide strong evidences that all genes 
belonging to group I, II or III are directly activated by EBNA2, the mechanism by 
which EBNA2 does so could only be indirectly addressed. Very recently, a direct 
biochemical approach towards the identification of target genes of a given 
transcription factor has been developed. This methodology identifies transcription 
factors bound to the chromatin of a given gene in vivo and is called chromatin 
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immunoprecipitation (ChIP). Briefly, cells are lysed, chromatin associated 
transcription factors and DNA are chemically crosslinked and protein/DNA 
complexes are immunoprecipitated. DNA fragments bound to the immunoprecipitate 
are quantified by PCR. This technique can now be used to identify genomic regions to 
which EBNA2 is bound and thus provide a direct biochemical approach by which 
EBNA2 target genes can be identified (Weinman et al., 2001).
3.3 A search for potential cis-acting elements relevant for EBNA2 function   
within the promoters of EBNA2 target genes
In order to define a common denominator of EBNA2 pathways, the putative promoter 
region (-1000 region upstream from the transcription start site) of candidate EBNA2 
target genes was inspected by using complex software tools (Genomatix Software 
GmbH, Germany) containing a large predefined library of individual consensus 
transcription factor binding sites and modules. 
Numerous potential cis-acting elements were identified. Only three of them were 
found in the putative promoters of all analysed genes: a TATA-box element and 
binding sites for Oct-1 and NFAT1. 
Although EBNA2 binds weakly to the TATA-binding protein (TBP) it interacts with 
TAF40 through its acidic activation domain creating a potential link between EBNA2 
and TBP (Tong et al., 1995a). The TATA-box-dependence of EBNA2 responsive 
genes had been shown in experiments by Wu et al., 2000, which demonstrated that the 
deletion of TATA-box element from the episomal promoters abolishes transcription.
The octamer binding protein 1(Oct-1) is a member of a POU family of homeodomain 
proteins which regulate the transcription of snRNA and histone H2B genes (LaBella 
et al., 1988, Murphy et al., 1989). The active form of Oct-1 was also observed in B 
cells where it acts as a regulator of Ig gene transcription during B cell development 
(Shah et al., 1997). The combinatorial action of the Oct-1 site and the PU.1 
autoregulatory site has been shown to contribute to the activity of the PU.1 promoter 
itself (Chen et al., 1996). A direct interaction of the EBNA2 protein with the POU 
domain proteins has been described by Sjöblom et al., 1995 in the context of the 
LMP1 promoter. However, Sjöblom et al., 1995 excluded Oct-1 and Oct-2 as a 
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candidate POU-box proteins in their experiments. Thus, a direct interaction of 
EBNA2 and Oct-1 has never been demonstrated.   
Nuclear factor of activated T cells (NFAT) transcription factors play critical roles in 
gene transcription during the immune response. CD40 activates the cyclosporine-
sensitive, calcium regulated phosphatase calcineurin, which dephosphorylates 
cytoplasmic NFATs and enables them to translocate to the nucleus and thereby assist 
in the gene transcription (Flanagan et al., 1991). NFAT1 is required for the normal 
homeostasis and the differentiation of B and T cells (Peng et al., 2001). It has been 
shown that the NFAT1 site plays a critical role in the induction of TNF alpha by 
calcium ionophore (Tsai et al., 1996). 
In addition to the individual roles of Oct-1 and NFAT1 as effectors during B cell 
development and activation, a functional synergy of these two transcription factors 
has been demonstrated by Zabel et al., 2002. They performed the comparative 
analysis of mouse and human intron 1 of the CD21 gene and identified seven areas of 
significant sequence homology which are located at or near sites previously identified 
as important for cell specific CD21 gene expression. Sequence competition and Ab 
supershift analyses utilizing nuclear extracts from T and B cells identified the primary 
constituents as Oct-1, YY1 and NFAT4, and potentially other NFAT members as 
well. In that complex Oct-1 and YY1 were proposed to act as regulatory elements 
which repress transcription in the CD21 non-expressing cells by recruiting HDAC to 
the regulatory elements. Association of NFATs with that complex is directly linked to 
the increased expression of CD21. The treatment of CD21-expressing cells with 
cyclosporine A, a potent and specific inhibitor of NFAT function, resulted in the 
specific loss of CD21 transcription (Zabel et al., 2002). 
The question regarding the physiologic role of the Oct-1 and NFAT1 transcription 
factors in EBNA2 transactivation remains unanswered, but it will be addressed in the 
future work.
Within each of three groups of genes directly activated by EBNA2, there were a 
number of common transcription factor binding sites identified. However, the attempt 
to identify module common to all promoters analysed failed and only one module 
consisting of two different ETS family members and AP1 was identified in the 
promoters of RDC1 and CCR7. 
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3.4 A potential role of binding sites for RBP-Jκ, PU.1, NF-κB and c-Myc in 
promoter and intron 1 of primary EBNA2 target genes
Since there is an increasing evidence that the intronic regions might participate in the 
regulation of transcriptional gene regulation, the search for cis-regulatory elements 
within the EBNA2 target genes was extended beyond the promoter regions and the 
intron 1 region was included in all further analyses. The analysis was limited to TF 
binding sites for RBP-Jκ, PU.1, NF-κB and c-Myc, which had been shown to bind to 
intronic regions also (Henkel and Brown, 1994, Nikolajczyk et al., 1996, van Dijk et 
al., 1998, Makar et al., 1998, Sica et al., 1997, Jones et al., 1997, Horikawa et al., 
2002, Ge at la., 2003) 
A functional significance of RBP-Jκ and PU.1 sites in transactivation by EBNA2 has 
been previously described for the viral LMP1, LMP2A and C promoters (Ling et al., 
1993, Henkel et al., 1994, Grossman et al., 1994, Waltzer et al., 1994, Zimber-Strobl 
et al., 1994, Laux et al., 1994, Johannsen et al., 1995). However, neither RBP-Jκ nor 
PU.1 alone could convey EBNA2 responsiveness to the LMP1 promoter (Ling et al., 
1993, Johannsen et al., 1995). As published data show, four out of eight genes 
identified as EBNA2 target genes in this work require a functional NF-κB element to 
be efficiently transcribed. In the context of EBV infection, NF-κB has been found to 
be one of the major activators of transcription. During the latent growth programme, 
LMP1, which is an EBNA2 regulated viral gene (Kaiser et al., 1999), activates also an 
NF-κB signalling pathway in order to mediate the up-regulation of target genes 
(Hammarskjold and Simurda, 1992, Laherty et al., 1992, D’Souza et al., 2000, 
Dudziak et al., 2003). A well defined primary EBNA2 target gene c-myc encodes a 
transcription factor which, as a next link in the cascade, can also be a potential co-
activator in the gene transactivation process by EBNA2.
As shown herein, RBP-Jκ binding site was only found in the putative promoter of the 
bfl-1 gene. The most striking result was that all analysed genes had at least one RBP-
Jκ binding site in intron 1. An exception was CD83, which has a very short intron 1 of 
only 101 bp. A more extensive search ranging over 15 kb downstream of the TSS did 
not identify an RBP-Jκ binding site. Studies of Makar et al., 1998 have pointed out a 
critical function of RBP-Jκ as an intronic silencer of the CD21 gene. The CD21 
silencer must interact with the CD21-proximal promoter for function (Ulgiati and 
Holers, 2001). At this point it is not known, whether the RBP-Jκ binding sites within 
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the intronic regions of EBNA2 target genes are functional. As a first step in order to 
test for a potential functional relevance of these RBP-Jκ recognition sites it should be 
to test whether RBP-Jκ can bind to these sites in gel retardation assays or by ChIP. 
For gel retardation assays the protein/DNA complexes are assembled in vitro and 
anaylsed by gel electrophoresis. In contrast, the ChIP experiments visualize binding 
sites for a given transcription factor in vivo. The next step would be to functionally 
inactivate the RBP-Jκ binding site in the context of the gene and ectopically express 
this mutagenized gene fragment in B cells. This approach had been chosen by Makar 
et al. (2001). They could show that inactivation of the RBP-Jκ site within the intron of 
the CD21 gene activates a reporter gene. Technically, this experiment was difficult 
since the stable transfectants of the mutagenized gene fragments had to be established 
in order to see a significant change in activities. Thus, the intronic silencing most 
likely requires a proper chromatin assembly which cannot form after the transient 
transfection of the gene fragment into the cell. In order to test, whether the intronic 
RBP-Jκ binding sites of EBNA2 target genes are relevant for EBNA2 induction, the 
genomic loci should be mutagenized and reconstituted on episomal vectors, which can 
stably replicate and associate with ordered chromatin structures in nuclei of 
transduced cells.
The c-Myc, RDC1 and CCR7 mRNA were detected as primary EBNA2 target genes 
induced by EBNA2 in the absence of de novo protein synthesis. Thus, in addition to 
EBNA2 there are minimal requirements for transcription factors in the induction of 
these genes. Analysed regions of the RDC1 and c-myc genes contain NF-κB binding 
site. The relevance of the NF-κB binding site in the activation of B cells by c-myc has 
been demonstrated by Grumont et al., 2002. What would activate NF-κB pathway in 
the absence of de novo protein synthesis or is there an alternative regulatory 
mechanism which activates c-myc transcription, and possibly RDC1, in the EBV 
infected B cells is still an issue to be resolved.
A direct role of the NF-κB signalling pathway has been reported in the regulation of 
the expression of bfl-1 (D’Souza et al., 2000, Edelstein et al., 2003), MIP-1 beta (Guo 
et al., 2002, Guo et al., 2003), CD21 (Tolnay M et al., 2002) and CD83 (Berchtold et 
al., 2002, Dudziak et al., 2003). bfl-1 was found to be transcriptionally regulated by 
LMP1 (D’Souza et al., 2000, Dirmeier, 2002). The requirement for co-expression of 
EBNA2 and LMP1 explains a very low induction of this gene in BL41-K3 cell where 
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no viral protein is present. A similar mechanism is probably involved in the regulation 
of MIP-1 beta gene expression.
Recently, it was found that CD83 and PLEK are LMP1 regulated genes (Dudziak et 
al., 2003 and Dirmeier, 2002, respectively). In the work presented here, it is clear that, 
even in the absence of any of the viral proteins, these genes are highly induced. These 
genes could, therefore, have two independent mechanisms of regulation or this 
controversy can be explained by the usage of different in vitro systems. 
According to what is known about the regulation of the CD21 gene and the 
importance of RBP-Jκ site in intron 1, it is suggested that EBNA2 binding to RBP-Jκ 
has an important role in the activation of transcription. However, the minimal 
requirement for other factors in this process is still not clear. 
From the expression analysis of these eight genes in the BL41-K3 cells it is evident 
that neither of them was induced in c-Myc-dependent manner indicating that, 
although present, E-box is not rate limiting for the up-regulation of these genes. 
This study identified potential binding sites for either PU.1 or NF-κB in the promoters 
of CCR7, MIP-1 beta, CD21, CD83 and PLEK. In addition, NFAT1 and Oct-1 
binding sites are present in all promoters. Thus, PU.1, NF-κB NFAT1 and Oct-1 are 
candidate factors which might cooperate with protein/DNA complexes bound to 
intronic regions in order to regulate EBNA2 target genes.  
Given that these transcription factors are expressed in B cells that undergo 
immortalisation induced by EBV infection, there are several in vitro or in vivo
approaches that could be used to confirm the binding and relevance of these proteins 
for EBNA2 function. 
As discussed earlier, the binding of a transcription factor to its potential TF binding 
site within a specific gene fragment can be shown by gel retardation assays or 
chromatin immunoprecipitation. The functional relevance of a transcription factor 
binding site within a promoter region is routinely checked by the transient transfection 
of promoter reporter constructs of a given gene fragment. The interesting finding of in 
silico analysis of the EBNA2 target genes was the occurrence of the potential Oct-1 
binding site found in all promoters. Although a direct EBNA2/Oct-1 interaction has 
been previously excluded by Sjöblom et al., 1995, it would be worth testing, if 
EBNA2 can functionally interact with Oct1. 
In some cases, as discussed for intronic silencing before, stable transfectants have to 
be established in order to allow the necessary chromatin assembly for functional 
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analysis. Since all but one EBNA2 target genes might be regulated by its promoter 
regions as well as intronic silencing mechanisms, again episomal vectors carrying the 
corresponding gene fragments should be stably expressed in the cells. Within these 
plasmids the binding sites for the transcription factors PU.1, NF-κB, NFAT1 and Oct-
1 should be mutagenized and their function for basal activity of the genes as well as 
activation by EBNA2 should be tested.  
In addition, the function of the transcription factors could be tested by specific 
inhibition of their function or expression. For NF-κB and NFAT1 specific inhibitors, 
which block protein function are avaiable. A very attractive alternative would be to 
specifically destroy the transcripts for PU.1, NF-κB, NFAT1 and Oct-1 by siRNA and 
then test whether the transactivation by EBNA2 is abolished. 
3.5 A hypothetical model for EBNA2 function
Taken together, the results of this study suggest a novel working hypothesis for the 
mechanism by which EBNA2 activates cellular target genes (Fig. 26). While the viral 
promoters activated by EBNA2 are characterised by RBP-Jκ binding sites, the 
majority of cellular genes activated by EBNA2 lack an RBP-Jκ binding site in their 
promoter region. In contrast, a potential RBP-Jκ binding site was identified in the 
intronic region of the majority of genes analysed in this study. The binding of EBNA2 
to RBP-Jκ within intronic regions could cause alterations in chromatin structure. 
Thus, EBNA2 would facilitate chromatin accessibility to transcription factors, 
resulting in the relief of repression rather than by directly recruiting the transcription 
machinery. The second characteristic feature of all target promoters was a cluster of 
NFAT1 and Oct-1 binding sites. So far, a direct binding of EBNA2 to either of these 
two proteins has not been demonstrated. For genes belonging to group I, the 
requirement for additional factors is minimal, since transcriptional activation of these 
genes is successful even in the absence of de novo protein synthesis. A simple two 
step mechanism as illustrated in Fig. 26 (left part) might apply to this process. 
Nevertheless, a potential NF-κB binding site is shared by all promoters belonging to 
groups II and III. For several genes belonging to these two groups, an experimental 
data had been published showing that NF-κB can activate these genes via its 
recognition site within the promoter. Unfortunately, as discussed earlier, the relative 
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contribution of de novo protein synthesis to group III gene activation cannot be 
accessed for experimental reasons. This study suggest that the high level induction of 
group II and group III genes by EBNA2 might require NF-κB activation and therefore 
require de novo protein synthesis. Activation of cellular target genes by EBNA2 is 
performed by two synergistically and potentially sequentially acting mechanisms. The 
relief of repression due to changes in the chromatin state caused by EBNA2 are 
followed by the action of transcription factors, which might, although not necessarily, 
interact with EBNA2 directly. 
Figure 28.
A hypothetical model of transcriptional regulation by EBNA2.
Diagram outlines potential steps in the pathway from transcriptionally inactive promoter to the 
activation of transcription. The EBNA2-responsive promoter is tightly packed in chromatin what is 
mediated by RBP-Jκ and co-repressor complex bound to RBP-Jκ. EBNA2 displaces the co-repressor 
complex and binds to RBP-Jκ. Simultaneously, it binds co-activators responsible for chromatin 
modifications and remodelling. An open chromatin structure is accessible for the assembly of pre-
initiation complex (PIC) and the binding of other transcription factors (TFs). In the case of c-Myc, 
CCR7 and RDC (i.e. group I) the requirement for other TFs is minimal and transcription is at a high 
level even in the absence of de novo protein synthesis. Genes belonging to groups II and III need 
additional expression of some viral or cellular gene to acquire full induction.  
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3.6 Induction of TRRAP is a characteristic feature of the EBV/EBNA2 
controlled growth programme
3.6.1 The TRRAP protein
The TRRAP gene has been identified relatively recently (McMahon et al., 1998, 
Vassilev et al., 1998) as a 400 kDa cofactor for c-Myc and E1A mediated 
transformation. The assembly of DNA into nucleosomes and higher order chromatin 
represents a repressive block to transcription that must be overcome during 
transcriptional activation. One mechanism of alleviating chromatin repression 
involves the acetylation of histone tails. TRRAP is a common constituent of four 
mammalian multiprotein histone acetyltransferase (HAT) complexes: TFTC, STAGA, 
PCAF and TIP60 (Brand at al., 1999, Martinez et al., 2001, Vassilev et al., 1998, 
Ikura et al., 2000, respectively). These complexes acetylate not only histones, but also 
other proteins. So far it has been shown that TRRAP interacts with c-Myc and E2F 
and this interaction is necessary for the function and acetylation of these transcription 
factors (McMahon et al., 1998, McMahon, data published on the 
www.wistar.upenn.edu), as well as for p53 (Ard et al., 2002, McMahon, data
published on the www.wistar.upenn.edu). According to sequence homology TRRAP 
belongs to the ATM protein superfamily which includes the proteins ATM, ATR, 
FRAP and DNA-PK. The members of this protein family are involved in cell cycle 
check point signalling causing cell cycle arrest, apoptosis or DNA repair. However, 
unlike other members of the ATM superfamily, TRRAP is not a protein kinase as 
judged from the lack of essential amino acids in the kinase motif. It might play a role 
in DNA damage/repair response as TFTC, STAGA and TIP60 HAT complexes which 
contain TRRAP are involved in these processes (Brand et al., 2001, Martinez et al., 
2001, Ikura et al., 2000, respectively). In vivo evidence for TRRAP being essential for 
DNA repair, mitotic checkpoints and normal cell cycle progression was provided by 
Herceg et al., 2001. They showed that loss of TRRAP causes early embryonic 
lethality, block in cell proliferation accompanied by aberrant mitotic exit, abnormal 
nuclear morphology, cytokinesis failure and endoreduplication.
The primary sequence of TRRAP has no homology with the proteins that have been 
implicated in gene regulation and hence offers little insight into its precise function. 
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TRRAP has no apparent DNA-binding motif so it is unlikely that it binds to DNA in 
the absence or other factors. Extensive searches for motifs that might predict a 
function of TRRAP, such as acetylation, deacetylation or methylation, have proven 
negative to date. The lack of obvious motifs conferring biochemical activity and its 
unusually large size suggest that TRRAP may serve as a scaffold element for the 
assembly of multiprotein complexes (McMahon et al., 1998).
3.6.2 TRRAP is super-induced in EBV/EBNA2 driven proliferation
In the ExpressCode™ DNA microarray experiment described in this work, TRRAP 
was shown to be induced by EBNA2. EBNA2 plays a crucial role in the B cell 
transformation process (Cohen et al., 1989, Hammerschmidt et al., 1989) as a 
transactivator of both cellular and viral genes (Fahraeus et al., 1990, Zimber-Strobl et 
al., 1993, Ling et al., 1994, Kaiser et al., 1999). Referring to a functional necessity of 
TRRAP for the oncogenic transformation by c-Myc and E1A, it was of great interest 
to explore the mechanism and the role of TRRAP induction by EBNA2.
As a first step, the results derived from the microarray experiment were confirmed by 
real time PCR. EBNA2 activation mediated a strong induction of TRRAP, but failed 
to do so in the presence of the protein synthesis inhibitor cycloheximide. Thus, 
TRRAP is a secondary EBNA2 target gene. 
Therefore, in the work herein a potential link between EBNA2 and TRRAP induction 
was searched. 
The viral primary EBNA2 target gene LMP1 up-regulates a broad spectrum of genes 
(recently described by Dirmeier, 2002) by activating the NF-κB (Huen et al., 1995, 
Mitchell et al., 1995), AP-1 (Fos/Jun pathway) (Kieser et al., 1997, Kieser et al., 
1999), STAT (Gires et al., 1990) and p38 MAPK (Eliopolus et al, 1999, Vockerodt et 
al., 2001) signalling pathways. TRRAP induction was analysed in two complementary 
cell lines 1852.4 (Kilger et al., 1998) and 1194-3 (Zimber-Strobl et al., 1996). The 
1852.4 cells conditionally express LMP1 and constitutively express EBNA2. The cell 
line 1194-3 constitutively expresses LMP1, but can regulate EBNA2 function also. In 
both cases LMP1 expression is independent of EBNA2. Thus the effect of LMP1 on 
TRRAP induction could be analysed independently of EBNA2 function. The results 
show that: (i) LMP1 expression was not able to super-induce TRRAP above the level 
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induced by EBNA2 (showed in 1852.4 cells) or (ii) LMP1 per se was not enough to 
induce TRRAP in the absence of EBNA2 (1193-4 cells). This indicates that none of 
the LMP1 induced pathways is sufficient to activate TRRAP induction although there 
were STAT-1 and NF-κB binding sites found by in silico analysis in the putative 
promoter of TRRAP at positions -434 and -165, respectively (data not shown).  
The involvement of other viral proteins in the induction of TRRAP by EBNA2 was 
tested in the cell lines BL41-K3 (BL41-ER/EBNA2) and BJAB-K3 (BJAB-
ER/EBNA2) and the corresponding P3HR1 convertants (BL41-P3-9A and BJAB-P3-
B6). EBNA2 per se was already sufficient for TRRAP induction. Viral genes, 
although dispensable, may additionally increase induction up to twofold. 
Nevertheless, LMP1 can immediately be excluded since it fails to induce TRRAP in 
1852.4 cells. LMP2A has been shown to activate the phosphoinositide 3-kinase 
(PI3K) pathway (Swart et al., 2000) and therefore could be a potential candidate. 
In summary, viral proteins facilitate TRRAP induction, but a cellular protein 
downstream of EBNA2 initiates the induction of TRRAP. Also, a synergistic action of 
cellular and viral genes in this process cannot be excluded.
Since TRRAP induction coincided with the activation of cellular proliferation in all 
systems tested, it was hypothesised that TRRAP induction might be associated with 
the cell cycle entry or cell growth. The transcription factor c-Myc, activated by 
EBNA2, was a candidate protein, which could mediate TRRAP induction in the 
context of cell cycle entry. c-Myc activates a diverse group of genes as a part of a 
heterodimeric complex together with its partner protein Max (Dang, 1999, 
Schuhmacher et al., 2001). The c-Myc-Max heterodimers are capable of binding a 
specific DNA sequence CACGTG, called E-box (Blackwood et al., 1991). In order to 
distinguish the effect of EBNA2 and c-Myc on TRRAP induction, P493-6 cells were 
used (explained in more detail in Introduction). These cells proliferate in two distinct 
programs: EBV/EBNA2 growth programme or c-Myc growth programme. Here, it 
was evident that EBNA2 is able to induce TRRAP, but c-Myc was not able to do so. 
Germinal centre (GC) centroblasts strongly express c-myc and proliferate (Martinez-
Valdez et al., 1996). As shown herein, primary B cells stimulated with CD40L/IL-4 
also strongly express c-myc and proliferate vigorously. However, TRRAP mRNA 
abundance does not increase above basal level as it does in the primary B cells 
infected with B95.8 EBV. These results indicate that c-Myc has no influence on 
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TRRAP induction and also that TRRAP induction is not a phenomenon associated 
with cell proliferation per se. 
Since all TRRAP induction studies had been done in established cell lines, based on 
the ER/EBNA2 system, a secondary test system was used in order to ensure that 
TRRAP induction by EBV is of general relevance. To this end, the expression of 
TRRAP upon EBV infection was confirmed to CD40 ligation in the presence of IL-4. 
Again, the induction of TRRAP was exclusively seen in EBV stimulated cells, 
confirming that the EBV growth programme specifically activates TRRAP.
In order to gain further insights into the mechanism by which EBV might activate 
TRRAP, the putative promoter region of the TRRAP gene was submitted to an in 
silico analysis. This in silico analysis revealed potential binding sites for numerous 
transcription factors (data not shown). This analysis will be helpful in the mutational 
analysis of the TRRAP promoter by promoter reporter assay. Transient transfection 
assays should define elements in the promoter which are important for TRRAP 
regulation by EBV/EBNA2 growth programme. 
3.6.3 Functional analysis of TRRAP induction in the context of EBV infection
The next issue studied in this work was whether the TRRAP protein was a rate 
limiting for the growth and proliferation of EBV-infected B cells. To answer this 
question the TRRAP expression was knocked down in EBV immortalised B cells by 
the RNAi technology. The RNAi technology is sequence-specific, post-transcriptional 
gene silencing initiated by double-stranded RNA (dsRNA) that is homologous in 
sequence to the silenced gene (Fire, 1999, Hammond et al., 2001, Tuschl, 2001). To 
down-regulate the TRRAP protein expression, a small interfering RNA (siRNA) 
expression vector-based system which produces functional siRNA molecule was used. 
The 721 cells were cells of choice as they are LCL which can be transfected with 
acceptable efficiencies. 721 cells transfected with the TRRAP specific siRNA 
expression vector show the reduction of the TRRAP transcript and pronounced cells 
death as soon as 12 hours post-transfection. This effect is accompanied with a 
decreased number of cells in the G1 phase of cell cycle, while the numbers of cells in 
S or G2/M phase were not significantly modified compared with the non-transfected 
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cells. However, cells transfected with TRRAP specific siRNA show a reduced DNA 
synthesis, indicating that the cells in the S and G2 phase are rather cells in the early 
stage of apoptosis before DNA fragmentation and thus are not recognised as sub-G1 
cells. Herceg et al., 2001 reported on TRRAP requirement for the mitotic checkpoint 
and the normal cell cycle progression. Work presented here confirms that finding. 
Recently, it has been reported that siRNA can have non-specific effects. Sledz et al., 
2003 showed the activation of the interferon system by synthetic siRNA. To test for 
the gene specific effect of anti-TRRAP siRNA, cells were transfected with the 
mutated TRRAP specific siRNA expression vector or empty vector as a control. 
These cells behave in a very similar manner to the non-transfected cells with 
negligible differences which are probably due to the fact that these cells were robustly 
treated during transfection and the selection process. These data clearly show that a 
general toxicity of vector or the activation of the interferon response due to a dsRNA 
can be ruled out as a cause of the biological effect described in this work. 
In summary, these results indicate that TRRAP is intimately related and necessary for 
processes involved in proliferation and survival of LCLs.
The role of TRRAP in LCLs has not been elucidated, but according to the known 
facts about TRRAP there are several possible suggestions. As described above, 
TRRAP is a part of the HAT complexes which are the co-activators of the 
transcription machinery and are involved in the DNA repair process. Therefore 
TRRAP plays an important role in the regulation of transcription, cell cycle 
progression and cell viability. There is a need of TRRAP for cell cycle progression 
and survival of EBV-immortalised B cells since the latent EBV-driven proliferation of 
B cells requires constant and enormous gene activation accompanied by the 
enhancement of genetic instability (Gualandi et al., 2001). The effect of TRRAP 
knock-down in LCL resulting in cell death was not surprising as a similar effect was 
observed earlier in mouse embryonic fibroblasts (Herceg et al., 2001). However, the 
role of the elevated levels of TRRAP during B cell immortalisation by EBV remains 
unresolved. In contrast, the same is not needed for B cells activation by CD40L/IL-4. 
It would be of great interest to see whether lymphoblastoid cells would be viable if 
the level of TRRAP would be kept at the basal level. 
Although EBV transformed LCLs are generally believed to be immortalised, a series 
of studies (Counter et al., 1994, reviewed in Sugimoto et al., 1999, Okubo et al., 
2001) provide strong evidence that EBV infected B cells are mortal and have non-
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malignant properties, except for a small proportion of cells that acquire additional 
genetic changes as well as constitutive telomerase activity. Telomere shorting with 
each cell division in the absence of telomere maintenance mechanism is suggested to 
function as an intrinsic clock that counts cell division and eventually causes 
permanent cell growth arrest in human cells (Chiu and Harley, 1997, Meyerson, 
2000). Activation of telomerase is observed in ~90% of human cancers, but not in 
most normal somatic cells (Kim et al., 1994, Chiu and Harley, 1997, Meyerson, 
2000). Biochemical and genetic studies have established an association between 
telomere maintenance and extended lifespan mediated through expression of human 
telomerase reverse transcriptase (hTERT) (Sharma et al., 2003). Telomerase is a 
reverse transcriptase that synthesises telomeric DNA thereby compensating for 
telomere loss that occurs with each replication cycle. hTERT is silent in almost all 
somatic cells (Greider, 1999) but is up-regulated in the vast majority of human cancer 
cells. c-Myc was shown to be the only transcription factor capable of interacting with 
the hTERT promoter and inducing its expression from the chromosomal locus (Wang 
et al., 1998). It was found that activation of a silent hTERT gene in exponentially 
growing primary human fibroblasts requires TRRAP recruitment and is accompanied 
by both H3 and H4 acetylation. Importantly, c-Myc mutants that lose their ability to 
interact with TRRAP fail to activate hTERT in primary cells (Nikiforov et al., 2002). 
Induction of c-Myc and TRRAP which are required for hTERT expression, and thus 
for maintenance of the constant telomere length, could be the prerequisite, though not 
sufficient, for the immortalisation of EBV infected B cells. 
All studies addressing the function of TRRAP in EBV immortalised B cells were 
performed by transiently overexpressing TRRAP specific siRNA. In that system, high 
level expressing cells were selectively enriched and biologically investigated. Thus, 
TRRAP expression was most likely knocked-down below basal level seen in EBV-
negative situation. For the future it would be more interesting to generate cellular 
systems, which would allow the titrating of siRNA expression and eventually testing 
whether TRRAP expression above basal level is required in B cells immortalized by 
EBV. Such cellular systems could be established by expressing TRRAP specific 
siRNAs as conditional systems. 
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4.0 Materials
4.1 Bacterial and eukaryotic cell culture reagents
Invitrogen, UK
Bacto-tryptone, bacto-yeast extract, bacto-agar, Versene, Penicillin/Streptomycin, L-
glutamine
SIGMA-Aldrich, USA
Ampicillin, tryphan blue, β-oestradiol, tetracycline, cycloheximide, propidium iodide
Amersham Bioscience, Sweden
Ficoll-Paque™ PLUS
Biochrom KG, Germany
Foetal calf serum
PAA Diagnostics, Austria
RPMI 1649 (1x)
PeqLab, Germany
IPTG, X-gal
Promega, USA
Human recombinant IL-4
Clontech, USA
Tet system approved foetal calf serum
OXOID GmbH, Germany
Sheep blood
4.2 Molecular biology reagents
Roche Diagnostics GmbH, Germany
RNase, dNTP, NTP, oligo(dT)15, proteinase K, Complete protease inhibitor cocktail, 
hexanucleotide mix
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Invitrogen, UK
SuperScript II, E.coli DNA ligase, E.coli DNA polymerase, RNase H, T4 DNA 
polymerase
Promega, USA
M-MLV reverse transcriptase, Rnasin 
PeqLab, Germany 
Taq DNA polymerse
New England Biolabs, USA
Restriction endonucleases, alkaline shrimp phosphatase, T4 DNA ligase, DNA 
ladders
Amersham Bioscience, Sweden
Full range Rainbow protein marker
SIGMA-Aldrich, USA
Salmon testes shared DNA 
Merck KGaA, Germany 
Ethidium bromide, Coomasie Brilliant Blue
4.3 Antibodies
SEROTEC, UK
Rabbit anti-TRRAP
SIGMA-Aldrich, USA
Anti-mouse IgG-FITC conjugate
Promega, USA
Anti-rabbit IgG HRP conjugated
Roche Diagnostics GmbH, Germany
Mouse anti-DIG antibody AP conjugated
Elisabeth Kremmer, GSF, Germany
Mouse anti-NGFR HB8737
Dianova, Norway
Human anti-CD19-PE/CD3-FITC
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4.4 Radioactive isotopes
Amersham Pharmacia Biotech, Germany
[α-32P] dCTP (3000Ci/mmol, 10 mCi/ml)
[methyl-3H]Thymidine (1 mCi/ml)
4.5 Disposables and kits
Invitrogen, UK
Agarose
Roche Diagnostics GmbH, Germany
DIG DNA Labeling mix, LightCycler-FastStart DNA Master SYBR Green I, 
LightCycler capillaries, CSPD, BrdU ELISA
Qiagen, Germany
QIAquick Gel Extraction kit, Rneasy Midi, Rneasy Mini
Clontech, USA
ExpressHyb solution
Amersham Bioscience, Sweden
Hybond-N+, NICK-columns, ECL™ kit 
Affymetrix Inc., USA
GeneChip Human Genome U133A
Millipore, USA
Microcon-YM50 columns, Immobilion PVDF membrane
Enzo Diagnostics Inc., USA
RNA Transcript Labelling Kit
Whatman Ltd., USA
3MM-paper
Bio-Rad Laboratories, UK
Electroporation cuvettes 4 mm
Packard Bioscience GmbH, Germany
Uni-Filter 96 GF/C
Renner GmbH, Germany
0.8 µm filter
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Sartorius, Germany
0.45 µm filter, 0.2 µm filter
Machery Nagel, Germany
NucleoSpin Plasmid kit
Genomed, Germany
JET STAR kit
Miltenyi Biotec, USA
MACS separator, MACS goat anti-mouse IgG microbeads, MACS LS separation 
columns
Eastman Kodak Company, USA
Biomax MR-1 X-ray film
Plastic laboratory wares were purchased from NUNC GmbH, Germany, Greiner 
GmbH, Germany, Beckton-Dickinson GmbH, Germany and Eppendorf, Germany.
4.6 Chemical reagents
Chemical reagents were purchased from Merck KgaA, Germany, SIGMA-Aldrich, 
USA and ICN, USA.
4.7 Laboratory equipments
Bio-Rad Laboratories, USA
Electroporator
PeqLab, Germany
Gel electrophoresis units (DNA, RNA), UV-transiluminator
Amersham Bioscience, Sweden
Gel electrophoresis units (proteins) ˝Mighty Small˝
Bioscan Inv., USA
Radioisorope counter QC-4000
Biometra GmbH, Germany
Spectrophotometer
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Atomic Energy of Canada Ltd., Canada
Gammacell 40
SIGMA Centrifuges GmbH, Germany
6K10 centrifuge, 2K15 centrifuge
Roche Diagnostics GmbH, Germany
LyghtCycler
Heraeus Instruments, Germany
Fume hood work bench, eukaryotic cell incubator
Raytest GmbH, Germany
FUJI FILM BAS-1800 phosphoimager
Packard Bioscience GmbH, Germany
Micro Plate Scintilation Counter 
ThermoLifeSciences, Germany
-80 °C freezer
Perkin Elmer, Germany
PCR System 9600
Beckton-Dickinson GmbH
Flow cytometer FACSan
Eppendorf, Germany
5415D centrifuge, Thermomixer 5436
MWG Biotech, Germany
Hybaid hybridisation oven
SAVANT, USA
SpeedVac Concentrator
Sorvall Instruments, USA
RC5C centrifuge
Eastman Kodak Company, USA
X-ray film developer
New Brunswick Scientific, USA
C25 bacteria shaker
Sterling Diagnostic Imaging, USA
Quanta Rapid exposure cassette
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4.8 Bacteria
DH5α E.coli strain, purchased from Invitrogen, UK.
4.9 Eukaryotic cell lines
EREB2-5 a human, EBV-positive lymphoblastoid cell line, oestrogen 
dependant (Kempkes et al., 1995a)
P493-6 a stable transfectant of EREB2-5 with tetracycline-regulated 
myc expression construct (Pajic et al., 2001)
BL41-K3 a human, EBV-negative Burkitt's lymphoma cell line BL41 
stably transfected with the ER/EBNA2 construct (Kempkes et 
al., 1995b)
BL41-P3-9A a human, EBV-positive Burkitt's lymphoma cell line BL41-
P3HR1 stably transfected with the ER/EBNA2 construct 
(Kempkes et al., 1995b)
BJAB-K3 a human, EBV-negative lymphoblastoid cell line BJAB stably 
transfected with the ER/EBNA2 construct (Kempkes et al., 
1995b)
BJAB-P3-B6 a human, EBV-positive lymphoblastoid cell line BJAB-P3HR1 
stably transfected with the ER/EBNA2 construct (Kempkes et 
al., 1995b)
1852.4 a human, EBV-positive lymphoblastoid cell line infected with a 
mini-EBV carrying the Tet-inducible LMP1 gene (Kilger et al., 
1998)
1194-3 a human, EBV-positive lymphoblastoid cell line infected with a 
mini-EBV carrying an oestrogen-dependent EBNA2 and a 
constitutive LMP1 gene (Zimber-Strobl et al., 1996)
721 a human, EBV-positive lymphoblastioid cell line generated by 
infection of human B cells by B95.8
B95.8 a marmoset, EBV-positive B cell line (Sample et al., 1990)
L-CD40L a murine fibroblast cell line Ltk stably transfected with the 
human CD40 ligand gene (Garrone et al., 1995)
4.0 Materials
91
4.10 Oligonucleotides
All oligonucleotides were manufactured by Metabion GmbH, Germany.
Primers used in real-time PCR:
TRRAP cDNA:
MS119 5’ GGCCTGGAAGGTGAACATGTACCG 3’
MS120 5’ GCATGAACCCCAAGCATAGCGTTA 3’
c-myc cDNA:
MS331 5’ ATCATCATCCAGGACTGTATGTGG 3’
MS332 5’ CTCTTTTCCACAGAAACAACATCG 3’
LMP1 cDNA:
MS335 5’ GGTGTTCATCACTGTGTCGTTGTC 3’
MS336 5’ GCTACTGTTTTGGCTGTACATCGT 3’
GAPDH cDNA:
MS151 5’ AGAACATCATCCCTGCCTCTACTG 3’
MS152 5’ TGTCGCTGTTGAAGTCAGAGGAGA 3’
Primers used for the sequencing and DIG-labelling of inserts cloned into the pUC19 
vector:
M13 for 5’ GCTGGCGAAAGGGGGATGTG 3’
M13 rev 5’ CACTTTATGCTTCCGGCTCG 3’
Oligonucleotide used in the procedure of probe labelling for hybridisation of 
GeneChip®:
MSaffy dT 5’GGCCAGTGAATTGTAATACGACTCAC
TATAGGGAGGCGG(T)18 3’
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siRNA oligonucleotides:
MS537 5’ CG TGTCACGTCATCTCCTCAG TTTAGAGA       
CTGAGGAGATGACGTGACA TTTTT GAATTCATTATT 3’
MS537/mm 5’ CG TGTCACGTCGTCTCCTCAG TTTAGAGA
CTGAGGAGACGACGTGACA TTTTT GAATTCATTATT 3’
Primers for the amplification and DIG-labelling of cDNA fragments:
bfl-1
MS524 bfl-1 for 5’ ATTATTGAATTCACCAGCCTCCATGTATCA 3’
MS524 bfl-1 rev 5’ ATTATTGAATTCCATCCAGCCAGATTTAGG 3’
MIP-1 beta
MS524 mip-1 b for 5’ ATTATTGAATTCAGCTTCTGAGTTCTGCAG 3’
MS524 mip-1 b rev 5’ ATTATTGAATTCCCCCATAGGACACTTATC 3’
PLAB
MS524 plab for 5’ ATTATTGAATTCAAGATTCGAACACCGACC 3’
MS524 plab rev 5’ ATTATTGAATTCGTCATCATAGGTCTGGAG 3’
PI3K
MS524 pi3k for 5’ ATTATTGAATTCTACAGAACACAGAGCTCC 3’
MS524 pi3k rev 5’ ATTATTGAATTTCCATACCGTTGTTGGCTAC 3’
SLAM
MS524 slam for 5’ ATTATTGAATTCAATTCAGACAGCCTCTGC 3’
MS524 slam rev 5’ ATTATTGAATTCTGGACTTGGGCATAGATC 3’
DUSP2
MS524 dusp2 for 5’ ATTATTGAATTCCTTTGCCCTACCTGTTCCT 3’
MS524 dusp2 rev 5’ ATTATTGAATTCAAGGCTCACAGACAGACA 3’
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Lymphotactin
MS524 lymph for 5’ ATTATTGAATTCATGAGACTTCTCATCCTG 3’
MS524 lymph rev 5’ ATTATTGAATTCGTCACAGCTGTATTGGTC 3’
EGR-1
MS524 egr-1 for 5’ ATTATTGAATTCCTATACTGGCCGCTTTTC 3’
MS524 egr-1 rev 5’ ATTATTGAATTCCTTCCACAGATGTCGCAG 3’
IP-10
MS524 ip-10 for 5’ ATTATTGAATTCTACCTCTCTCTAGAACCG 3’
MS524 ip-10 rev 5’ ATTATTGAATTCTTCCAGGAGAGTACCTCA 3’
MIP-1 alpha
MS524 mip-1 a for 5’ ATTATTGAATTCAGAATCATGCAGGTCTCC 3’
MS524 mip-1 a rev 5’ ATTATTGAATTCGCATCCGATACACATTTG 3’
4.11 Plasmids used during this work
pUC19:
a small, high copy number E.coli plasmid.
pBJ2:
an expression vector containing the U6 promoter, EBNA1 ORF, the EBV origin of 
replication and the resistance genes for ampicillin and puromycin (a gift from Berit 
Jungnickel, GSF, Germany). 
pBJ3:
an expression vector containing the U6 promoter, an NGFR cassette, EBNA1 ORF, 
the EBV origin of replication and the resistance genes for ampicillin and puromycin 
(a gift from Berit Jungnickel, GSF, Germany).
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p432:
a pUC19 derived plasmid containing a fragment of the LMP1 gene (a gift from 
Wolfgang Hammerschmidt).
pBT34/2:
a pUC19 derived plasmid containing an ORF of the IgM gene (a gift from Bettina 
Kempkes).
The following plasmids were derived from the linker cloning of the cDNA libraries 
into pUC19 (obtained from GPC Biotec AG, Germany). They were either amplified 
or DIG-labelled with the M13 for and M13 rev primers. Subsequently, they were 
either spotted onto “self-made” arrays or used as probes for the Northern blot 
analysis, respectively 
Clone 11A7 contains a fragment of the gene for 30S ribosomal protein
Clone 11E6 contains a fragment of the gene for 30S ribosomal protein
Clone 11K11 contains a fragment of the RDC1 gene
Clone 12A22 contains a fragment of the eIF1 gene 
Clone 12B24 contains a fragment of the FJH1gene 
Clone 12E17 contains a fragment of the NMT1gene 
Clone 12H13 contains a fragment of the CD83gene 
Clone 12K22 contains a fragment of the tubulin alpha gene 
Clone 12M13 contains a fragment of the gene for G protein beta subunit
Clone 12N2 contains a fragment of the SUPTH6 gene
Clone 13L11 contains a fragment of the tubulin alpha gene
Clone 14K13 contains a fragment of the MDH2 gene
Clone 15K19 contains a fragment of the TRAP2 gene
Clone 15K5 contains a fragment of the GCN1 gene
Clone 15L16 contains a fragment of the prothymosin alpha gene 
Clone 15N14 contains a fragment of the prohibitin gene
Clone 16E18 contains a fragment of the isocitrate dehydrogenase gene
Clone 16F3 contains a fragment of the eIF4A gene
Clone 16I9 contains a fragment of the INSIG1 gene
Clone 16M14 contains a fragment of the LAK-4P gene
4.0 Materials
95
Clone 17D12 contains a fragment of the prothymosin alpha gene
Clone 17G5 contains a fragment of the prothymosin alpha gene
Clone 17J22 contains a fragment of the GOS24 gene
Clone 18L6 contains a fragment of the DKFZp434G012 cDNA
Clone 20G22 contains a fragment of the DKFZp762A227 cDNA
Clone 20L19 contains a fragment of the NUDT4 gene
Clone 20L2 contains a fragment of the TCP1 gene
Clone 21B16 contains a fragment of the c-myc gene
Clone 21F17 contains a fragment of the CD37 gene
Clone 21N4 contains a fragment of the spermidine synthetase gene
Clone 3D16 contains a fragment of the SUPTH6 gene 
Clone 3F23 contains a fragment of the p18 gene
Clone 3K5 contains a fragment of the Ser hydroxymethyltransferase 2 gene 
Clone 3L14 contains a fragment of the PTB-associated splicing factor gene
Clone 4C16 contains a fragment of the p38 MAPK gene
Clone 4N23 contains a fragment of the NUDT4 gene
Clone 5A5 contains a fragment of the ATFx gene
Clone 6B15 contains a fragment of the PLEK gene
Clone 8H4 contains a fragment of the ATF5 gene
Clone 9J10 contains a fragment of the CDC37 gene
4.12 Plasmids generated for this work
pMS122:
a pUC19 derived plasmid containing an ORF of the CCR7 gene.
pMS123:
a pUC19 derived plasmid containing an ORF of the CD21 gene.
pMS540/1
a pUC19 derived plasmid containing a fragment of the MIP-1 alpha gene amplified 
with the pair of primers MS524 mip-1 a for/MS524 mip-1a rev.
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pMS540/2
a pUC19 derived plasmid containing a fragment of the SLAM gene amplified with the 
pair of primers MS524 slam for/MS524 slam rev.
pMS540/3
a pUC19 derived plasmid containing a fragment of the PI3K gene amplified with the 
pair of primers MS524 pi3k for/MS524 pi3k rev.
pMS540/4
a pUC19 derived plasmid containing a fragment of the DUSP2 gene amplified with 
the pair of primers MS524 dusp2 for/MS524 dusp2 rev.
pMS540/5
a pUC19 derived plasmid containing a fragment of the bfl-1 gene amplified with the 
pair of primers MS524 bfl-1 for/MS524 bfl-1 rev.
pMS540/6
a pUC19 derived plasmid containing a fragment of the MIP-1 beta gene amplified 
with the pair of primers MS524 mip-1 b for/MS524 mip-1 b rev.
pMS540/7
a pUC19 derived plasmid containing a fragment of the EGR-1 gene amplified with 
the pair of primers MS524 egr-1 for/MS524 egr-1 rev.
pMS540/8
a pUC19 derived plasmid containing a fragment of the lymphotactin gene amplified 
with the pair of primers MS524 lymph for/MS524 lymph rev.
pMS540/9
a pUC19 derived plasmid containing a fragment of the IP-10 gene amplified with the 
pair of primers MS524 ip-10 for/MS524 ip-10 rev.
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pMS540/10
a pUC19 derived plasmid containing a fragment of the PLAB gene amplified with the 
pair of primers MS524 plab for/MS524 plab rev.
pMS500/1
a plasmid generated by the insertion of the MS537 oligonucleotide in the PmlI/EcoRI
linearised pBJ2.
pMS500/2
a plasmid generated by the insertion of the MS537/mm oligonucleotide in the 
PmlI/EcoRI linearised pBJ2.
pMS537
a plasmid generated by the insertion of the NGFR expression cassette in the 
XhoI/BamHI linearised pMS500/1.
pMS537/mm
a plasmid generated by the insertion of the NGFR expression cassette in the 
XhoI/BamHI linearised pMS500/2.
4.13 WWW provided software
BLASTN programme www.ncbi.nlm.nih.gov/blast
GEMS Launcher www.genomatix.de
The design of PCR primers www.alces.med.umn.edu/rawprimer.html
The design of the siRNA sequences www.oligoengine.com
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5.0 Methods 
5.1 Bacterial cell culture
5.1.1. Cultivation and maintenance of bacteria
Bacteria were cultured in the liquid LB-medium at 37 °C with agitation, usually 
overnight (approximately 16 hours). The volume of the culture was adjusted 
according to downstream application. If a single colony was required, bacteria were 
streaked out on the solid LB-agar plates and kept at 37 °C overnight. 
Transformed bacteria were selected for the antibiotic resistance of the transformed 
plasmid through the addition of specific antibiotic required. If bacteria were 
transformed with a plasmid containing the lacZ gene (e.g. pUC19) they were grown 
on LB-agar plates containing isopropyl β-D-thiogalactosidase (IPTG) and X-gal (a 
synthetic analogue of lactose). This process facilitated the distinction of transformants 
containing a plasmid that carries an insert in lacZ (white colonies, indicating non-
functional β-galactosidase) versus transformants with an empty plasmid (blue 
colonies, indicating functional β-galactosidase).
LB-medium: 20 mM MgSO4; 10 mM KCl; 1 % Bacto-Tryptone; 0.5 % 
Bacto-yeast extract; 0.5 % NaCl
LB-agar: 20 mM MgSO4; 10 mM KCl; 1 % Bacto-Tryptone; 0.5 % 
Bacto-yeast extract; 0.5 % NaCl; 1.2 % Bacto-agar
Ampicilin: 100 µg/ml ( for liquid LB-medium)
50 µg/ml (for LB-agar plates)
IPTG: 40 µl of the 100 mM stock solution spread evenly on LB-agar plate
X-Gal: 40 µl of the 40 mg/ml stock solution (in dimethylformamide) spread evenly on LB-
agar plate
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5.1.2 Preparation of competent E.coli
The following procedure yields competent cultures of E.coli that can be transformed 
at frequencies >5 x 108 transformed colonies per microgram of supercoiled plasmid 
DNA. 
Bacteria were streaked on the surface of LB-agar plate directly from a frozen stock 
and incubated at 37 °C overnight. A single bacterial colony was transferred into 5 ml 
of liquid LB-medium and grown at 37 °C overnight. The fresh overnight culture was 
diluted 1:100 in LB-medium and grown at 37 °C with shaking to an OD595=0.15- 0.2. 
Bacteria were kept on ice for 10 min and then centrifuged at 1 100 x g for 15 min at 4 
°C. Pellet was gently resuspended in 1/25 volume of the initial volume of culture of 
ice-cold TFB I. Suspension was kept on ice for 10 min and centrifuged at 1 100 x g 
for 15 min at 4 °C. Pellet was resuspended in 1/8 V of the initial volume of culture of 
ice-cold TFB II. Suspension was kept on ice for 10 min and 0.5 ml aliquots were
stored at -80 °C. 
TFB I: 30 mM KAc; 50 mM MnCl2; 100 mM KCl (or RbCl); 10 mM CaCl2; 15 % glycerol
TFB II: 10 mM MOPS; 10 mM CaCl2; 10 mM KCl (or RbCl); 15 % glycerol
5.1.3 Introduction of plasmid DNA into bacteria
For the transformation of 100 µl of competent bacteria a ligation mixture or 100 ng of 
plasmid DNA were used. Suspension of plasmid and bacteria was incubated on ice for 
30 min, heat shocked at 42 °C for 1.5 min and re-incubated on ice for 2 min. Bacterial 
suspension was kept at room temperature for 10 minutes. 0.9 ml of LB medium was 
added to the bacteria and they were incubated at 37 °C for 1 to 2 hours to acquire the 
antibiotic resistance encoded by the transformed plasmid. Following transformation, 
bacteria were centrifuged at 1 100 x g. Supernatant was decanted and pellet was 
resuspended in 100 µl of the fresh LB-medium. Bacteria were plated on LB-agar plate 
containing the selective antibiotic and incubated at 37 °C overnight. 
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5.1.4 Isolation of plasmid DNA
Essentially, all three methods used for the isolation of plasmid DNA are based on the 
SDS/alkaline lysis method (Sambrook et al., 1989), but are modified according to the 
yield and the purity of the plasmid DNA preparation required for the specific 
application.
5.1.4.1 Small-scale preparation of plasmid DNA
For small-scale preparation of plasmid DNA two methods were used. 
If there were no special requirements for a high quality of the isolated plasmid DNA 
(e.g. digestions following cloning procedure), the following method was used. Single 
colonies obtained from LB-agar plates were inoculated into 5 ml LB-medium 
containing selective antibiotic and kept at 37 °C overnight with agitation. 1.5 ml of 
the overnight culture was pelleted and the supernatant was removed. Pellet was 
resuspended in 200 µl of Solution I until suspension was homogeneous. The equal 
volume of Solution II was added. Mixture was gently mixed by turning the tube 
upside-down and this mixture was kept at room temperature for 5 min. Solution III 
was subsequently added for neutralisation and the mixture was gently mixed. This 
mixture was centrifuged at 4 °C for 10 min at >4 600 x g. The 1 volume of 
isopropanol was added to the supernatant and re-centrifuged at 4 °C for 30 min at >4 
600 x g. The precipitated plasmid DNA formed a visible white pellet. Pellet was 
washed twice with 300 µl of 70 % ethanol, air-dried and dissolved in 50 µl of water. 
For a small-scale preparation of a highly pure plasmid DNA (for sequencing, cloning 
etc.) a NucleoSpin Plasmid kit was used according to the manual. Briefly, the 
bacterial pellet was obtained as described above. The homogeneous bacterial 
suspension containing RNase was lysed by adding lysis solution and neutralised by 
addition of the neutralisation solution. Mixture was centrifuged at 4 °C for 10 min at 
>4 600 x g. Supernatant containing DNA was loaded onto a silica membrane packed 
in a column. After several centrifugation steps in which a DNA bound to a column 
was washed and precipitated, the elution step was done by applying 50 µl of water to 
a column and centrifuging.
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Solution I: 50 mM Tris-HCL, pH 8.0; 10 mM EDTA
Solution II: 200 mM NaOH; 1 % (w/v) SDS
Solution III: 3.1 M K-acetate, pH 5.5
5.1.4.2 Large-scale preparation of plasmid DNA
If large amounts of a highly pure plasmid DNA were required (for cloning, 
transfection etc.) a JET STAR plasmid purification system based on an anion 
exchange separation was used according to instructions supplied by manufacturer. 
Briefly, a bacterial culture was prepared by inoculating 1 ml of 5 ml overnight 
suspension culture in 400 ml of LB-medium with the selective antibiotic. Following 
overnight incubation at 37 °C with agitation the bacteria were centrifuged at 1 100 x g 
for 15 min. Pellet was resuspended in solution containing RNase and lysed in 1 V of 
SDS/NaOH solution for 5 min. Mixture was neutralised by adding 1 V of neutralising 
solution containing K-acetate. Suspension was centrifuged and the supernatant was 
applied to a previously equilibrated column. A column was allowed to empty by 
gravity flow and washed. Elution has been done with a solution containing Tris-HCl, 
pH 8.5. DNA was precipitated with 0.7 V of isopropanol and centrifuged at 4 °C and 
> 4 600 x g for 30 min. The plasmid DNA pellet was washed with 70 % ethanol and 
re-centrifuged. Air-dried pellet was dissolved in 200 µl of water. 
5.2 Eukaryotic cell culture
5.2.1 Cultivation of eukaryotic cells in culture
Eukaryotic cells were cultured in either suspension or as adherent cells in complete 
medium at 37 °C in a 6 % CO2 atmosphere. Cells in suspension were usually split 
every third day 1:3 with the fresh complete medium so that the final density of the 
cells was 5 x 105cell/ml. Some cells used in this work required additional supplements 
in order to grow: oestrogen or tetracycline. In some experiments cells were grown in 
the presence of the protein synthesis inhibitor cycloheximide. 
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Adherent cells CD40L-L were treated with 1 ml of Versene solution per approx. 15 
cm2 of the growing surface. Cells were detached from the flask surface with the splash 
of complete medium and washed from Versene in 5 V of complete medium at 310 x g 
for 6 min. These cells were split 1:6 every third day. 
The living cells were distinguished from the dead cells by tryphan-blue exclusion. 
Cell suspension was diluted 1:1 with 0.4 % tryphan-blue solution and counted in the 
improved Neubauer chamber. Dead cells were identified by blue staining, which is 
caused by the incapability of dead cells to exclude the dye.
Complete medium: RPMI 1640-medium; 100 U/ml penicillin; 100 µg/ml streptomycin; 
2 mM L-glutamine; 10 % foetal calf serum (FCS)  
Medium with oestrogen: 1 µM β-oestradiol in complete medium
Medium with tetracycline: 1 µg/ml tetracycline in complete medium
Medium with cycloheximide: 50 µg/ml cycloheximide in complete medium
5.2.1.1 Activation of the ER/EBNA2 fusion protein by oestrogen
Cells were grown in complete medium supplemented with oestrogen up to density of 
1 x 106 cells/ml and then harvested. Pellet was washed three times in PBS 
supplemented with 10 % FCS. Cells were then counted and seeded at density 5 x 105
cells/ml in the plain complete medium. Oestrogen was re-added to the culture 72 
hours later and cells were further treated according to the experimental conditions.
PBS, pH 7.3: 137 mM NaCl; 2.7mM KCl; 4.3 mM Na2HPO4 x 7 H2O; 1.4 mM KH2PO4
5.2.2 Transfections of 721 lymphoblastoid cells
Recombinant plasmids are introduced into eukaryotic cells by electroporation. 721 
cells are lymphoblastoid cells and were grown up to a density of 1 x 106 cells/ml. 
Cells were harvested, washed once in PBS and resuspended at density 4 x 107
cells/ml. 1 x 107 cells was added to sufficient amount of vector and electroporated in 
the 4 mm electroporation cuvette at 220 V/950 µF. Immediately after electroporation 
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the cells were resuspended in 1 ml of complete medium and transferred into 9 ml of 
the fresh complete medium. Cells were cultured under the standard conditions.
5.2.3 Ficoll-Paque cell separation
Ficoll-Paque™ PLUS (Pharmacia, USA) was used for simple and rapid lymphocyte 
separation from cell debris, dead cells and other types of cells. Suspension of cells 
was layered onto a Ficoll-Paque™ PLUS in 1:1 ratio and centrifuged at room 
temperature for 30 min at 400 x g with a slow acceleration and deceleration. The 
interphase containing lymphocytes was collected and washed with PBS three times at 
380 x g, 350 x g and 310 x g, respectively. The final cell suspension was resuspended 
in an appropriate volume of complete medium.
5.2.4 Cell sorting on magnetic microbeads
MACS colloidal super-paramagnetic microbeads conjugated to goat anti-mouse IgG 
F(ab)2 fragments (Miltenyibiotec, USA) were used for the positive selection of cells 
labelled with primary mouse IgG antibodies according to the instruction of the 
manufacturer. Before separation, a cell suspension was subjected to density gradient 
centrifugation using Ficoll-Paque™ PLUS to remove the dead cells and cell debris. 
Cells were labelled with primary mouse IgG antibody. Subsequently, cells were 
incubated with with goat anti-mouse IgG coupled microbeads and separated on a 
column which was placed in the magnetic field of a MACS separator. Cells adhering 
to magnetic beads were retained in the column while the unlabeled cells ran through. 
Thus, unlabelled cells were depleted from the labelled cells. After removal of the 
column from the magnetic field, the magnetically retained cells were eluted as a 
positively selected cell fraction.
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5.2.5 Indirect immunofluorescence labelling
Usually, 1 x 106 cells were washed once with PBS and resuspended in10 µl of FACS 
buffer containing a sufficient amount of the primary antibody. After 30 min on ice, 
cells were washed twice at 310 x g, resuspended in 10 µl of FACS buffer containing a 
sufficient amount of the secondary antibody and incubated for another 30 min on ice. 
The secondary antibody was a fluorochrome-labelled antibody directed towards the 
primary antibody. Finally, cells were washed twice with FACS buffer and 
resuspended in 1 ml of FACS buffer and analysed by flow cytometry.
FACS buffer: PBS with 0.1 % sodium azide; 2 % FCS 
5.2.6 Cell fixation and DNA staining for cell cycle analysis
This method of DNA staining utilizes ethanol to fix the cells and permeabilize the 
membrane, which allows the propidium iodide dye (PI) to enter the cells. Cells were 
pelleted and resuspended in 500 µl of PBS and chilled on ice for 10 min. The cold cell 
suspension was rapidly mixed with the 1 volume of ice-cold absolute ethanol and kept 
on ice for 15 min. Subsequently, cells were centrifuged for 3 min at 310 x g, 
supernatant was carefully removed and the RNase solution was added followed by 
incubation at 37 °C for 15 min. The PI solution was added and the cells were allowed 
to stand at room temperature at least 30 min. Cells were analysed on the flow 
cytometer using the FL3 channel detection (620 nm).
RNase solution: 20 µg/ml RNase in PBS
Propidium iodide (PI) solution: 50 µg/ml propidium iodide (PI) in PBS
5.2.7 Isolation of primary B cells 
Primary B cells were isolated from the human tonsils and separated from the rest of 
tonsillar cells by the method of sheep red blood cells (SRBC) rosetting. Tissue was 
minced, then teased into a single cell suspension through the net and layered onto 
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Ficoll-Paque™ PLUS cushion. The lymphocyte fraction was isolated as described 
above. The lymphocyte suspension was diluted to 1 x 107 cells/ml and mixed with 
1:50 volume of sheep blood and incubated at 37 °C for 10 min. The cell suspension 
was transferred on ice and incubated for another 50 min. Subsequently, the cell 
suspension was again layered onto a Ficoll-Paque™ PLUS cushion followed by 
centrifugation. The interphase contained >95 % B cells while the SRBC-T cell 
rosettes were clumped at the bottom. The purity of the cell populations before and 
after separation was confirmed by flow cytometry using the CD19-specific 
phycoerythrin conjugated and CD3-specific fluorescein-isothiocyanate conjugated 
monclonal antibodies. 
5.2.8 EBV infection of B cells
EBV was obtained from B95.8 cells. Cells were grown in complete medium to the 
density of 1 x 106 cells/ml and were kept in culture for another five days until medium 
was completely yellow. Cells and cellular debris were removed from the virus by 
centrifugation at 310 x g followed by filtration through a 0.8-µm filter. Primary B 
cells were resuspended in the viral supernatant. Cells were cultured under the standard 
conditions. After 24 h, half of the medium was replaced by the fresh medium.  
5.2.9 Cultivation of primary B cells on the CD40L monolayer
CD40L cells grow as adherent cells. At confluence >80% these cells were irradiated 
with 6 000 rad and washed with PBS. Primary B-cells, isolated as described above, 
were resuspended in complete medium containing 100 U/ml of the human 
recombinant IL-4 and seeded on the CD40L monolayer at density 1 x 106 cells/ml.
5.2.10 DNA synthesis and cell proliferation assays
Methods which measure the DNA synthesis rate were used for the determination of S 
phase entry, cellular proliferation, viability and activation.
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5.2.10.1 BrdU Enzyme Linked Immunosorbent Assay
5-bromo-2’-deoxy-uridine (BrdU) incorporates into DNA during DNA synthesis. The 
amount of incorporated BrdU can be easily quantified using monoclonal antibody 
against BrdU by enzyme linked immunosorbent assay (ELISA). The experiment was 
done according to the instructions of the kit used herein. Briefly, cells were cultured 
in triplicate in 96-well plate in the presence of BrdU for 4 hours. Cells were spun 
down at 310 x g for 10 min in a centrifuge with a rotor device for microtiter plates. 
Supernatant was removed and the cells were fixed in fixative at -20 °C for 30 min. 
Subsequently, the fixative was removed and cells were treated with nuclease at 37 °C 
for 30 min. Cells were washed, the anti-BrdU antibody conjugated with peroxidase 
was added and incubated at 37 °C for 30 min, cells were washed again and a 
peroxidase substrate was added. The incubation of the reaction with a substrate was 
determined by the coloured reaction of the control cells and ranged between 20 and 45 
minutes. Extinction of the samples was measured in a microtiter plate reader at 465 
nm. Culture medium alone and cells incubated with the peroxidase-labelled anti-BrdU 
antibody in the absence of BrdU were used as controls for non-specific binding.
Fixative: 70 % ethanol; 0.5 M HCl
5.2.10.2 3H-thymidine incorporation assay
As an alternative to the BrdU ELISA the incorporation of radioactive 3H-thymidine 
into DNA was performed when a high sensitivity was required. Cells were cultured in 
triplicate cultures in 96-well plates and pulsed for 4 h with 0.5 µCi of 3H-thymidine 
per 150 µl of culture. Cells were lysed with water and the cell content was harvested 
on Uni-Filterplates-96 which immobilises DNA. Plates were dried and taped at the 
bottom. 25 µl of the scintillation fluid was added to each sample. Plates was taped at
the top and measured in a Micro Plate Scintilation Counter.   
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5.3 Molecular biology techniques
5.3.1 Polymerase chain reaction 
Polymerase chain reaction (PCR) is an in vitro method for the enzymatical synthesis 
of defined sequences of DNA. It uses sequence-specific oligonucleotide primers that 
hybridize to complementary strands and flank the target DNA sequence which is to be 
amplified. The elongation of the primers is catalysed by DNA polymerase. In this 
work, reactions were performed in either 100 or 50 µl volume. In the case of multiple 
reactions a master mix containing all components was prepared and divided in the 
separate PCR tubes. The amount of template was variable and depended on DNA 
used as a template: for the genomic DNA 100 ng was used, for plasmid DNA 20 ng 
and for cDNA 3 µl of reverse transcription reaction. The amplification was performed 
in a PCR System 9600 cycler machine. A standard PCR consisted of initial 
denaturation performed at 93 °C for 3 min, followed by the multiple rounds of 
reactions (30-40 cycles) with the conditions as follows: denaturation at 93 °C for 1 
min, primer annealing at temperature usually 3-6 °C lower then the Tm of primers for 
30 s and elongation at 72 °C for 1 to 2 min depending on the size of the amplified 
product. The final step of every PCR was final elongation at 72 °C for 7 min.
PCR Master Mix: 1 x PCR buffer (including 0.15 mM MgCl2); dNTP mix (0.1 mM of each 
dNTP); 0.25 mM MgCl2;  0.1 µM primer A; 0.1 µM primer B; 5 U Taq 
DNA polymerse; variable amount of template; water up to final volume of 
50 or 100 µl
5.3.2 Agarose gel electrophoresis and purification of DNA fragments 
Electrophoresis through agarose gel is a standard method used to separate, identify 
and purify DNA fragments. Agarose gel was prepared by melting a sufficient amount 
of agarose powder in 1 x electrophoresis buffer. Buffers used for electrophoresis were 
either TAE or TBE. An 1 % agarose gel is usually of sufficient density to separate 
fragments from 0.5 to 5 kb. For smaller fragments of DNA, an agarose gel of higher 
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density (1.5-2 %) should be used. For larger DNA, an agarose gel of lower density 
(0.3-0.7 %) is useful. Voltage used for electrophoresis is adjusted according to the 
size of gel and is usually 5 V per 1 cm of the gel length. Ethidium bromide, a 
fluorescent dye that intercalates between the stacked base pairs, is used to visualise 
DNA in the gel on the source of UV light. The size of DNA fragment is determined 
by comparison with the standardised DNA ladder containing dsDNA fragments in the 
same range as expected ones. 
PCR products were purified by electrophoresis and isolated from agarose gel with a 
QIAquick Gel Extraction Kit according to manual instructions. Briefly, a band of 
expected size was excised from gel with a clean scalpel and 3 volume of the QB 
solution (a solution provided by kit, the composition unknown) was added. Tube 
containing the excised fragment was kept on the 50 °C for 10 min for agarose to melt. 
Suspension containing the melted agarose was applied to the column and the several 
washing and precipitation steps have been performed. As the final step, DNA was 
eluted from the column with 50 µl of water. PCR products purified in this way can be 
subjected to sequencing or used for cloning.
TAE: 40 mM Tris-acetate, 1 mM EDTA
TBE: 45 mM Tris-borate, 1 mM EDTA
5.3.3 Strategies for cloning in plasmid vectors
All cloning procedures in this work were done as a straightforward ligation of inserts 
carrying protruding termini identical to termini in the linearised plasmid vector 
(Sambrook et al., 1989). Plasmid DNA is cleaved with one or alternatively two 
restriction enzymes and the 5’-phosphate groups were removed with alkaline 
phosphatase to prevent self ligation and the circularisation of plasmid DNA in the 
following ligation step. Insert DNA fragments were designed to carry sites for the 
identical restriction enzymes used for linearization of the plasmid vector. DNA 
fragments were obtained either as oligonucleotides or the products of PCR. After the 
digest step both, plasmid and insert were purified by the agarose gel electrophoresis. 
Ligation reaction was set up in 10 to 20 µl volume. The molecular ratio of vector to 
insert was 1:3. Ligation was performed at 16 °C overnight in the presence of 40 U of 
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T4 DNA ligase. 100 µl of competent bacteria was transformed with the total ligation 
reaction and plated on the selective LB-agar plates. Single colonies were inoculated 
for the miniprep isolation of plasmid DNA and the correct clones were verified 
according to the restriction fragment size in comparison to an empty vector.
5.4 Methods for the analysis of RNA
5.4.1 Isolation of the total RNA
The total RNA was isolated from animal cells growing in the cell suspension or from 
primary B cells. For that purpose, a Qiagen RNeasy kit was used according to manual 
instructions. For samples containing 5 x 106 cell to 1 x 108 cells the Midi version of 
this kit was used, for less cells the Mini version was used. Cells were spun down at 
300 x g for 7 min and washed once with PBS. Cells were then lysed and homogenised 
under the highly denaturing conditions of guanidinium isothiocynate and β-
mercaptoethanol, which immediately inactivate RNase to ensure the isolation of intact 
RNA. Ethanol was added to provide appropriate binding conditions and the sample 
was applied to a spin column where the total RNA bound and contaminants were 
washed away. After washing steps, RNA was eluted in 500 or 50 µl of DEPC-water, 
for Midi or Mini version, respectively. RNA was precipitated with 2 volumes of 
absolute ethanol and 0.1 volume Na-acetate at -20 °C for 2 h. The precipitated RNA 
was pelleted at 4 °C for 30 min. Pellet was dissolved in 20-100 µl of DEPC-water. 
The RNA concentration was determined by measuring the absorbance at wave length 
260 nm.
The purified RNA was ready for any of the downstream application such as Northern 
blotting, cDNA synthesis, real-time PCR and poly A+ RNA selection.
5.4.2 Northern blot analysis
One way to detect and/or quantitate the specific mRNA molecules in the preparations 
of the cellular RNA is the Northern blot analysis. It consists of the following steps: 
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labelling of the probe specific for the target mRNA, RNA formaldehyde agarose gel 
electrophoresis, blotting, hybridisation of the blot with the labelled probe and 
detection of the signals from the labelled probe. 
5.4.2.1 Labelling of the probe
The specific probe was PCR-labelled with digoxigenin-dUTP. PCR was set up by 
adding all reagents (see below) to a template DNA. cDNA or plasmid DNA with a 
specific insert can serve as a template. Plasmid DNA used as a template gives higher 
yield and a purer probe, and was therefore used in this work. The PCR conditions 
were the following: initial denaturation at 95 °C for 2 min, 30 cycles of denaturation 
at 95 °C for 30 s, annealing at temperature depending on the primer design for 30 s, 
elongation at 72 °C for 40 s with the prolongation of 5 s for each subsequent cycle, 
finally, elongation at 72 °C for 10 min was performed as a last step. The size and the 
concentration of the DIG-labelled probe was determined by agarose gel 
electrophoresis. 
PCR mix: 1 x buffer, 0.5 mM dNTP, 0.5 x DIG labelling mixture, 0.625 mM MgCl2,                    
0.25 mM of each primer, 2.5 U Taq DNA polymerase, 40 ng DNA plasmid as                           
template, water up to 20 µl
DIG labelling mix: 1 mM dATP, 1 mM dGTP, 1 mM dCTP, 0.65 mM dTTP, 0.35 mM DIG dUTP
5.4.2.2 RNA formaldehyde agarose gel electrophoresis
RNA was separated according to size by electrophoresis through a denaturing agarose 
gel containing formaldehyde. The electrophoresis chamber was cleaned with 0.1% 
SDS before pouring the gel. 1 % agarose gel containing formaldehyde was poured in 
the clean gel support and left to solidify for at least 20 min. The amount of RNA 
sufficient for the Northern blot analysis ranged between 5 and 10 µg. RNA was 
placed in the clean tube and subjected to speedvac evaporation. The dried RNA was 
dissolved in 20 µl of the denaturing buffer and denatured at 70 °C for 5 min. The 
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denatured RNA was loaded on the gel and electrophoresis was run at 40 V overnight 
in the 1 x MOPS running buffer. 
1 % RNA agarose gel: 1 % agarose, 1 x MOPS, 6.4 % formaldehyde
RNA denaturing buffer: 1 x MOPS, 6.4 % formaldehyde, 5 % glycerol, 0.005 % ethidium 
bromide, 0.05 % bromphenol blue, water up to final volume  
5.4.2.3 Transfer of the denatured RNA to the nylon membrane
After the gel electrophoresis ran far enough the equal loading of RNA was visualised 
by UV-light and documented by the Polaroid photography. The transfer of RNA from 
gel to the positively charged nylon membrane (Hybond-N+) was done overnight by 
the capillary elution in 20 x SSC. Ribosomal RNAs were used as size markers and the 
positions were marked on the membrane. Finally, membranes with the bound RNA 
were UV-crosslinked.
20 x SSC: 3 M NaCl, 0.3 M trisodium citrate, pH 7.0
5.4.2.4 Hybridisation and detection of the probe/target hybrids by 
chemiluminescence
Membrane was washed with 2 x SSC and prehybridised in Hyb-mix solution at 68 °C 
for 30 min. A DIG-labelled probe (10 ng/ml of Hyb-mix solution) was denaturated in 
boiling water bath for 10 min, cooled on ice and added to the pre-heated Hyb-mix 
solution. The prehybridisation solution was replaced by the Hyb-mix solution 
containing the probe. Hybridisation was performed at 68 °C overnight. The following 
day, the membrane was washed 3 x with Hyb-wash buffer at 65 °C. All subsequent 
incubations and washings were done at room temperature. Membrane was incubated 
in blocking solution for 60 min, then 30 min in Ab-blocking solution, washed 4 x with 
wash buffer, equilibrated 5 min with substrate buffer and finally incubated with 
CSPD-Ready-to-use substrate and exposed to the X-ray film. Time required for the 
detection of signals on the film ranged between 2 min to 16 hours. 
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Hyb-mix: 25 mM Na2HPO4, pH 7.2; 1 mM EDTA; 10 % SDS, 0.5 % blocking reagent
Hyb-wash buffer: 20 mM Na2HPO4, pH 7.2; 1 mM EDTA; 1 % SDS
Blocking solution: 0.5 % blocking reagent; 100 mM maleic acid, pH 8.0; 3 M NaCl; 0.3 % 
Tween 20
Ab-blocking solution: anti-DIG-AP-antibody diluted 1:15 000 in blocking solution
Wash buffer: 100 mM maleic acid, pH 8.0; 3 M NaCl; 0.3 % Tween 20
Substrate buffer: 100 mM Tris HCl, pH 9.5; 100 mM NaCl; 50 mM MgCl2
5.4.3 Reverse transcription
In order to quantify the specific mRNA by real-time PCR the mRNA had to be 
transcribed into cDNA by a process called reverse transcription (RT). 2 µg of total 
RNA were mixed with 1 µg of (dT)15 primer in a total volume of 14 µl and heated at 
70 °C for 5 min to denature the secondary structure. Tubes were placed on ice and 11 
µl of the RT reaction mix was added. Reaction was incubated at 42 °C for 60 min.
RT reaction mix: 1 x M-MLV buffer; 0.625 mM of each dNTP; 200 U M-MLV reverse 
transcriptase; 25 U RNase inhibitor
5.4.4 Real time PCR
Real-time PCR is yet another technique for quantification of mRNA in a sample. It is 
based on the measuring of the increasing incorporation of the fluorescent SYBR 
Green I dye into dsDNA. It was performed on a LightCycler (Roche, Germany) by 
using LightCycler-FastStart DNA Master SYBR Green I ready-to-use kit according to 
the instruction manual with minor modifications. LC master mix was prepared for all 
samples and 18 µl aliquots were given to each capillary. Sample cDNA was diluted 
1:20 and added to the LC master mix. Previously amplified PCR products of the same 
sequence were diluted in several subsequent 1:100 dilutions and used as relative 
standards for quantification. Capillaries were sealed and centrifuged at 700 x g for 5 s. 
Each real-time PCR started with initial denaturation at 95 °C for 10 min. 55 cycles 
followed, each containing the following conditions: heating up to 95 °C, annealing at 
65 °C for 10 s and amplification at 72 °C. The amplification time depended on the 
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sequence length and it was calculated according to the DNA polymerase amplification 
rate which is 25 bp in 1 s. The authenticity of amplicon was verified by melting curve 
made by slowly increasing the temperature from 65 °C up to 95 °C with a ramp time 
0.15 °C/s. Additionally, PCR products can be subjected to agarose gel electrophoresis 
to verify the PCR quality. Finally, the reaction was cooled to 40 °C. 
LC master mix: 13.4 µl water; 1.6 µl MgCl2 (25 mM); 1 µl of each primer (10 mM); 1 µl 
MasterSYBR Green I 
5.4.5 Nuclear run-on
Nuclear run-on was performed essentially as described by Eick and Bornkamm, 1986.
It consists of several steps including the isolation of nuclei, run-on reaction, 
hybridisation, wash and the detection of signals.
5.4.5.1 Isolation of nuclei
Nuclei were isolated from 1 x 108 cells per one run-on reaction. Cells were spun down 
at 310 x g for 7 min at 4 °C and washed once with the ice-cold PBS. Cells were 
resuspended in 20 ml lysis-buffer and incubated for 5 min on ice. The nuclei 
suspension was spun down at 472 x g for 10 min at 4 °C and the supernatant was 
carefully removed. Nuclei were resuspended in 100 µl of storage buffer and snap-
frozen in liquid nitrogen followed by storage at -80 °C.
Lysis buffer: 10 mM NaCl; 10 mM MgCl2; 10 mM Tris-HCl, pH 7.5; 0.5 % NP40
Storage buffer: 40 % glycerol; 5 mM MgCl2; 0.1 mM EDTA; 50 mM Tris, pH 8.3
5.4.5.2 Nuclear run-on
The nuclei suspension was defrosted on ice and 100 µl of 2 x Run-on buffer and 100 
µCi of 32P-CTP were added. Mixture was incubated at 28 °C for 15 min. DNA was 
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degraded by the two rounds of DNaseI treatment at room temperature for 10 min. 
Proteins were degraded by adding 20 µl of proteinase K/SDS solution and incubation 
at 40 °C for 60 min. The reaction products were purified by size exclusion columns 
(NICK-Columns, Pharmacia). The radioactive nuclide incorporation should range 
between 50 and 80 million DPM/sample. The run-on probes were hybridised to “self-
made” DNA arrays.
4 x Run-on buffer: 600 mM KCl; 10 mM MgCl2; 1 mM ATP; 1 mM GTP; 1 mM UTP; 20 mM 
Tris, pH 8.0; 2.4 % sarcosyl
Proteinase K/SDS: 3 V proteinase K (10 mg/ml); 1 V SDS (10 %)
5.4.5.3 Hybridisation and washing of „self-made“ DNA arrays
„Self-made“ arrays were prepared by spotting the PCR products of genes of interest 
onto the nylon membrane. Membrane was dried and DNA was denatured by soaking 
the membrane into denaturising solution for 1 min, neutralised by neutralisation 
solution for 1 min, washed with 2 x SSC and finally crosslinked by UV. Each 
membrane was equilibrated with an Express-Hyb solution (Clontech, Sao Paolo, 
USA) containing 0.1 mg/ ml denatured shared salmon testes DNA at 68 °C for 30 
min. The labelled RNAs were denatured at 95 °C for 5 min, added to a preheated 
Express-Hyb and together they were applied to the membrane. Membrane was 
hybridised at 68 °C for 48 h, and then washed at 45 °C twice with solution I and twice 
with solution II. Solution III was used to wash away SDS and then the membrane was 
washed with solution III/Rnase at room temperature for 20 min. Subsequently, the 
membrane was washed twice with solution II and exposed to the phosphoimager 
plate.
Denaturing solution: 0.5 M NaOH; 1.5 M NaCl
Neutralisation solution: 0.5 M Tris, pH 7.4; 1.5 M NaCl
Solution I: 2 x SSC; 1 % SDS
Solution II: 0.1 x SSC; 0.5 % SDS
Solution III: 2 x SSC; 1mM EDTA
Solution III/RNase: 2 x SSC; 1 mM EDTA; 2 µg/ml RNase A
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5.4.6 DNA microarray techniques
5.4.6.1 ExpressCode™ DNA microarray 
The ExpressCode™ DNA microarray was developed by GPC Biotec AG, Germany, 
and hybridisation and analysis were done in collaboration. 
The 9 600 PCR products of three different cDNA libraries were arrayed at high 
densities on the 8x12 cm nylon membrane and hybridised with the 32P-labelled DNA 
generated by reverse transcription from different RNA populations. Briefly, 200 ng of 
mRNA was reverse transcribed with random hexamers as primers in the presence of 
the master mix at 42 °C for 1 h. Samples were purified on a SpinColumns (Roche) 
and added to Hybsolution. Hybsolution with the probe was applied to UV crosslinked 
membranes and hybridised at 50 °C for 40 h. Membranes were washed twice with 
wash solution I and twice with wash solution II. Each washing step was performed at 
65 °C for 15 min. The expression pattern on the membranes was analysed by 
phosphoimager. A statistical confidence derived from the four replicates of each 
experiment. Clones which show induction were sequenced and identified by 
BLASTN programme.
Master mix: 1 x First Strand Synthesis Buffer; 50 µCi 32P-dCTP; 0.6 mM dATP; 0.6 mM 
dTTP; 0.6 mM dGTP; 4 µM dCTP; 100 mM DTT; 100 U RNase inhibitor; 
200 U SuperScript reverse transcriptase 
Hybsolution: 0.7 % SDS; 50 % formamide; 5 x SSC; 50 mM Na2HPO4; 2 % milk powder
Wash solution I: 1 % SDS; 2 x SSC
Wash solution II: 0.5 % SDS; 0.1 x SSC
5.4.6.2 GeneChip® DNA microarray
The hybridisation and data analysis of the GeneChip® DNA microarray (Affymetrix 
Inc., USA) were done in collaboration with Jörg Mages (Institute of Medical 
Microbiology, Munich) and Reinhard Hoffmann (Max von Pettenkofer Institute, 
Munich). GeneChip® Human Genome U133A was used in this work. It contains 
>15000 genes on an array of 1.28 x 1.28 cm. 
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RNA was isolated from the different cell populations. Quality control of all RNAs 
was performed by the measurement of OD260/280 ratio (>1.6) and gel 
electrophoresis. 5-20 µg of total RNA were subjected to a first strand cDNA synthesis 
with 100 µmol of oligo-dT-T7 primer in the presence of the First Strand master mix at 
42 °C for 1 h. Second strand cDNA was synthesised in the presence of Second Strand 
master mix at 16 °C for 2 h. Subsequently, the mixture was incubated with 10 U of T4 
DNA polymerase at 16 °C for 5 min to fill the protruding 3’ tails. RNA was digested 
with RNase at 37 °C for 30 min and 25 µg of proteinase K was used to degrade 
proteins at 37 °C for 30 min. cDNA was extracted with 
phenol/chloroform/isoamylalcohol (50:49:1) three times. The final volume was 
reduced by Microcon-YM50 Columns (Millipore, USA). cRNA was made from 
cDNA by in vitro transcription using RNA Transcript Labelling kit (Enzo 
Diagnostics, Inc., USA) according to the manual instructions and purified with the 
RNeasy kit (Qiagen, Germany). The final step in the preparation of probes was 
fragmentation of 15 µg of cRNA with 5 x fragmentation buffer at the 95 °C for 20 
min. cRNA was added to Hybridisation Cocktail and heated at 95 °C for 5 min. The 
probe array cartridge was filled up with Hybridisation Cocktail and hybridised for 16 
h. Following hybridisation, chip was washed in Affymerix FluidicsStation 400 with 
the non-stringent and stringent buffer. The fluorescent signals were detected by 
washing the chip with Stain solutions I, II and III. Chip was scanned and the data 
were analysed. 
First Strand Master mix: 100 U RNase inhibitor; 1 x First Strand buffer; 10 mM DTT; 0.5 mM each 
dNTP; 200 U Superscript II reverse transcriptase
Second Strand Master mix: 1 x Second Strand buffer; 0.2 mM each dNTP, 10 U E. coli DNA ligase; 
40 U E.coli DNA polymerase I; 2 U RNase H; water up to final volume
5 x fragmentation buffer: 200 mM Tris-acetate, pH 8.1; 500 mM KOAc; 150 mM MgOAc
Hybridisation Cocktail: 50 pM control oligonucleotide B2; 1X eukaryotic hybridisation controls 
(bioB, bioC, bioD, cre); 0.1 mg/ml herring sperm DNA; 0.5 mg/ml BSA; 1 
hybridisation buffer, water up to final volume
Non-stringent buffer: 75 mM MES sodium salt; 27.5 mM MES free acid monohydrate; 0.1 M 
NaCl; 0.01 % Tween 20
Stringent buffer: 0.9 M NaCl; 60 mM NaH2PO4; 6 mM EDTA; 0.01 % Tween 20
Stain solution I: 1 mg/ml streptavidin in Stain buffer
Stain solution II: 10 mg/ml anti-streptavidin goat antibody; 0.5 mg/ml biotinylated anti-
streptavidin goat antybody in Stain buffer
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Stain solution III: 1 mg /ml Streptavidin-Phycoerytrin (SAPE) in Stain buffer
Stain buffer: 150 mM MES sodium salt; 200 mM MES free acid monohydrate; 1.85 M 
NaCl; 0.1 % Tween 20
5.5 Methods for the analysis of proteins
5.5.1 Preparation of protein extracts
Protein extracts were usually made from 1 x 107 cells. Cells were harvested and 
washed in PBS at 310 x g for 6 min at room temperature. They were resuspended in 
100 µl of single-detergent lysis buffer (Sambrook et al., 1989) containing DTT and 
protease inhibitor. Suspension was incubated on ice for 30 min. Proteins were 
separated from the cellular debris by centrifugation at 12 000 x g for 30 min at 4 °C. 
Supernatant containing proteins was separated into a clean tube and kept on ice or 
stored at -80 °C. The protein concentration was determined using Bradford method 
and measured at OD595 with the BSA dilutions as standards. 
Single-detergent lysis buffer: 50 mM Tris-HCl, pH 8.8; 150 mM NaCl; 0.02 % Na-azide; 1 % 
NP-40; 2 mM DTT; 1 x Complete protease inhibitor cocktail 
solution (Roche, Germany)
Bradford solution: 100 mg/l Coomassie brilliant blue, 5 % absolute ethanol, 8.5 % 
phosphoric acid, water up to final volume
5.5.2 Western blot analysis
The sufficient amount of proteins (between 10 and 80 µg) was denatured by the 
addition of loading buffer and heating at 95 °C for 10 min. The protein suspension 
was separated on an 8 % denaturing SDS-polyacrylamide gel electrophoresis in 
conjunction with a 5 % polyacrylamide stacking gel. Gel electrophoresis was 
performed at 30 mA in 1 x running buffer. The stained marker standards were 
separated simultaneously on the same gel and were used for the estimation of 
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molecular weight. Proteins were blotted to a PVDF membrane using electroblotting at 
400 mA in blotting buffer for 60 min. Following the transfer, membrane was 
incubated with blocking buffer for 1 h at room temperature in order to reduce the 
unspecific protein-binding capacity of the membrane. The primary antibody was 
diluted in a fresh blocking buffer which was added to the membrane. Membrane was 
incubated for 30 min and then washed 4 x with washing buffer. The peroxidase 
conjugated secondary antibody was diluted also in a fresh blocking buffer and applied 
to the membrane. Following 30 min of incubation with the secondary antibody, the 
membrane was washed 4 x with washing buffer. The ECL solution was used as a 
substrate for the peroxidase and the protein-antibody complex were detected by the 
chemoluminescence reaction by exposure to the X-ray film.
4 x loading buffer: 60 mM Tris, pH 6.8; 4 % SDS; 4 % glycerol; 0.05 % bromphenol blue;                                    
4 µM DTT; 0.2 µM EDTA
8 % polyacrylamide gel: 8 % acrylamide mix (37 %); 375 mM Tris, pH 8.8; 0.1 % SDS; 0.1 %   
ammonium persulfate; 0.6 µl/ml TEMED, water up to final volume
5 % stacking gel:          5 % acrylamide mix (37 %); 125 mM Tris, pH 6.8; 0.1 % SDS; 0.1 %         
ammonium persulfate; 1 µl/ml TEMED; water up to final volume 
Running buffer: 25 mM Tris-base; 200 mM glycin; 0.1 % SDS
Blotting buffer: 25 mM Tris-base; 0.2 M glycin; 0.1 % SDS; 20 % methanol
Blocking buffer: 5 % milk powder; 0.5 M Tris, pH 7.5; 150 mM NaCl
Washing buffer: 0.05 % Tween 20 in PBS
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6.0 Summary
EBNA2 is one of the first viral proteins expressed post-EBV infection and is 
absolutely required for the process of B cell immortalisation. EBNA2 transactivates 
other viral genes, but it also enhances or represses the transcription of many cellular 
genes. These primary viral and cellular EBNA2 target genes initiate a cascade of 
secondary events which finally cause the immortalisation of infected B cell.
To elucidate the process of B cell immortalization by EBV it is essential to understand 
the mechanism by which EBNA2 activates its target genes. In the first part of this 
study, the cellular EBNA2 target genes were identified and the regulatory regions of 
primary EBNA2 target genes were analysed in order to gain more insights into the 
complex EBNA2 signalling pathways. 
EREB2-5 is a lymphoblastoid cell line conditional for EBNA2. It provides a tool for 
monitoring very early events following EBNA2 activation. Three different DNA 
microarray techniques were used to identify novel cellular EBNA2 target genes. 
Genes identified by these DNA microarray techniques were additionally verified by 
the nuclear run-on and Northern blot analyses using cellular systems which permit the 
discrimination of primary EBNA2 genes among numerous genes up-regulated upon 
EBNA2 activation. c-myc, CD21 and CCR7 had been identified earlier as primary 
EBNA2 targets and herein they were confirmed. RDC1, bfl-1, MIP-1 beta, CD83 and 
PLEK were identified as novel primary EBNA2 target genes. In order to identify 
common cis-regulatory elements of the EBNA2 signalling pathway, an in silico 
analysis was performed on the promoter and intron 1 region of these genes. The in 
silico analyses of primary EBNA2 target genes identified potential binding sites for 
several transcription factors which appear in all or almost all genes: (i) the putative 
binding site for NFAT1 and Oct-1 were identified in the promoters of all target genes 
indicating potential novel transcription factors which might contribute to the EBNA2 
signalling; (ii) RBP-Jκ binding sites was identified in the intron 1 region of all genes 
except for CD83 suggesting that EBNA2 does not only recruit transcriptional 
machinery to promoters, but might also induce a chromatin modification and 
remodelling resulting in an open chromatin accessible to transcriptional machinery; 
(iii) PU.1, a previously identified transcription factor important for EBNA2 
transactivation was found in the majority of genes and (iv) NF-κB was also identified 
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in the majority of primary EBNA2 target genes. The viral protein LMP1, co-
expressed with EBNA2 in EBV immortalised B cells, acts as a potent activator of the 
NF-κB pathway. Thus, the presence of the NF-κB binding sites within EBNA2 target 
genes could result in a convergence or a crosstalk of LMP1 and EBNA2 signalling 
pathways. 
The second part of this work characterizes the function of TRRAP, which was found 
to be specifically induced by the EBV infection of primary B cells in this study. In 
contrast, B cell activation by crosslinking CD40 on the surface of primary B cells in 
the presence of IL-4 failed to induce TRRAP expression. TRRAP activation was 
dependent on EBNA2, but it required the activity of the additional cellular proteins. 
Activation of c-Myc in the absence of EBNA2 could not induce TRRAP. Further viral 
proteins enhanced TRRAP induction by EBNA2, but could not replace EBNA2 
function. Thus, elevated TRRAP levels could be defined as a characteristic feature of 
EBV immortalized cells. 
The TRRAP gene was chosen for further functional studies, since it is known that 
TRRAP function is crucial for the transformation processes driven by c-Myc or the 
adenoviral E1A protein. Thus, it was of great interest to test whether TRRAP is 
relevant for the immortalisation process driven by EBV. In order to address a 
potential function of TRRAP in this process, short interfering RNAs (siRNAs) 
specific for the TRRAP transcript were expressed in EBV immortalised B cells. 
Expression of siRNA specific for TRRAP repressed TRRAP expression below the 
detection limits. Within 12 hours the transfected cells ceased to proliferate and 
apoptosed indicating that TRRAP expression is crucial for the viability of EBV 
immortalized B cells. 
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8.0 Supplementary material
(complete data from each screen can be found on a CD enclosed herewith)
Table 1. 
EBNA2 induced genes identified by the ExpressCode™ DNA microarray two hours after 
activation of EBNA2. Genes are shown that were up-regulated 2 hours post-oestrogen stimulation in 
EREB2-5 cells. Up-regulated genes have been considered those which showed at least 2-fold induction. 
(p.c. denotes up-regulation in the proliferating EREB2-5 cells)
611316817,71hypothetical protein FLJ20157NM_017692CLONE-12A2
3536,315375,81Chromosome 11 Cosmid cSRL186g7U73627CLONE-9A10
3126,5121271cytoplasmic phosphoprotein PACSIN2 AF128536CLONE-16A19
1534,42533,61cDNA FLJ13070 fisAK023132CLONE-10B2
2621,41161,91TB1 gene HUMFAPTB1CLONE-14E20
4446,31092,61c-myc oncogeneHSMYCCCLONE-21B16
3088,7857,91cell division protein FtsJ (FJH1)NM_013393CLONE-12B24
295,6827,31cDNA clone:CBFBQB01AV737985CLONE-11H18
3193,1722,31orphan G protein-coupled receptor (RDC1) HSU67784CLONE-11K11
4199,5679,41TNF type 1 receptor assoc.pr.(TRAP2)HSU12596CLONE-15K19
2168,9412,11clone DKFZp564D116HSM800105CLONE-13G19
970,5395,71NUDT4NM_019094    CLONE-4N23
392,6364,41misatoAF272833CLONE-21J15
505354,11D-site binding protein geneHUMDSITE1CLONE-13O4
351,7333,1112p BAC RP11-253I19 AC007619CLONE-8P22
6503,2283,41ATF5NM_012068    CLONE-8H4
4747,72781asparaginyl-tRNA synthetaseNM_004539    CLONE-16C15
2110,1254,51insulin induced gene 1 (INSIG1)NM_005542    CLONE-16I9
1354,72381CD83XM_004500CLONE-12H13
2740,8201,21cDNA: FLJ23020 fisAK026673CLONE-4L21
512,8170,71N-myristoyltransferase 1 (NMT1)NM_021079    CLONE-12E17
1503,6164,91URIM proteinHSA295637CLONE-8E18
347160,61NUDT4 AF191654CLONE-20L19
84,696,21hypotethical protein FLJ10079NM_017990CLONE-21E12
168,891,21clone IMAGE:4139956 BF308884CLONE-12J18
20,838,91mousecDNA clone UI-M-BZ1-bed-g-05-0-UI BE650475CLONE-21A19
12,9271clone CTA-57G9 on chromosome 22q12.1HS57G9CLONE-13A17
79,521,81sec6 homologAF055006CLONE-18M22
133,417,11GTP-binding protein HUMGTPBPCLONE-16O17
217,49,71heat shock 90kD protein 1, beta (HSPCB)NM_007355    CLONE-21B11
2,991lecithin-cholesterol acyltransferase mRNAHUMLCATCLONE-15E12
458,31G protein beta subunit AF195883CLONE-12M13
22,86,71cellular repressor of E1A-stimulated genes (CREG)NM_003851CLONE-11D9
4,76,41clone RP1-93K22HSDJ93K22CLONE-12E11
28,35,61putative nucleolar RNA helicase (NOH61)NM_019082    CLONE-17B12
24,54,61ATF4NM_001675    CLONE-5E2
10,23,81FLJ21504 fisAK025157CLONE-21B17
5,43,71adaptor-related protein complex 1NM_001127    CLONE-10L11
303,11KH-type splicing regulatory proteinNM_003685    CLONE-7C13
12,231cDNA: FLJ23435 fisHS211D12CLONE-9F16
52,81anaphase-promoting complex 2 (APC2)NM_013366CLONE-11D24
9,72,71nicastrinAF240468CLONE-2J4
6,32,71mRNA for putative progesterone binding proteinHSAJ2030CLONE-17L8
12,92,61metalloprotease 1 (pitrilysin family) (MP1)NM_014889    CLONE-16G19
18,92,61regulator of G protein signaling RGS14-variantAF037194 CLONE-10C13
15,32,51PAC 57A13 HS57A13CLONE-8L19
13,32,51DKFZP566C243 protein (DKFZP566C243)NM_015388CLONE-12H9
12,52,41three prime repair exonuclease 1 (TREX1)NM_007248    CLONE-16J4
24,62,41mRNA for KIAA0652 proteinNM_014741    CLONE-12G7
4,52,21WD-repeat protein 6 (WDR6) AF099100CLONE-13M13
6,42,11inducible poly(A)-binding proteinHSU33818CLONE-12I17
3,12130S ribosomal protein S7 homologBC000241CLONE-11E6
GPC clone Accession number Gene
Fold induction
0 hr 2 hrs p.c.
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Table 2. 
EBNA2 induced genes identified by the ExpressCode™ DNA microarray in proliferating 
EREB2-5 cells.
Genes are shown that were up-regulated in at least 48 hours post-oestrogen stimulation in EREB2-5 
cells. Up-regulated genes have been considered those which showed at least 2-fold induction. (p.c. 
denotes up-regulation in the proliferating EREB2-5 cells)
90,51arsenite translocating A TPase (ASNA1)AF047469CLO NE-10E21
8,921clone RP11-264E12 on chrom osome 7AC009329CLO NE-15H15
8,20,61pM5 protein, mRNANM_014287CLO NE-5P5
8,10,71ATP-dependent metalloprotease YMEILAJ132637CLO NE-14L2
7,911clone 738, translational activator GCN1 HSU88836CLO NE-15K5
7,10,71M6 antigenHSM6CLO NE-21J4
6,50,91tryptophanyl tRNA synthetaseHUM IF NWRSCLO NE-20F17
6,50,91clathrin assembly protein 50HSU36188CLO NE-11M2
6,40,91pleckstrin (PLEK)NM_002664CLO NE-6B15
6,40,31NAD+-specific isocitrate dehydrogenase gamma subunitHSU40272CLO NE-16E18
6,41,51phosphogluconate dehydrogenase (PG D)NM_002631    CLO NE-13A19
6,42,11inducible poly(A)-binding proteinHSU33818CLO NE-12I17
6,32,71mRNA for putative progesterone binding proteinHSAJ2030CLO NE-17L8
5,40,61FLJ21105 fisAK024758CLO NE-8F7
5,43,71adaptor- related protein complex 1NM_001127    CLO NE-10L11
5,20,71phosphatase XX70218, S55208CLO NE-3A10
5,11,31PAC 57A13 between markers DXS6791-DXS8038HS57A13CLO NE-8E6
5,11,51adenylyl cyclase-associated protein 2 (CAP2) NM_006366    CLO NE-5B6
511Era G TPase B protein (HE RA-B )AF082658CLO NE-6G5
52,81anaphase-promoting com plex 2 (APC2)NM_013366CLO NE-11D24
4,811mRNA for K IAA0143 geneD63477 CLO NE-21L10
4,80,61heat shock 40kD protein 1 NM_006145CLO NE-21I8
4,76,41clone RP1-93K22HSDJ93K 22CLO NE-12E11
4,70,8130S ribosom al protein S7 hom ologBC000241CLO NE-11A7
4,70,81TRAF4XM_008483CLO NE-10I19
4,61,21TRRAPNM_003496   CLO NE-10G 24
4,511TAP1L21208CLO NE-3C15
4,52,21W D-repeat protein 6 (WDR6) AF099100CLO NE-13M13
4,40,61CDC37 homolog HSU43077CLO NE-9J10
4,40,81sec61 homolog (HSEC61)XM_003286CLO NE-8N11
4,211splicing factor Prp8 mRNAAF092565CLO NE-16I15
4,10,41Rho GAP p190-A m RNAAF159851CLO NE-3H2
4,11,81putative chromatin structure regulator (SUP T6H) HSU46691CLO NE-3D16
4,10,91SUPT6HNM_003170CLO NE-12N2
3,91,71translation initiation factor 1(eIF1(A121/SUI1))NM_005801     CLO NE-12A22
3,30,51hypothetical protein SP192 NM_021639    CLO NE-16M2
3,21,41phosphotyrosyl-protein phosphatase (SH-P TP2)HUMS HP TP2ACLO NE-13I7
3,10,51clone 24561 unknown mRNAAF055010CLO NE-3B12
3,10,71clone r56121 formin 2-like protein mRNAAF218942CLO NE-11M13
3,12130S ribosom al protein S7 hom olog, clone MGC:711BC000241CLO NE-11E6
2,991lecithin-cholesterol acyltransferase mRNAHUM LCA TCLO NE-15E12
2,81,81cDNA: FLJ23507 fis, clone LNG03128AK027160CLO NE-18C1
2,80,81eukaryotic translation initiation factor 4 gamma 1 NM_004953    CLO NE-10I3
2,70,71misato AF272833CLO NE-12G 13
2,60,41CDC5like (CDC5L)NM_001253CLO NE-12A7
2,50,21phosphatidylinositol-4 -phosphate 5-kinase, type INM_003557CLO NE-7J10
2,20,31erythrocyte membrane protein mRNAHUM CTICLO NE-2P22
2,10,31chromosom e 19, CIT-HSP-146e8AC005255CLO NE-6J12
2,10,41signaling molecule SPEC1 beta mRNAAF286592CLO NE-4L15
GPC clone Accession number Gene
Fold induction
0 hr 2 hrs p.c.
Table continues
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Table 2. continued
295,6827,31cDNA clone:CBFBQB01AV737985CLONE-11H18
217,49,71heat shock 90kD protein 1, beta (HSPCB)NM_007355    CLONE-21B11
168,891,21clone IMAGE:4139956 BF308884CLONE-12J18
133,417,11GTP-binding protein HUMGTPBPCLONE-16O17
870,21barrier-to-autointegration factorAF068235CLONE-5H12
84,696,21hypotethical protein FLJ10079NM_017990CLONE-21E12
79,521,81sec6 homologAF055006CLONE-18M22
48,80,61alpha-tubulinAF141347CLONE-12K22
45,41,11alpha-tubulinAF141347CLONE-13L11
458,31G protein beta subunit AF195883CLONE-12M13
38,911mitochondrial proteolipid 68MP homolog AF054175CLONE-4H15
33,90,51cytochrome c oxidase subunit VIIa polypeptide 2 likeNM_004718    CLONE-9D11
303,11KH-type splicing regulatory proteinNM_003685    CLONE-7C13
28,35,61putative nucleolar RNA helicase (NOH61)NM_019082    CLONE-17B12
27,701phosphatase XX70218, S55208CLONE-3A18
261,21serine hydroxymethyltransferase 2 NM_005412    CLONE-3K5
25,81,11cytochrome b5AB009282CLONE-4B15
24,62,41KIAA0652 proteinNM_014741    CLONE-12G7
24,54,61ATF4NM_001675    CLONE-5E2
240,61prothymosin alpha NM_002823    CLONE-17D12
241,21eukaryotic initiation factor 4AIHUM4AICLONE-13G15
22,86,71cellular repressor of E1A-stimulated genes (CREG)NM_003851CLONE-11D9
20,838,91mousecDNA clone UI-M-BZ1-bed-g-05-0-UI BE650475CLONE-21A19
20,60,61KIAA0268, partial sequenceD87742CLONE-5M13
191,31prohibitin (PHB)NM_002634    CLONE-15N14
18,92,61regulator of G protein signaling RGS14-variantAF037194 CLONE-10C13
18,811phosphatase XX70218, 255208CLONE-2G4
1811chaperonin containing TCP1, subunit 4XM_002285CLONE-20L2
17,61,11eukayotic translation initiation factor 4A (EIF4A1)NM_001416CLONE-16F3
17,30,81prothymosin alpha NM_002823    CLONE-15L16
15,70,71prothymosin alpha NM_002823    CLONE-17G5
15,32,51PAC 57A13 between markers DXS6791-DXS8038HS57A13CLONE-8L19
13,90,91spermidine synthetaseNM_003132CLONE-21N4
13,32,51DKFZP566C243 protein (DKFZP566C243)NM_015388CLONE-12H9
12,92,61metalloprotease 1 (pitrilysin family) (MP1)NM_014889    CLONE-16G19
12,9271clone CTA-57G9 on chromosome 22q12.1HS57G9CLONE-13A17
12,52,41three prime repair exonuclease 1 (TREX1)NM_007248    CLONE-16J4
12,41,41apurinic/apyrimidinic endonuclease (HAP1h) mRNAHUMAPEACLONE-11C19
12,231cDNA: FLJ23435 fisHS211D12CLONE-9F16
11,91,91PP3111 mRNAAF202637CLONE-9G24
11,30,61KIAA0247 gene product NM_014734    CLONE-6M11
10,23,81FLJ21504 fisAK025157CLONE-21B17
10,20,51HSPC235 mRNAAK026171CLONE-16G17
10,20,81Ca<2+>dependent activator proteinNM_012061CLONE-16A14
10,10,61casein kinase 2, beta polypeptide (CSNK2B)NM_001320    CLONE-7D1
101,11repressor of estrogen receptor activity (REA)AF150962CLONE-8B15
9,71,41KH type splicing regulatory proteinHSKHSRP4CLONE-7D8
9,72,71nicastrinAF240468CLONE-2J4
9,30,91transcription factor ATFx AF305687CLONE-5A5
9,30,81malate dehydrogenase 2NM_005918    CLONE-14K13
GPC clone Accession number Gene
Fold induction
0 hr         2 hrs             p.c.
Table continues
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Table 2. continued
GPC clone Accession number Gene
Fold induction
0 hr 2 hrs p.c.
9014,61,31p18 (stathmin)X53305,CLONE-3F23
6503,2283,41ATF5NM_012068    CLONE-8H4
611316817,71hypothetical protein FLJ20157NM_017692CLONE-12A2
4747,72781asparaginyl-tRNA synthetaseNM_004539    CLONE-16C15
4446,31092,61c-myc oncogeneHSMYCCCLONE-21B16
4199,5679,41TNF type 1 receptor assoc.pr.(TRAP2)HSU12596CLONE-15K19
3536,315375,81Chromosome 11 Cosmid cSRL186g7U73627CLONE-9A10
3193,1722,31orphan G protein-coupled receptor (RDC1) HSU67784CLONE-11K11
3126,5121271cytoplasmic phosphoprotein PACSIN2 AF128536CLONE-16A19
3088,7857,91cell division protein FtsJ (FJH1)NM_013393CLONE-12B24
2740,8201,21cDNA: FLJ23020 fisAK026673CLONE-4L21
2621,41161,91TB1 gene HUMFAPTB1CLONE-14E20
2168,9412,11clone DKFZp564D116HSM800105CLONE-13G19
2110,1254,51insulin induced gene 1 (INSIG1)NM_005542    CLONE-16I9
1534,42533,61cDNA FLJ13070 fisAK023132CLONE-10B2
1503,6164,91URIM proteinHSA295637CLONE-8E18
1354,72381CD83XM_004500CLONE-12H13
1311,71,31PTB-associated splicing factorX70944CLONE-3L14
1213,71,31exportin 5AF298880CLONE-14M10
1129,51,31clone hRPC.4_G_17AC003688CLONE-3P2
970,5395,71NUDT4NM_019094    CLONE-4N23
872,61,31HT022AF242729CLONE-20L17
800,21,31clone RP11-264E12 on chromosome 7AC009329CLONE-13P1
743,11,31breast cancer antigen NY-BR-81AF308297CLONE-12D14
512,8170,71N-myristoyltransferase 1 (NMT1)NM_021079    CLONE-12E17
505354,11D-site binding protein geneHUMDSITE1CLONE-13O4
392,6364,41misato AF272833CLONE-21J15
351,7333,1112p BAC RP11-253I19 AC007619CLONE-8P22
347160,61NUDT4 AF191654CLONE-20L19
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Table 3. 
EBNA2 induced genes identified by lymphochip two hours after activation of EBNA2 in 
EREB2-5 cells.
Genes are shown that were up-regulated 2 hours post-oestrogen stimulation in EREB2-5 cells. Up-
regulated genes have been considered those which showed at least 2-fold induction. 
Fold induction
0 hr 2hrsGene
Table continues
Lymphochip 
identifier
2, 312640 9 M IP -1 beta
2,213043 3 Te rm inal Deox ynuc le otide Trans fer as e
2,213128 2 M M S E T type II
2,213509 0 CD2 1
2, 212797 0   Ly m photac tin
2, 211588 9 RD C1
2, 211588 9 RD C1
2, 211927 7 S LA M
2,113697 9   dy s trophin
2, 112931 2   os teopontin
2, 112798 7 CD2 1
2, 111661 0 CD8 3
112882 6 TC L-1A
2, 112482 6 M A D2 
2,011938 8 CD9 
2,012804 9 S LA M
2,012778 5 HE S -1
2,012778 5 HE S -1
2,012746 3 IP -10 
2,012753 6 pros tate diffe rentiatio n fac tor
2, 812434 8 unknow n UG Hs.26 559 2  ES Ts
2, 712932 0   deoxy ribon uc lease I-like 3 
2, 712620 0   profili n 2
2, 712665 7 RGS 13
2, 612447 9 M yos in c lass I
2, 613737 1 TOP K
2, 612729 4 M M P -7
2, 612849 4 CHK 1 (ch eckpoint, S .pom be) h om ol og
2,513001 3   c yc lin A 2 
2, 512523 7 CD2 1
2, 512698 9 W E E 1-like protein k inase
2, 513053 4 E g5
2,412724 0 M A D2 (m itotic arres t defic ient, yeas t, hom olog )-like 1 
2, 413158 5 hom olog o f yeas t M CM 1 0
2,312482 7   Cyc lin B 1 
2,311667 1 phosphoi nos itide-3-k in ase p85 al pha
2,311608 9 B fl-1
2, 313673 3 transcription fac tor 19 (S C1 )
2, 312863 9 B fl-1
2, 311925 0 IR TA 4
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Table 3. continued
Table continues
4,212476 2 E G R-1
4, 112833 6 G uanin e nuc leotid e bindi ng pr otein 
4,011737 3 IL-7 rec epto r alph a c hain
4,012874 6 IL-7 rec epto r alph a c hain
3,912964 7 W N T2
3, 912944 8 P NA S -108 
812768 6 DUS P 2
3, 511728 1   hy aluron an -m edi ated m oti l i ty rec epto r (R HA M M ) 
3, 413803 0   l ipom a HM G IC fus ion pa rtne r-lik e 2
3,212982 0 RA -re gulate d nuc lea r m atrix - as s oc iated prote in
3,111706 6 CD8 3
3,111718 5 DUS P 2
3,013691 9   deox y ribon uc leas e I -lik e 3
3,012810 0 N-C adh eri n
2,912647 5 M IP -1 alp ha
2,913761 3 DNA polym e ras e theta
2,813542 8   deox y ribon uc leas e I -lik e 3
2, 812754 5 CD8 3
2, 811599 7 CE NP -E
2, 812837 7 phos phoi nos it ide-3-k in as e p85 al pha
7, 613217 1 CD10
7,411584 1    c -m y c
7,013332 3 s perm as soc iated ant ige n
6, 813660 2 CO -0 29
6, 812838 3 CD2 1
6, 612885 3 TA LLA
6, 113370 5 DHF R
6, 111656 1 A RK 2
6,012837 9 protein k inas e, c A M P -dep end ent ,  reg ulatory , ty pe II
5,613658 1   IgE c ons tant  regio n
5,512021 2 E B V EB NA -1
5,413494 8 T c ell recepto r delta c hain
5,313263 5 CD3 Z
5, 112729 3   M ononc y te/neutr ophi l el as tas e inhibitor
5,012635 3   Cy c lin E 2 
4,912896 1 CD4 9F
4, 712612 9 B rus h-1
4, 713662 7   annex in A 1
4, 611736 4 CD2 1
4, 313534 5 s im ilar to S 68401 (c att le) g l uc os e induc e d gen e 
Gene
Fold induction
0 hr       2hrs
Lymphochip 
identifier
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Table 3. continued
242,913044 9 CD3 Z
20,612989 7 F LJ105 17
17,013590 1 P E P -19
15,213496 6 E B V LM P 1
12,512895 9 E DG -1
12,3111938 5 S LA P
12,311938 5 S LA P
12,113498 0 E B V LM P 2A (TP 1 ) 
10,411938 1    c -m yc
9,912438 5 unk nown U G Hs .291 994 E S T
9,812021 0 E B V LM P 1
9,212972 3    c -m yc
9,013015 7 CE NP -F k inetocho re p rotein
8, 212840 1    c -m yc
Gene
Fold induction
0 hr       2hrs
Lymphochip 
identifier
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Table 4. 
EBNA2 induced genes identified by GeneChip® two hours after activation of EBNA2 in EREB2-5 cells.
Genes are shown that were up-regulated 2 hours post-oestrogen stimulation in EREB2-5 cells. Genes have been considered to be up-regulated if they showed at least1.4-fold 
induction in at least 2 experiment from 4 experiments done (Ex1, Ex2, Ex3, Ex4). YES denotes induction more then 1.4-fold, NO denotes induction less then 1.4 fold.
Gene
Fold induction
Ex1             Ex2      Ex3 Ex4              Probe set
a Accesion
number
Table continues
8.0 Supplem
entary m
aterial
0 ,1 21 ,1 99 ,7 85 ,2 3F Y N b in d in g p ro te in (F Y B -1 2 0 /1 3 0 )A I 6 3 3 8 8 82 0 5 2 8 5 _ s _ at
0 ,41 ,3 61 ,5 71 ,8 7m ito g e n -a c t iv a t e d p ro te in  k in a s e k in a s e k in a s e 8N M _ 0 0 5 2 0 42 0 5 0 2 7 _ s _ at
0 ,1 61 ,21 ,1 60 ,2 5c y c l in -d e p e n d e n t k in a se 5 , r e g u la to ry s u b u n it 1 (p 3 5 )A L 5 6 7 4 1 12 0 4 9 9 5 _ at
0 ,1 21 ,5 61 ,1 60 ,9 8p ro s ta g la n d in E r e c e p to r  4 ( su b ty p e E P 4 )N M _ 0 0 0 9 5 82 0 4 8 9 6 _ s _ at
0 ,4 11 ,4 81 ,8 20 ,3 9f ib ro b las t  g ro w th fa c to r r e c e p to r  4N M _ 0 0 2 0 1 12 0 4 5 7 9 _ at
0 ,1 21 ,1 31 ,4 30 ,9 3p e p t id y lp ro ly l i so m e r a se C (c y c lo p h i l in C )N M _ 0 0 0 9 4 32 0 4 5 1 8 _ s _ at
0 ,7 81 ,7 81 ,4 60 ,3C D 8 3 a n t ig e n ( a c tiv a t e d B ly m p h o c y tes ,  im m u n o g lo b u l in  s u p e r f a m ily )N M _ 0 0 4 2 3 32 0 4 4 4 0 _ at
0 ,2 81 ,3 82 ,0 52 ,5 1e c h in o d e rm m ic ro tu b u le  a s s o c i a te d p ro te in l ik e  2N M _ 0 1 2 1 5 52 0 4 3 9 7 _ at
0 ,7 91 ,71 ,9 30 ,5 1ru n t- re l a t ed t r an sc r ip t io n f a c to r  3N M _ 0 0 4 3 5 02 0 4 1 9 7 _ s _ at
0 ,5 71 ,2 41 ,0 90 ,0 6c h e m o k in e (C -C m o t i f )  l ig a n d 4N M _ 0 0 2 9 8 42 0 4 1 0 3 _ at
0 ,6 21 ,5 92 ,3 70 ,3 8K IA A 0 4 6 7 p r o te inN M _ 0 2 4 5 4 72 0 3 9 0 0 _ at
1 ,0 92 ,4 42 ,2 60 ,7 6P T P R F in te ra c t in g p ro te in ,  b in d in g p ro te in 1 ( l ip r in b e t a  1 )N 3 5 8 9 62 0 3 7 3 5 _ x _ a t
0 ,4 94 ,5 63 ,5 20 ,3A T P a s e ,  N a + /K + t ran s p o r t in g ,  a lp h a  2 (+ )  p o ly p e p t id eN M _ 0 0 0 7 0 22 0 3 2 9 6 _ s _ at
1 ,0 72 ,4 51 ,5 62 ,2 1s a r c o m a  a m p l i f i ed s e q u e n ceN M _ 0 0 5 9 8 12 0 3 2 2 7 _ s _ at
1 ,9 42 ,7 23 ,8 21 ,9 5H o m o s a p ien s  m R N A ; c D N A D K F Z p 4 3 4 B 1 4 2 A W 1 3 4 5 3 52 0 2 7 6 9 _ at
0 ,71 ,6 41 ,50 ,7 9in te r f e r o n g a m m a r e c e p to r  1N M _ 0 0 0 4 1 62 0 2 7 2 7 _ s _ at
1 ,7 82 ,5 92 ,0 30 ,9 5N iem a n n -P ic k d i s ea se ,  ty p e C 1N M _ 0 0 0 2 7 12 0 2 6 7 9 _ at
1 ,5 42 ,4 71 ,6 81 ,2 4p h o s p h o p ro te in r e g u la te d b y m ito g e n ic p a th w a y sN M _ 0 2 5 1 9 52 0 2 2 4 1 _ at
0 ,1 71 ,12 ,43 ,4 7i so p re n y lcy s t e in e c a r b o x y l m e th y l t ran s fe r a s eA L 5 7 8 5 0 22 0 1 6 1 0 _ at
1 ,5 41 ,3 91 ,9 41 ,9 6in h ib ito r  o f  D N A b in d in g 2 ,  d o m in a n t  n e g a t iv e  h e l ix - lo o p -h e lix p ro te inD 1 3 8 9 12 0 1 5 6 6 _ x _ a t
0 ,32 ,4 33 ,8 60 ,3in s u l in - l ik e g ro w th fa c to r  b in d in g p ro te in 7N M _ 0 0 1 5 5 32 0 1 1 6 3 _ s _ at
1 ,71 ,3 89 ,6 30 ,2 4v in c u l inA A 1 5 6 6 7 52 0 0 9 3 0 _ s _ at
1 ,0 12 ,4 12 ,0 42 ,3 2K IA A 0 1 7 4 g e n e  p ro d u c tN M _ 0 1 4 7 6 12 0 0 8 5 1 _ s _ at
1 ,4 31 ,8 91 ,5 22 ,3 2p ro te in k in a s e , c A M P -d e p e n d e n t ,  r e g u la to ry ,  ty p e  IA L 0 5 0 0 3 82 0 0 6 0 3 _ at
1 ,3 92 ,5 61 ,4 60 ,2 6K IA A 0 3 4 6 p r o te inA B 0 0 2 3 4 44 1 3 8 6 _ i_ at
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Table 4. continued
Gene
Fold induction
Ex1          Ex2  Ex3 Ex4              
Accesion  
number
Table continues
Probe seta
8.0 Supplem
entary m
aterial
0 ,3 21 ,4 71 ,0 70 ,2 4C D 6 9 a n tig e n (p 6 0 , e a rly T -c e ll a c tiv a tio n a n tig e n )L 0 7 5 5 52 0 9 7 9 5 _ a t
1 ,4 52 ,4 83 ,2 23 ,5 1C D 2 4 a n tig e n (sm a ll c e ll  lu n g c a rc in o m a c lu s te r  4 a n tig e n )A A 7 6 1 1 8 12 0 9 7 7 1 _ x _ a t
0 ,5 41 ,3 42 ,4 30 ,6 9s e rin e (o r c y ste in e ) p ro te in a se in h ib ito r, c la d e B (o v a lb u m in ),  m e m b e r 9L 4 0 3 7 82 0 9 7 2 2 _ s_ a t
0 ,4 11 ,4 11 ,3 20 ,3 8E S T s , N o sim ila rityA I3 4 9 5 0 62 0 9 5 7 4 _ s_ a t
0 ,4 31 ,6 11 ,3 10 ,1 8E S T s , N o sim ila rity  A I3 4 9 5 0 62 0 9 5 7 3 _ s_ a t
1 ,3 13 ,0 74 ,4 81 ,4 9C D 2 4 a n tig e n (sm a ll c e ll  lu n g c a rc in o m a c lu s te r  4 a n tig e n )M 5 8 6 6 42 0 8 6 5 1 _ x _ a t
0 ,51 ,0 75 ,1 20 ,3 5d o u b le h o m e o b o x , 3N M _ 0 1 2 1 4 82 0 8 5 8 2 _ s_ a t
0 ,7 41 ,6 21 ,6 60 ,3 1h y p o th e tic a l p ro te in F L J 1 0 2 1 0N M _ 0 1 8 0 2 72 0 8 4 7 6 _ s_ a t
0 ,4 41 ,3 11 ,8 16 ,2 7m y o sin , h e a v y p o ly p e p tid e 1 3 , s k e le ta l m u s c leN M _ 0 0 3 8 0 22 0 8 2 0 8 _ a t
0 ,7 61 ,6 92 ,5 40 ,3 1F A T tu m o r s u p p re sso r h o m o lo g 2 (D ro so p h ila )N M _ 0 0 1 4 4 72 0 8 1 5 3 _ s_ a t
0 ,1 11 ,1 33 ,4 21 ,5 3M H C b in d in g fa c to r,  b e taN M _ 0 0 6 0 8 12 0 8 1 3 3 _ a t
0 ,1 11 ,4 17 ,1 80 ,5sia ly ltra n sfe ra se 8 C N M _ 0 1 5 8 7 92 0 8 0 6 4 _ s_ a t
4 ,2 21 ,3 23 ,3 40 ,7 7o n c o m o d u linN M _ 0 0 6 1 8 82 0 7 9 4 4 _ a t
1 ,3 62 ,8 11 ,8 71 ,3 6p h o sp h a tid y lin o sito l-4 -p h o s p h a te 5 -k in a s e , ty p e I,  a lp h aN M _ 0 0 3 5 5 72 0 7 3 9 1 _ s_ a t
0 ,4 61 ,6 21 ,6 50 ,9 8c ry s ta llin , b e ta B 2N M _ 0 0 0 4 9 62 0 6 7 7 8 _ a t
0 ,4 71 ,2 51 3 ,2 30 ,2 4g e n e ra l tra n s c rip tio n fa c to r I IA , 1 , 1 9 /3 7 k D aN M _ 0 1 5 8 5 92 0 6 5 2 1 _ s_ a t
0 ,4 31 ,1 82 ,8 61 ,3P T K 6 p ro te in ty ro s in e k in a se 6N M _ 0 0 5 9 7 52 0 6 4 8 2 _ a t
0 ,2 11 ,21 ,4 90 ,3 1w in g le ss - ty p e M M T V in te g ra tio n site fa m ily , m e m b e r  2 BA B 0 4 5 1 1 72 0 6 4 5 9 _ s_ a t
0 ,1 21 ,6 21 0 ,8 20 ,5 8p h o sp h o in o sit id e -3 -k in a s e , c a ta ly tic , g a m m a p o ly p e p tid eN M _ 0 0 2 6 4 92 0 6 3 7 0 _ a t
0 ,9 22 ,0 31 ,5 80 ,3 9sig n a lin g ly m p h o c y tic a c tiv a tio n m o le c u leN M _ 0 0 3 0 3 72 0 6 1 8 1 _ a t
0 ,2 51 ,2 31 ,1 80 ,1 4e a r ly g ro w th re sp o n s e 3N M _ 0 0 4 4 3 02 0 6 1 1 5 _ a t
0 ,6 11 ,4 13 ,1 21 ,9g lu ta m a te re c e p to r, m e ta b o tro p ic 3N M _ 0 0 0 8 4 02 0 5 8 1 4 _ a t
0 ,1 51 ,1 32 ,81 ,6a c y lo x y a c y l h y d ro la se (n e u tro p h il )N M _ 0 0 1 6 3 72 0 5 6 3 9 _ a t
0 ,1 51 ,7 14 ,8 80 ,6 1a n g io p o ie tin 2N M _ 0 0 1 1 4 72 0 5 5 7 2 _ a t
0 ,5 31 ,3 91 ,2 20 ,2 5E p ste in -B a rr  v i ru s  in d u c e d g e n e 2 N M _ 0 0 4 9 5 12 0 5 4 1 9 _ a t
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Table 4. continued
Gene Fold induction
Ex1           Ex2          Ex3          Ex4              
Accesion  
number
Table continues
Probe seta
8.0 Supplem
entary m
aterial
0 ,2 51 ,2 24 ,2 60 ,7 9H o m o s a p ie n s  c lo n e 2 4 4 8 8 m R N A s e q u e n c eA F 0 7 0 6 4 22 1 4 9 9 3 _ a t
0 ,0 71 ,1 71 ,4 50 ,5 6E G F - lik e -d o m a in , m u ltip le 4A B 0 1 1 5 4 12 1 4 7 7 8 _ a t
0 ,1 31 ,6 62 ,9 55 ,6 7p o ta ss iu m v o lta g e -g a te d c h a n n e lA I3 3 2 9 7 92 1 4 5 9 5 _ a t
0 ,2 61 ,4 43 ,4 30 ,2 9le u k o c y te im m u n o g lo b u lin -lik e re c e p to rN M _ 0 2 4 3 1 72 1 4 5 6 1 _ a t
0 ,1 21 ,2 54 ,0 70 ,3 7s p h in g o m y e lin p h o s p h o d ie s te r a se 2A I7 3 9 4 8 02 1 4 2 0 6 _ a t
0 ,1 61 ,1 31 ,6 50 ,0 4U n k n o w n [H o m o sa p ie n s] ,  m R N A se q u e n c eA I4 3 5 9 5 42 1 4 0 2 9 _ a t
1 ,2 41 ,4 21 ,6 20 ,5 9E G F - lik e -d o m a in , m u ltip le 3A L 1 3 4 3 0 32 1 3 9 4 2 _ a t
0 ,8 71 ,7 51 ,4 60 ,3 6in h ib ito r  o f  D N A b in d in g 2 , d o m in a n t n e g a tiv e h e lix - lo o p -h e lix p ro te inA I8 1 9 2 3 82 1 3 9 3 1 _ a t
0 ,8 91 ,2 94 ,6 70 ,4tu b u lin , g a m m a c o m p le x a sso c ia te d p ro te in 2A A 0 1 6 0 3 52 1 3 5 6 3 _ s_ a t
4 ,6 61 ,2 81 ,6 40 ,3 4K IA A 0 3 4 6 p ro te inA A 5 2 1 2 6 72 1 3 1 4 6 _ a t
0 ,4 51 ,1 22 ,3 81 ,6 4N IM A (n e v e r in m ito s is  g e n e a ) - re l a te d k in a se 3A I1 9 1 9 2 02 1 3 1 1 6 _ a t
1 ,0 12 ,4 51 ,4 80 ,3 6K IA A 1 0 1 0 p ro te inA B 0 2 3 2 2 72 1 2 8 3 8 _ a t
1 ,9 41 ,1 22 ,5 60 ,0 8S p 2 tra n sc rip tio n fa c to rB C 0 0 5 9 1 42 1 1 7 3 6 _ a t
0 ,6 51 ,0 74 ,8 60 ,8 1a lk a lin e p h o s p h a ta se , p la c e n ta l (R e g a n iso z y m e )M 1 3 0 7 72 1 1 6 1 9 _ s_ a t
0 ,3 21 ,3 44 ,4 51 ,1 8L IM d o m a in p ro te inB C 0 0 3 0 9 62 1 1 5 6 4 _ s_ a t
0 ,6 82 ,7 12 ,3 91 ,7 8c y c lin G 2L 4 9 5 0 62 1 1 5 5 9 _ s_ a t
0 ,1 61 ,1 91 ,6 30 ,7 7F c fra g m e n t o f Ig G , lo w a ff in ity I Ib , re c e p to r  fo r (C D 3 2 )U 9 0 9 4 12 1 1 3 9 6 _ a t
0 ,1 81 ,2 12 ,7 80 ,5 8c a lc iu m c h a n n e l,  v o lta g e -d e p e n d e n t, a lp h a 1 G s u b u n itA B 0 1 2 0 4 32 1 1 3 1 5 _ s_ a t
0 ,1 71 ,1 42 ,0 80 ,0 6F c fra g m e n t o f Ig A , re c e p to r  fo rU 5 6 2 3 72 1 1 3 0 6 _ s_ a t
0 ,21 ,4 61 ,8 40 ,9 8X -ra y re p a ir  c o m p le m e n tin g d e fe c tiv e re p a ir in C h in e se h a m ste r c e lls  4B C 0 0 5 2 5 92 1 0 8 1 2 _ a t
0 ,0 41 ,1 11 ,6 40 ,5 8n e u ro f ib ro m in 2 (b ila te r a l a c o u st ic  n e u ro m a )B C 0 0 3 1 1 22 1 0 7 6 7 _ a t
0 ,0 71 ,1 91 ,0 60 ,1 1in d u c ib le T -c e l l  c o - stim u la to rA B 0 2 3 1 3 52 1 0 4 3 9 _ a t
0 ,5 91 ,4 24 ,6 91 ,4 6p o ta ss iu m in w a rd ly - r e c t i fy in g c h a n n e l,  s u b fa m ily J ,  m e m b e r  1U 1 2 5 4 32 1 0 4 0 3 _ s_ a t
0 ,21 ,1 31 ,3 50 ,1a la n in e -g ly o x y la te a m in o tra n s f e ra seD 1 3 3 6 82 1 0 3 2 7 _ s_ a t
0 ,1 21 ,3 11 ,9 46 ,4 3h y a lu ro n a n b in d in g p ro te in 4A F 2 4 1 8 3 12 0 9 8 1 9 _ a t
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1 ,2 92,4 12 ,341,4 8h yp othetical  pro tein F L J10 83 0N M _ 01 82 3521 77 52_ s_a t
0 ,4 91,5 71 ,631,8 9m esen ch ym al ste m c ell pro tein D S C 92N M _ 01 66 4521 77 22_ s_a t
0 ,1 71,6 81 ,921,1 5k eratin 19 pse ud og eneA B 0 41 26921 73 38_ at
0 ,2 21,4 69,61H u nting ton 's dise ase can dida te re gio n m R N A frag m e ntL 3 71 9821 72 57_ at
0,61,5 77 ,080,9 7im m un og lo bu lin hea vy co n stant m uS 74 63 921 72 36_ x_ at
0 ,0 71,1 23 ,510,3 2E M B L : H o m o sap ien s B A C clo n e G S1 -30 3P 24 fA C 0 03 07921 72 28_ s_a t
0,61,3 53 ,040,3 5N o rep in ep hrin e tra nsp orter isofo rm 2 [H o m o sapiens],  m R N A seq uen ceA B 0 22 84721 72 13_ at
0 ,1 12,0 89 ,520 ,8E M B L : H o m o sap ien s p artial M T H F R g ene A J24 92 7521 70 71_ s_a t
0 ,1 61,9 11 ,070,3 2B cell  ac tiv ation g ene [H o m o sap ien s], m R N A seq uen ceS 59 04 921 68 34_ at
0 ,2 71,4 82 ,981,9 2H o m o sap ien s m R N A ; c D N A D K F Z p 761 N 13 23 A L 1 374 2821 66 16_ at
1 ,4 32,7 53 ,033,4 5H o m o sap ien s cD N A F L J20 16 1 fisA K 00 016 821 63 79_ x_ at
0,41,4 51,70,5 6H C G II -7 pro teinX 8 100 121 62 27_ at
0 ,3 71,4 85 ,841 1,1 9h yp othetical  pro tein F L J21 77 7A K 02 543 021 61 69_ at
0 ,5 71,3 61 ,940,5 4E M B L : H u m a n D N A sequ en ce fro m clo n e R P 5-1 00 9E 2 4A L 1 098 0421 61 19_ s_a t
1 ,2 51,2 81 ,131 4,0 7E M B L : H o m o sap ien s D N A for alp ha (1 ,3 /1,4) fu cosy ltran sfera seD 8 932 421 60 10_ x_ at
0 ,6 81,3 11 ,370,0 5P D Z do m ain co ntain ing g uan in e n uc leo tid e  ex ch an ge facto r(G E F )1A L 1 173 9721 59 92_ s_a t
0,21,3 54 ,120,1 3sy nta ph ilinA L 0 490 3721 59 17_ at
0 ,2 81,1 31 ,871,4 3p rostag lan d in D 2 rece ptor  (D P )U 3 109 921 58 94_ at
0 ,3 51,2 611 ,751,7 2clo ne R P1 -169 O 23 on ch rom oso m e 1 A L 1 581 7221 58 70_ s_a t
0,21,2 83 ,850,6 7E p h A 1Z 2 74 0921 58 04_ at
0 ,4 51,3 62 ,582,1 5E p h A 5X 9 542 521 56 64_ s_a t
0 ,3 22,6 211 ,450,6 6K IA A 10 53 p roteinA L 1 175 2321 54 95_ s_a t
2,22 ,74 ,690,2 1ad en ylate cy clase 1 (b rain )L 0 55 0021 53 40_ at
0 ,2 71,2 86 ,711,3 1K IA A 04 51 g en e p ro du ctA K 02 700 021 52 96_ at
0 ,6 11,4 22,13,1 5im m un og lo bu lin lam bd a loc usA I95 27 7221 50 36_ at
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0 ,3 71 ,4 31 ,50 ,4 9H o m o s a p ie n s m R N A ; c D N A D K F Z p 4 3 4 M 0 5 4 A L 0 8 0 1 6 02 1 7 4 4 6 _ x _ a t
0 ,5 81 ,5 41 ,3 40 ,3 6d u a l sp e c if ic ity p h o s p h a ta se 5U 1 6 9 9 62 0 9 4 5 7 _ a t
0 ,7 91 ,5 71 ,3 60 ,7 3E H -d o m a in c o n ta in in g 1A W 1 8 2 8 6 02 0 9 0 3 7 _ s _ a t
0 ,1 71 ,5 56 ,0 51 ,0 8ly m p h o id n u c le a r p ro te in re la te d to A F 4A I9 9 0 4 6 52 0 5 7 3 4 _ s _ a t
0 ,2 22 ,42 ,8 20 ,3 6in s u lin -lik e g ro w th fa c to r b in d in g p ro te in 6N M _ 0 0 2 1 7 82 0 3 8 5 1 _ a t
1 ,1 42 ,2 61 ,9 31 ,0 6a n n e x in A 2B C 0 0 1 3 8 82 1 0 4 2 7 _ x _ a t
0 ,3 21 ,3 95 ,1 80 ,4 7H o m o s a p ie n s c D N A F L J1 4 0 2 5 fisA K 0 2 4 0 8 72 2 2 1 7 4 _ a t
0 ,3 11 ,3 66 ,1 90 ,0 4p ro sta te d iffe re n tia tio n fa c to rB C 0 0 0 5 2 92 2 1 5 7 6 _ a t
0 ,11 ,1 61 ,7 30 ,3sia lid a se 2 (c y to s o lic s ia lid a se )N M _ 0 0 5 3 8 32 2 1 3 6 8 _ a t
1 ,1 42 ,3 71 ,5 80 ,5 1G p ro te in -c o u p le d re c e p to r  4 3N M _ 0 0 5 3 0 62 2 1 3 4 5 _ a t
1 ,1 71 ,1 82 ,8 13 ,7 5p p a rlN M _ 0 1 6 5 6 62 2 1 1 1 6 _ a t
0 ,7 61 ,8 21 ,6 10 ,6 7h y p o th e tic a l p ro te in F L J 2 2 4 5 7N M _ 0 2 4 9 0 12 2 1 0 8 1 _ s _ a t
0 ,5 61 ,0 75 ,5 12 ,1 6tra n s p o s o n -d e riv e d B u ste r3 t ra n s p o s a se - lik eN M _ 0 2 2 0 9 02 2 0 7 7 0 _ s _ a t
0 ,0 81 ,2 33 ,2 71 ,1 5h y p o th e tic a l p ro te in P R O 0 7 5 8N M _ 0 1 8 5 6 32 2 0 7 0 4 _ a t
0 ,3 81 ,1 83 ,5 80 ,9ta x o l re s is ta n c e a s s o c ia te d g e n e 3N M _ 0 0 4 9 0 92 2 0 4 4 5 _ s _ a t
0 ,1 21 ,6 22 ,3 65 ,1 8h y p o th e tic a l p ro te in F L J 1 2 2 2 9N M _ 0 2 4 8 7 62 2 0 4 3 4 _ a t
0 ,5 71 ,3 93 ,1 41 ,7 4h y p o th e tic a l p ro te in F L J 1 1 2 3 5N M _ 0 1 9 0 3 32 2 0 3 6 4 _ a t
0 ,8 42 ,1 21 ,3 80 ,5 6S A M d o m a in , S H 3 d o m a in a n d n u c le a r  lo c a lisa tio n s ig n a ls,  1N M _ 0 2 2 1 3 62 2 0 3 3 0 _ s _ a t
0 ,4 91 ,0 91 4 ,3 10 ,3 5su lfo tra n sfe ra se , e s t ro g e n -p re fe rr in gN M _ 0 0 5 4 2 02 1 9 9 3 4 _ s _ a t
0 ,1 71 ,63 ,6 40 ,5 7h y p o th e tic a l p ro te in M G C 2 7 4 2N M _ 0 2 3 9 3 82 1 9 8 5 6 _ a t
0 ,1 41 ,22 ,0 21 ,2 7fru c to s a m in e -3 -k in a seN M _ 0 2 2 1 5 82 1 9 7 4 4 _ a t
0 ,61 ,6 31 ,3 60 ,4 2h y p o th e tic a l p ro te in F L J 2 1 8 0 2N M _ 0 2 4 6 4 42 1 9 5 2 6 _ a t
0 ,2 85 ,4 31 ,7 13 ,5 6B ly m p h o c y te a c tiv a to r m a c ro p h a g e e x p re s se dN M _ 0 2 0 1 2 52 1 9 3 8 6 _ s _ a t
0 ,31 ,0 45 ,4 32 ,5 9h y p o th e tic a l p ro te in F L J 2 2 8 3 3N M _ 0 2 2 8 3 72 1 9 3 3 4 _ s _ a t
0 ,5 11 ,4 31 ,7 60 ,9 5M R S 2 -lik e , m a g n e s iu m h o m e o sta s i s  fa c to r  (S . c e re v isia e )N M _ 0 2 0 6 6 22 1 8 5 3 8 _ s _ a t
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0 ,8 21 ,4 73 ,2 31 , 1 4l i n - 7 h o m o l o g A ( C . e l e g a n s )N M _ 0 0 4 6 6 42 0 6 4 4 0 _ a t
0 ,6 21 ,6 22 ,6 21 , 2 2z i n c f i n g e r p r o te i n 7 ( K O X 4 , c lo n e H F .1 6 )N M _ 0 0 3 4 1 62 0 5 0 8 9 _ a t
0 ,7 71 ,6 91 ,4 70 , 8 2r a s h o m o l o g g e n e f a m i ly ,  m e m b e r HN M _ 0 0 4 3 1 02 0 4 9 5 1 _ a t
0 ,7 41 ,6 81 ,4 10 , 1 8d u a l  s p e c i f i c i ty  p h o s p h a ta s e 2N M _ 0 0 4 4 1 82 0 4 7 9 4 _ a t
1 ,6 51 ,1 95 ,50 , 3 5p r o s t a g la n d in - e n d o p e r o x id e s y n t h a s e 2 N M _ 0 0 0 9 6 32 0 4 7 4 8 _ a t
0 ,8 81 ,8 21 ,5 80 , 4 8i n t e r f e r o n c o n s e n s u s s e q u e n c e b i n d in g p r o t e i n 1A I 0 7 3 9 8 42 0 4 0 5 7 _ a t
0 ,7 41 ,7 81 ,7 81 , 5 9s e r in e / th r e o n in e k in a s e 1 7 a ( a p o p to s is - i n d u c in g )N M _ 0 0 4 7 6 02 0 2 6 9 3 _ s _ a t
1 ,22 ,4 22 ,2 91 , 3 2b in d e r o f A r l T w oN M _ 0 1 2 1 0 62 0 2 0 9 2 _ s _ a t
0 ,8 31 ,7 21 ,6 50 , 3 7s ia l y l t r a n s f e r a s e 1 ( b e ta - g a l a c t o s id e a lp h a - 2 ,6 - s ia ly t r a n s f e r a s e )A I 7 4 3 7 9 22 0 1 9 9 8 _ a t
1 ,52 ,0 72 ,0 21 , 5 2d is h e v e l l e d , d s h h o m o lo g 3 ( D r o s o p h i l a )N M _ 0 0 4 4 2 32 0 1 9 0 8 _ a t
0 ,4 61 ,6 21 ,1 90 , 1 7e a r l y g r o w t h r e s p o n s e 1N M _ 0 0 1 9 6 42 0 1 6 9 4 _ s _ a t
0 ,5 71 ,5 71 ,4 80 , 5 8z i n c f i n g e r p r o te i n 3 6 ,  C 3 H ty p e - l ik e 2N M _ 0 0 6 8 8 72 0 1 3 6 9 _ s _ a t
0 ,5 61 ,61 ,5 50 , 9 5z i n c f i n g e r p r o te i n 3 6 ,  C 3 H ty p e - l ik e 2A I 3 5 6 3 9 82 0 1 3 6 8 _ a t
0 ,91 ,8 11 ,4 20 , 6 1B T G f a m i l y ,  m e m b e r 2N M _ 0 0 6 7 6 32 0 1 2 3 6 _ s _ a t
0 ,8 62 ,1 71 ,3 10 , 3 6B T G f a m i l y ,  m e m b e r 2B G 3 3 9 0 6 42 0 1 2 3 5 _ s _ a t
1 ,4 62 ,5 83 ,0 22 ,9t h i o r e d o x in i n t e r a c t i n g p r o te inN M _ 0 0 6 4 7 22 0 1 0 1 0 _ s _ a t
1 ,5 32 ,6 42 ,7 73 , 8 8t h i o r e d o x in i n t e r a c t i n g p r o te inN M _ 0 0 6 4 7 22 0 1 0 0 9 _ s _ a t
1 ,5 93 ,0 12 ,5 95 , 5 2t h i o r e d o x in i n t e r a c t i n g p r o te inN M _ 0 0 6 4 7 22 0 1 0 0 8 _ s _ a t
0 ,5 81 ,4 64 ,1 91 , 6 6B a c i l l u s s u b t i l i s l y s g e n e f o r d ia m i n o p im e l a te d e c a r b o x y la s eX 1 7 0 1 3A F F X - L y s X - 3 _ a t
0 ,6 31 ,5 31 ,5 40 , 9 4R A B 9 A ,  m e m b e r R A S o n c o g e n e f a m i lyN M _ 0 0 4 2 5 12 2 1 8 0 8 _ a t
0 ,5 11 ,61 ,3 10 , 1 8l i p a s e p r o te inA F 2 2 5 4 1 82 2 1 6 7 9 _ s _ a t
0 ,5 11 ,61 ,2 50 , 1 5l i p a s e p r o te inB C 0 0 1 6 9 82 2 1 5 5 2 _ a t
1 ,3 21 ,9 81 ,3 60 , 1 8l e u k o c y te m e m b r a n e a n t i g e nA J 0 1 0 1 0 22 1 7 0 7 8 _ s _ a t
0 ,31 ,3 91 ,2 40 , 8 7E M B L :  H o m o s a p i e n s C X C R 4 g e n e e n c o d i n g r e c e p t o r C X C R 4A J 2 2 4 8 6 92 1 7 0 2 8 _ a t
0 ,5 71 ,71 ,1 40 , 0 8c h e m o k in e ( C m o t i f ) l i g a n d 2N M _ 0 0 3 1 7 52 1 4 5 6 7 _ s _ a t
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0 ,8 81 ,71 ,6 71 ,3 9K ru p p e l- lik e fa c to r 2 (lu n g )N M _ 0 1 6 2 7 02 1 9 3 7 1 _ s_ a t
1 ,4 52 ,2 32 ,6 72 ,5 8p h a fin 2N M _ 0 2 4 6 1 32 1 8 6 4 0 _ s_ a t
0 ,1 61 ,2 73 ,60 ,0 9U n k n o w n (p ro te in fo r IM A G E :4 1 1 1 0 9 4 ) A W 1 8 8 2 1 42 1 7 6 6 0 _ a t
0 ,5 61 ,72 ,9 90 ,4 9H o m o s a p ie n s c D N A : F L J 2 3 2 5 7 fis ,  c lo n e C O L 0 5 5 7 9A K 0 2 6 9 1 02 1 6 8 0 1 _ a t
1 ,1 12 ,2 91 ,5 10 ,2 7H u m a n c lo n e 2 3 9 3 3 m R N A se q u e n c eU 7 9 2 7 32 1 4 8 0 5 _ a t
0 ,1 11 ,1 22 3 ,50 ,5 5a d v illinA I7 9 6 8 1 32 1 4 3 3 1 _ a t
0 ,7 52 ,2 31 ,71 ,6 2E 7 4 -lik e fa c to r 1 (e ts d o m a in tra n s c rip tio n fa c to r)M 8 2 8 8 22 1 2 4 1 8 _ a t
1 ,0 51 ,8 81 ,40 ,4 8z in c fin g e r p ro te in 3 6 , C 3 H ty p e -lik e 1X 7 9 0 6 72 1 1 9 6 5 _ a t
1 ,1 52 ,4 11 ,8 93 ,1 8e c o tro p ic v ira l in te g ra tio n site 2 BB C 0 0 5 9 2 62 1 1 7 4 2 _ s_ a t
0 ,4 53 ,33 ,1 70 ,9 4tro p h in inA F 3 4 9 7 2 02 1 1 7 0 1 _ s_ a t
0 ,7 91 ,7 71 ,4 90 ,5 4in te r fe ro n g a m m a re c e p to r 1A F 0 5 6 9 7 92 1 1 6 7 6 _ s_ a t
0 ,1 41 ,1 46 ,7 20 ,9 6P O U d o m a in , c la ss  4 , tra n s c r ip tio n fa c to r 1L 2 0 4 3 32 1 1 3 4 1 _ a t
0 ,4 11 ,7 91 ,6 80 ,4 3p u rin e rg ic re c e p to r P 2 X , lig a n d -g a te d io n c h a n n e l,  5U 4 9 3 9 62 1 0 4 4 8 _ s_ a t
2 ,4 51 ,1 34 ,4 46 ,4 1R h e su s b lo o d g ro u p , D a n tig e nX 6 3 0 9 72 1 0 4 2 9 _ a t
0 ,2 41 ,51 3 ,4 10 ,9 9b ra in a n d n a s o p h a ry n g e a l c a rc in o m a s u sc e p tib ility p ro te inA F 1 9 1 4 9 22 1 0 1 0 9 _ a t
1 ,6 62 ,61 ,74 ,8 6rin g f in g e r p ro te in 1 1A B 0 2 4 7 0 32 0 8 9 2 4 _ a t
1 ,7 62 ,4 51 ,9 82 ,3 5T N F -in d u c e d p ro te inN M _ 0 1 4 3 5 02 0 8 2 9 6 _ x _ a t
0 ,1 81 ,1 630 ,1 8in te r fe ro n , b e ta 1 , fib ro b la stN M _ 0 0 2 1 7 62 0 8 1 7 3 _ a t
1 ,0 71 ,1 21 ,0 20 ,0 1e a rly g ro w th re s p o n s e 4N M _ 0 0 1 9 6 52 0 7 7 6 8 _ a t
0 ,6 21 ,7 61 ,4 90 ,5 9b a s e m e n t m e m b ra n e - in d u c e d g e n eN M _ 0 0 4 8 4 82 0 7 5 7 1 _ x _ a t
0 ,9 21 ,9 31 ,5 20 ,5 8tra n sfe rrin re c e p to r (p 9 0 , C D 7 1 )N M _ 0 0 3 2 3 42 0 7 3 3 2 _ s_ a t
0 ,5 61 ,5 15 ,4 40 ,5 6sa rc o g ly c a n , g a m m a (3 5 k D a d y stro p h in -a sso c ia te d g ly c o p ro te in )N M _ 0 0 0 2 3 12 0 7 3 0 2 _ a t
0 ,7 91 ,3 42 9 ,3 50 ,5 3d ia c y lg ly c e ro l k in a se , io taN M _ 0 0 4 7 1 72 0 6 8 0 6 _ a t
1 ,2 82 ,22 ,2 11 ,7 2tu m o r n e c ro sis  fa c to r r e c e p to r s u p e rfa m ily , m e m b e r 1 7N M _ 0 0 1 1 9 22 0 6 6 4 1 _ a t
0 ,9 72 ,2 72 ,6 13 ,9 55 -h y d ro x y try p ta m in e ( se ro to n in ) re c e p to r  2 BN M _ 0 0 0 8 6 72 0 6 6 3 8 _ a t
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aUnique Affymetrix identifier.
0,791,881,50,34EH -domain containing 1AY007161222221_x_at
0,451,315,610,91nucleolar protein 3 (apoptosis repressor with CARD domain)AF043244221566_s_at
0,491,564,770,88hypothetical protein FLJ13769NM_025012220719_at
0,931,982,793,29activation-induced cytidine deaminaseNM_020661219841_at
0,71,627,181,2solute carrier family 13 (sodium/sulfate symporters), member 4NM_012450219824_at
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